data_1b03_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1b03 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 88.2 p . . . . . 0 C--O 1.233 0.234 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.8 pt -132.01 147.61 32.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 112.113 0.412 . . . . 0.0 112.113 179.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.483 ' O ' ' CD ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -91.19 91.6 8.3 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 176.118 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.408 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.59 150.51 6.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.613 -176.776 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 22.5 mp0 -89.0 12.52 15.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.621 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -96.88 177.94 5.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.32 -179.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.48 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.97 178.2 29.4 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.966 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -73.37 108.26 0.95 Allowed 'Cis proline' 0 C--N 1.344 0.326 0 C-N-CA 123.337 -1.526 . . . . 0.0 112.279 0.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.48 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 67.41 156.36 0.62 Allowed Glycine 0 C--N 1.333 0.391 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.422 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -60.27 126.04 25.96 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.766 0.317 . . . . 0.0 110.502 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.408 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -149.18 177.84 9.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.887 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.4 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -109.67 120.09 41.4 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.674 179.553 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.1 m -109.27 152.8 11.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.759 178.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.6 m -89.44 156.37 18.71 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.957 0.408 . . . . 0.0 111.24 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 8.3 mt -120.63 163.06 18.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.022 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.503 -1.165 . . . . 0.0 112.075 179.978 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.507 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 14.7 m . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.465 0.174 . . . . 0.0 110.849 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.473 ' O ' ' HB2' ' A' ' 17' ' ' PHE . 1.6 pt -131.43 146.05 34.26 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.567 0 N-CA-C 113.696 0.998 . . . . 0.0 113.696 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -78.8 102.24 8.04 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 176.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 16' ' ' ALA . 1.8 pt -77.54 151.28 5.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.657 -177.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -100.95 10.49 41.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.464 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 36.0 ptt180 -109.25 -178.31 3.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.827 0.346 . . . . 0.0 111.017 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.54 -172.64 30.78 Favored Glycine 0 C--N 1.329 0.187 0 C-N-CA 121.108 -0.568 . . . . 0.0 112.308 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.98 117.66 5.33 Favored 'Cis proline' 0 N--CA 1.462 -0.349 0 C-N-CA 123.34 -1.525 . . . . 0.0 112.407 0.143 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 145.64 4.73 Favored Glycine 0 C--N 1.33 0.221 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.293 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.493 ' C ' ' HD2' ' A' ' 15' ' ' ARG . 4.8 ppt_? -66.72 128.8 37.66 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.427 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -169.52 -166.47 0.6 Allowed 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 121.199 0.523 . . . . 0.0 110.593 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.507 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.1 OUTLIER -137.62 152.57 49.5 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.367 179.572 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.5 m -115.75 154.9 17.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.972 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 86.3 m -113.74 110.71 20.61 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.359 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.8 pt -100.22 173.06 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.674 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.711 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.242 -1.31 . . . . 0.0 112.287 179.744 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.6 m . . . . . 0 CA--C 1.528 0.122 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.8 pt -130.95 152.04 36.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.318 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -179.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.484 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 22.8 ttm180 -94.97 104.32 16.2 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 175.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -77.37 144.29 11.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 C-N-CA 119.845 -0.742 . . . . 0.0 110.791 -177.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.1 tp-100 -93.88 12.46 25.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.426 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.3 mtt-85 -97.47 173.46 7.16 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.332 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.74 -179.83 30.52 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.1 108.63 1.14 Allowed 'Cis proline' 0 C--N 1.345 0.381 0 C-N-CA 123.34 -1.525 . . . . 0.0 112.256 0.039 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.54 152.18 3.48 Favored Glycine 0 C--N 1.332 0.335 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.467 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.462 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -62.34 152.64 33.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.875 0.369 . . . . 0.0 111.096 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -170.17 178.54 3.81 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.998 0.428 . . . . 0.0 111.152 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.484 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.6 OUTLIER -120.56 129.7 53.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.0 179.718 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 6.2 t -120.85 159.92 22.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.8 m -102.77 156.11 17.86 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.204 0.526 . . . . 0.0 111.316 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 8.7 mt -118.1 164.73 14.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.177 -0.92 . . . . 0.0 109.816 -179.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.999 0 CA-C-O 118.416 -1.214 . . . . 0.0 111.977 179.789 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.428 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 17.4 m . . . . . 0 C--O 1.232 0.145 0 N-CA-C 110.588 -0.153 . . . . 0.0 110.588 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.438 ' O ' ' HB2' ' A' ' 17' ' ' PHE . 2.9 pt -132.42 146.04 33.59 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.501 0 N-CA-C 113.933 1.086 . . . . 0.0 113.933 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.489 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 48.7 mtt85 -86.9 108.92 19.0 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 175.249 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.438 HG12 ' O ' ' A' ' 16' ' ' ALA . 1.3 pt -77.76 157.66 5.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.714 -177.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -100.57 11.0 40.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.598 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 5.3 ttm180 -98.95 -170.13 1.88 Allowed 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -108.95 179.35 21.13 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.155 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.56 112.42 2.34 Favored 'Cis proline' 0 C--N 1.344 0.297 0 C-N-CA 122.971 -1.679 . . . . 0.0 112.44 0.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.5 155.4 6.13 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.353 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.2 ttp85 -62.28 88.22 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.222 0.534 . . . . 0.0 110.293 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.438 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -101.58 -170.81 1.88 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.883 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.489 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -148.74 149.98 32.34 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.38 179.574 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.4 t -121.92 162.23 21.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.72 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 89.6 m -111.01 126.95 55.34 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.761 0.791 . . . . 0.0 112.05 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.5 mt -103.22 156.49 5.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.901 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.49 -1.172 . . . . 0.0 113.043 179.037 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 C--O 1.232 0.175 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.407 ' HA ' HH21 ' A' ' 8' ' ' ARG . 3.4 pt -132.0 148.67 32.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -179.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.564 ' HE ' ' N ' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -88.14 102.64 14.98 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 175.586 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.448 HG22 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.48 142.23 14.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 120.154 -0.618 . . . . 0.0 110.751 -177.379 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.65 11.47 24.28 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.805 -178.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -98.28 175.28 6.12 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.734 0.302 . . . . 0.0 110.646 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.49 -177.04 31.34 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.272 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 81.0 Cg_endo -78.87 110.4 1.84 Allowed 'Cis proline' 0 C--N 1.343 0.284 0 C-N-CA 123.062 -1.641 . . . . 0.0 112.796 0.181 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.06 141.57 4.93 Favored Glycine 0 C--N 1.331 0.299 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.663 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.462 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -60.14 142.47 54.22 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.956 0.407 . . . . 0.0 111.156 179.83 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.41 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -170.28 -168.12 0.69 Allowed 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.113 0.483 . . . . 0.0 110.624 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.428 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -144.56 145.48 31.84 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.486 179.12 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 t -125.61 162.32 28.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.243 -179.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 98.0 m -100.39 152.27 20.54 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.042 0.449 . . . . 0.0 110.8 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.0 mt -114.47 163.86 11.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.573 -179.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.527 -1.151 . . . . 0.0 112.002 179.889 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 64.9 m . . . . . 0 CA--C 1.529 0.145 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.6 pt -131.41 148.44 32.72 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.36 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 -179.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 65.4 mtt85 -85.06 99.06 10.78 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 176.063 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.431 HD11 HG22 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.59 151.63 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.846 0.355 . . . . 0.0 111.18 -177.23 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -95.09 8.41 43.07 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.392 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 16.4 ptp180 -99.72 -175.89 3.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.458 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.34 -177.73 31.48 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.392 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.79 114.2 3.09 Favored 'Cis proline' 0 C--N 1.343 0.279 0 C-N-CA 123.381 -1.508 . . . . 0.0 112.532 0.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.59 161.81 8.6 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.5 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.407 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 1.0 OUTLIER -78.35 122.9 26.37 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.148 0.499 . . . . 0.0 111.043 179.734 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.411 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -160.48 -165.16 1.37 Allowed 'General case' 0 CA--C 1.512 -0.495 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.614 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -135.28 143.96 46.53 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.102 0.477 . . . . 0.0 110.707 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 31.1 m -118.49 168.42 10.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.678 -179.294 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.6 m -96.4 152.22 18.81 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 120.979 0.419 . . . . 0.0 111.071 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 9.5 mt -107.85 163.71 5.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.376 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.12 0 CA-C-O 118.117 -1.379 . . . . 0.0 111.827 179.871 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.413 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.9 m . . . . . 0 C--O 1.23 0.053 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.433 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 2.4 pt -132.3 146.68 32.67 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.504 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.452 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 45.9 mtp85 -84.46 103.46 13.63 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.438 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.3 OUTLIER -78.01 153.83 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.188 -177.299 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . 0.514 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 13.3 mp0 -92.61 13.21 20.61 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.241 -179.167 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 49.5 mtp85 -97.3 -176.06 3.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.921 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.76 177.35 30.42 Favored Glycine 0 C--N 1.332 0.323 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.409 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.96 135.9 38.66 Favored 'Cis proline' 0 C--N 1.344 0.317 0 C-N-CA 122.987 -1.672 . . . . 0.0 112.697 0.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 59.68 -104.34 0.55 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.112 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 8.0 ttp180 -160.07 134.11 7.31 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.438 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -159.79 -167.96 2.13 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.599 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.452 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -137.02 148.71 47.01 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.5 179.455 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.4 t -121.52 164.05 18.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.29 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 91.7 m -113.55 140.49 48.11 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.981 0.42 . . . . 0.0 111.238 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.462 ' N ' ' CD1' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -124.98 156.6 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.724 179.705 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.263 -1.299 . . . . 0.0 112.372 179.792 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.4 m . . . . . 0 C--O 1.232 0.142 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.404 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 8.5 pt -131.85 147.35 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 113.564 0.95 . . . . 0.0 113.564 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.576 ' H ' ' HD2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -85.02 101.91 12.78 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 106.325 -1.731 . . . . 0.0 106.325 175.235 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.434 HD11 HG22 ' A' ' 9' ' ' ILE . 0.1 OUTLIER -76.25 150.05 6.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.911 -176.404 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . 0.439 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 17.7 mp0 -94.11 9.47 37.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.998 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 10.6 ptp180 -99.09 -173.62 2.54 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.908 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.35 -176.1 31.47 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.423 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -80.7 108.98 1.36 Allowed 'Cis proline' 0 CA--C 1.531 0.334 0 C-N-CA 122.886 -1.714 . . . . 0.0 112.597 0.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.23 169.77 38.0 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.682 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -71.36 123.79 23.1 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.742 0.306 . . . . 0.0 110.952 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.411 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -160.96 -169.32 2.33 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.243 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.434 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -145.36 141.15 28.23 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.942 178.994 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.5 t -115.5 163.95 12.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.398 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 92.6 m -100.07 158.37 15.89 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.292 0.567 . . . . 0.0 110.786 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -140.99 153.67 20.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.918 -178.762 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.443 -1.198 . . . . 0.0 112.153 179.688 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.498 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.4 m . . . . . 0 N--CA 1.456 -0.137 0 CA-C-O 120.573 0.225 . . . . 0.0 110.785 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 2.8 pt -132.48 147.85 31.91 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -86.67 102.93 14.66 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 175.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.455 HG21 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.78 153.63 5.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.859 -177.451 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 -99.02 10.96 40.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.363 -179.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -98.69 -177.03 3.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.751 0.31 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -108.76 -176.24 21.68 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.245 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -77.37 114.59 3.28 Favored 'Cis proline' 0 C--N 1.343 0.245 0 C-N-CA 122.93 -1.696 . . . . 0.0 112.337 -0.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.91 147.35 6.92 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.109 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.9 mpt_? -77.56 127.01 31.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.996 0.426 . . . . 0.0 110.877 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.406 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -156.19 -169.0 2.91 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.888 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.498 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -133.88 142.18 47.68 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.977 0.418 . . . . 0.0 110.948 179.521 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.8 t -110.58 162.73 7.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.053 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 78.8 m -124.91 114.18 18.83 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.83 0.348 . . . . 0.0 111.379 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.42 179.65 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.774 178.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.739 -1.034 . . . . 0.0 113.103 -179.867 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.3 m . . . . . 0 CA--C 1.529 0.172 0 CA-C-O 120.373 0.13 . . . . 0.0 111.084 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.409 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 3.4 pt -131.28 145.96 34.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 113.742 1.016 . . . . 0.0 113.742 -179.311 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.3 mtt-85 -83.56 95.64 8.38 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 176.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.443 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.1 OUTLIER -76.37 142.94 13.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.102 0.477 . . . . 0.0 111.19 -176.933 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 58.7 mm-40 -92.66 11.43 26.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.453 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -98.03 173.25 7.14 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.25 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.7 -175.46 30.95 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.723 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -80.65 119.66 6.6 Favored 'Cis proline' 0 C--N 1.347 0.453 0 C-N-CA 123.326 -1.531 . . . . 0.0 112.34 -0.066 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.67 166.61 41.65 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.548 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.42 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 1.7 mpt_? -89.18 134.99 33.81 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.736 0.303 . . . . 0.0 110.593 179.546 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.443 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -168.85 -166.63 0.67 Allowed 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.141 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.409 ' HB2' ' C ' ' A' ' 7' ' ' ILE . 0.4 OUTLIER -141.75 139.88 32.94 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.923 178.681 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 26.8 m -112.39 166.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.899 -179.258 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 83.3 m -98.89 156.48 16.87 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.171 0.51 . . . . 0.0 111.594 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 8.5 mt -120.21 167.17 13.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.195 -0.912 . . . . 0.0 109.945 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.911 0 CA-C-O 118.281 -1.288 . . . . 0.0 112.017 179.756 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.1 m . . . . . 0 N--CA 1.462 0.135 0 CA-C-O 120.584 0.231 . . . . 0.0 110.568 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.6 pt -130.33 150.41 34.58 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.314 0 CA-C-O 121.022 0.439 . . . . 0.0 112.005 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.425 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 12.3 ptm180 -95.67 90.98 5.89 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 176.47 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.438 HD11 HG22 ' A' ' 9' ' ' ILE . 0.1 OUTLIER -76.92 144.35 11.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.131 -177.122 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -97.87 9.95 41.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.811 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.541 ' HD2' ' N ' ' A' ' 11' ' ' ARG . 2.1 mpt_? -101.84 -179.49 4.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.241 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -102.45 -178.86 27.23 Favored Glycine 0 CA--C 1.516 0.156 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.272 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.47 114.4 3.33 Favored 'Cis proline' 0 C--N 1.346 0.409 0 C-N-CA 123.538 -1.442 . . . . 0.0 111.985 0.055 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 87.5 147.38 12.36 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.394 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 20.2 mmt85 -99.96 122.22 42.54 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -169.76 -173.86 1.71 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.136 0.494 . . . . 0.0 110.991 -179.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.0 120.85 34.82 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.547 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.2 t -109.65 162.04 7.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.44 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 97.0 m -100.66 158.83 15.65 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.389 0.614 . . . . 0.0 111.802 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.2 mt -129.0 165.61 28.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.273 -179.309 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.192 179.139 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.3 m . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.795 0.331 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.0 pt -130.46 152.83 38.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.147 -179.571 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.457 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 32.9 ptt180 -95.79 93.36 7.03 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 176.407 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.455 HD11 HG22 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -76.3 148.02 7.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.06 0.457 . . . . 0.0 111.395 -176.872 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . 0.539 HE21 HH21 ' A' ' 15' ' ' ARG . 0.4 OUTLIER -89.85 11.27 20.74 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.805 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 65.2 mtt85 -98.35 -173.54 2.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.352 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.44 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.79 178.19 29.63 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.68 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -75.39 108.06 1.01 Allowed 'Cis proline' 0 C--N 1.344 0.33 0 C-N-CA 123.449 -1.479 . . . . 0.0 112.268 -0.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.44 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 68.97 160.37 2.08 Favored Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.572 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.539 HH21 HE21 ' A' ' 10' ' ' GLN . 16.3 tpp85 -64.42 118.1 8.26 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.576 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -151.32 -178.55 6.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.249 0.547 . . . . 0.0 111.622 -179.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.457 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -111.01 130.0 55.73 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.44 179.567 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.5 m -119.11 142.34 34.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.705 179.206 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 68.1 m -100.11 115.28 29.43 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.479 -179.317 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.5 pt -102.19 148.25 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.781 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.187 179.02 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.623 -1.098 . . . . 0.0 112.314 -179.82 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.8 m . . . . . 0 C--O 1.231 0.098 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.406 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 6.2 pt -131.45 145.07 35.78 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.561 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.465 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 14.4 ptt85 -90.43 98.44 11.78 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 175.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.422 HG21 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -78.17 147.04 7.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.963 0.411 . . . . 0.0 111.485 -176.853 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 21.8 mp0 -94.15 9.48 37.68 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.46 -179.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.3 ptt180 -99.21 -177.75 3.71 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.736 0.303 . . . . 0.0 110.744 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.15 -176.33 30.39 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.466 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -79.08 106.91 0.94 Allowed 'Cis proline' 0 C--N 1.345 0.361 0 C-N-CA 122.958 -1.684 . . . . 0.0 112.779 -0.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.24 148.28 10.12 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.402 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 18.3 mmt85 -65.71 131.79 47.2 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.688 0.28 . . . . 0.0 110.829 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -167.6 -173.45 2.19 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.033 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.465 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -136.36 138.65 41.84 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.38 179.301 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 t -110.28 162.5 7.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.252 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 99.1 m -104.62 152.37 22.53 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.487 0.66 . . . . 0.0 111.063 179.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.9 mt -114.9 166.79 8.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.776 -179.113 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.111 0 CA-C-O 118.458 -1.19 . . . . 0.0 112.305 179.722 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.476 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 13.2 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.707 0.289 . . . . 0.0 111.244 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.8 pt -132.35 148.23 31.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.369 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 82.3 mtm180 -87.08 98.53 11.34 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 175.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.42 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.71 141.96 14.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 120.231 -0.587 . . . . 0.0 110.731 -177.539 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -93.21 12.34 24.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.732 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 37.8 ptt180 -98.53 -175.7 3.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.395 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.79 177.98 29.5 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.496 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -78.99 109.34 1.44 Allowed 'Cis proline' 0 C--N 1.345 0.381 0 C-N-CA 123.223 -1.574 . . . . 0.0 112.506 0.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.12 157.84 21.47 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.723 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -74.08 135.32 42.97 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.586 0.232 . . . . 0.0 110.414 179.552 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.42 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -170.42 -168.13 0.68 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.052 0.453 . . . . 0.0 110.536 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.476 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.1 OUTLIER -139.02 145.48 39.68 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.26 179.129 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 t -119.53 161.46 18.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.455 -178.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 90.3 m -117.87 113.45 21.78 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.558 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 34.1 pt -102.24 163.36 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 C-N-CA 122.938 0.495 . . . . 0.0 111.606 -179.745 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.181 0 CA-C-O 117.986 -1.452 . . . . 0.0 113.359 178.791 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.486 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 14.2 m . . . . . 0 N--CA 1.456 -0.145 0 CA-C-O 120.522 0.201 . . . . 0.0 110.652 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.2 pt -130.9 150.44 34.61 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.437 ' H ' ' HD3' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -89.11 99.82 12.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 176.382 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.433 HG22 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -78.7 144.12 11.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.506 -0.478 . . . . 0.0 111.446 -177.542 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 44.9 mt-30 -83.57 11.5 7.05 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.837 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -98.52 -175.07 2.98 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.352 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -102.18 -178.12 27.65 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.288 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.66 107.62 1.0 Allowed 'Cis proline' 0 C--N 1.343 0.265 0 C-N-CA 123.103 -1.624 . . . . 0.0 112.412 0.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.99 155.33 6.55 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.385 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.404 ' H ' ' NE ' ' A' ' 15' ' ' ARG . 0.1 OUTLIER -62.31 111.41 1.98 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.911 0.386 . . . . 0.0 110.723 179.762 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.418 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -144.13 -172.76 3.84 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 115.806 -0.633 . . . . 0.0 109.95 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.486 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -136.17 142.69 44.18 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.526 179.278 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.0 t -111.64 161.26 10.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.26 -179.262 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 71.8 m -118.32 111.0 18.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.579 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.405 ' CD1' ' N ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -109.02 178.28 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.931 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.758 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.438 -1.201 . . . . 0.0 112.165 179.69 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.4 m . . . . . 0 N--CA 1.456 -0.142 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 pt -130.98 149.79 33.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -179.014 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.418 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 7.4 ptm180 -93.32 92.3 7.62 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 176.024 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.441 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.57 147.26 7.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.39 -176.63 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -95.17 11.12 33.41 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.25 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -98.26 -174.72 2.91 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.454 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -100.24 177.74 28.81 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.485 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.98 108.69 1.08 Allowed 'Cis proline' 0 C--N 1.344 0.31 0 C-N-CA 123.096 -1.626 . . . . 0.0 112.264 -0.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.454 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 72.47 150.67 1.19 Allowed Glycine 0 C--N 1.333 0.363 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.347 -179.601 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.408 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 1.3 mpt_? -73.34 133.26 43.79 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.344 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.441 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -164.88 -175.29 3.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.19 0.519 . . . . 0.0 111.31 -179.695 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.418 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -106.74 119.05 38.28 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.793 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.4 m -110.02 154.78 11.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.977 179.078 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 98.8 m -105.53 154.44 20.37 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.417 0.627 . . . . 0.0 111.933 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -130.42 147.26 33.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.505 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.4 -1.222 . . . . 0.0 112.482 179.702 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.5 m . . . . . 0 CA--C 1.529 0.142 0 CA-C-O 120.62 0.248 . . . . 0.0 111.102 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.9 pt -131.38 148.28 32.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 121.135 0.493 . . . . 0.0 112.219 179.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.436 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 38.9 ttt180 -93.8 98.09 10.85 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 176.419 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.459 ' O ' ' HD3' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -75.6 149.21 6.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 C-N-CA 120.766 -0.373 . . . . 0.0 110.558 -177.328 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . 0.426 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 53.7 tt0 -94.68 11.41 31.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.243 -179.089 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 5.5 ptp180 -98.48 178.29 5.07 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.461 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.98 -177.01 30.67 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.59 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -77.0 110.7 1.77 Allowed 'Cis proline' 0 C--N 1.343 0.285 0 C-N-CA 123.287 -1.547 . . . . 0.0 112.323 -0.015 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.61 156.22 9.25 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.473 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.459 ' HD3' ' O ' ' A' ' 9' ' ' ILE . 17.7 tpp85 -71.9 129.35 38.37 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 179.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -152.04 -176.58 5.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.308 0.575 . . . . 0.0 111.875 -179.464 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.436 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -119.34 128.15 53.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.601 179.706 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 m -116.5 150.51 18.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.155 178.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 97.0 m -96.1 159.32 15.02 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.518 0.675 . . . . 0.0 111.877 -179.282 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.4 mt -135.48 155.15 36.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 114.537 -1.21 . . . . 0.0 108.945 -179.355 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.302 -1.277 . . . . 0.0 112.559 179.618 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.455 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 13.4 m . . . . . 0 N--CA 1.456 -0.172 0 CA-C-O 120.539 0.209 . . . . 0.0 110.778 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.451 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 1.7 pt -131.79 148.39 32.4 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 N-CA-C 113.313 0.857 . . . . 0.0 113.313 -179.332 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.432 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 5.8 ptm180 -84.38 108.7 17.35 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 175.756 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.493 HG21 HD11 ' A' ' 9' ' ' ILE . 0.3 OUTLIER -78.16 152.2 5.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.671 -177.79 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -90.5 11.63 21.19 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.019 -179.382 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.5 mtp85 -98.02 174.89 6.33 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.457 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.4 179.45 32.04 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.65 -179.376 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_exo -70.3 137.8 47.08 Favored 'Cis proline' 0 C--N 1.342 0.196 0 C-N-CA 123.124 -1.615 . . . . 0.0 112.527 0.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.439 ' C ' ' HD2' ' A' ' 15' ' ' ARG . . . 55.75 -145.31 32.98 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.087 -179.838 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.439 ' HD2' ' C ' ' A' ' 14' ' ' GLY . 9.5 mpt_? -117.99 128.16 54.52 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.53 -175.97 5.21 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.55 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.451 ' HB2' ' C ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -139.83 148.79 42.64 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.975 179.746 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 6' ' ' SER . 9.1 t -117.68 161.74 16.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.103 -179.661 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 80.9 m -118.33 112.57 20.21 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.249 179.576 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.45 ' N ' ' CD1' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -117.52 152.69 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-O 120.9 0.381 . . . . 0.0 111.431 -179.728 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.528 -1.151 . . . . 0.0 112.139 -179.737 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.645 0.259 . . . . 0.0 111.143 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.9 pt -131.02 146.11 34.44 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-O 121.152 0.501 . . . . 0.0 112.351 179.123 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 13.4 tpt180 -96.87 85.9 3.89 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 176.605 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.466 HD11 HG22 ' A' ' 9' ' ' ILE . 0.1 OUTLIER -77.31 144.5 11.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.827 -177.354 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 38.6 tt0 -96.52 7.01 47.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.187 0.518 . . . . 0.0 110.131 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -99.43 -177.03 3.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.536 179.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.84 -178.28 29.37 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.126 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -80.14 108.87 1.32 Allowed 'Cis proline' 0 C--N 1.345 0.352 0 C-N-CA 123.428 -1.488 . . . . 0.0 112.328 0.161 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.52 133.06 5.75 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.884 179.611 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -81.61 110.91 17.42 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.404 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -163.29 -168.86 1.81 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.267 0.556 . . . . 0.0 111.087 -179.238 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -97.79 128.19 44.26 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.758 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.5 t -109.13 162.69 6.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 178.876 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.2 m -104.22 160.1 15.15 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.561 0.696 . . . . 0.0 111.541 -179.48 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 9.1 mt -140.71 167.73 17.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.714 -179.557 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.324 -1.264 . . . . 0.0 112.846 179.924 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.3 m . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.642 0.258 . . . . 0.0 110.714 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.0 pt -130.96 149.37 33.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.5 ttp85 -91.95 92.03 8.13 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 176.112 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.431 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.32 145.07 10.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.135 0.493 . . . . 0.0 111.046 -177.034 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -91.92 11.84 23.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.053 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 10.1 mtp-105 -98.31 -168.02 1.59 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.628 -179.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.4 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -115.17 179.81 18.33 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.416 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -75.54 109.6 1.35 Allowed 'Cis proline' 0 C--N 1.344 0.336 0 C-N-CA 123.088 -1.63 . . . . 0.0 112.394 -0.023 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.4 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 82.29 133.32 1.77 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.227 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.444 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -77.97 116.61 18.59 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.786 0.327 . . . . 0.0 110.337 179.672 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.431 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -153.2 -172.22 4.17 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.289 0.566 . . . . 0.0 111.076 -179.343 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -96.55 120.85 37.63 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.062 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.7 m -109.63 148.27 13.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.169 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 65.0 m -113.58 131.46 56.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.128 0.49 . . . . 0.0 111.511 -179.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 pt -123.33 143.31 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 C-N-CA 123.83 0.852 . . . . 0.0 110.952 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.029 0 CA-C-O 118.11 -1.383 . . . . 0.0 113.511 179.306 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.5 m . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.691 0.282 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.9 pt -131.79 152.27 36.68 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.272 0 CA-C-O 121.257 0.551 . . . . 0.0 112.32 179.908 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.445 ' HD3' ' NH2' ' A' ' 15' ' ' ARG . 28.9 ttm105 -93.71 91.46 7.03 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 107.278 -1.378 . . . . 0.0 107.278 176.555 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.441 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.42 146.58 8.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.836 -177.717 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . 0.459 ' H ' ' CD ' ' A' ' 10' ' ' GLN . 0.1 OUTLIER -98.95 9.54 43.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.906 -179.805 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -99.7 -169.94 1.82 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.224 179.926 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.17 174.2 27.21 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.455 -0.879 . . . . 0.0 112.404 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -81.65 108.13 1.2 Allowed 'Cis proline' 0 C--N 1.345 0.388 0 C-N-CA 123.152 -1.603 . . . . 0.0 112.777 0.132 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.03 137.02 0.66 Allowed Glycine 0 C--N 1.332 0.358 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.788 179.61 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.544 ' C ' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -66.02 130.98 45.12 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.388 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.441 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -170.22 -174.74 1.79 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.136 0.493 . . . . 0.0 111.007 -179.44 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -103.39 121.18 42.26 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.61 179.825 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 m -108.96 156.98 9.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.778 178.825 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 75.6 m -118.48 148.28 42.76 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.08 0.467 . . . . 0.0 112.157 -178.658 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.424 ' N ' ' CD1' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -124.97 177.75 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.187 179.119 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.157 0 CA-C-O 118.814 -0.992 . . . . 0.0 113.567 -179.761 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.3 m . . . . . 0 N--CA 1.462 0.13 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 pt -130.99 148.13 33.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 -179.502 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 13.7 tpp180 -95.56 91.48 6.17 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 176.037 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -76.47 144.71 11.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.819 -177.237 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . 0.419 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 46.4 tt0 -88.66 11.64 16.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.826 -179.485 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.0 mtp-105 -96.59 -176.04 3.49 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.207 -179.23 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.475 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -107.73 -179.54 22.15 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.849 -179.412 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -73.4 107.28 0.87 Allowed 'Cis proline' 0 C--N 1.343 0.288 0 C-N-CA 123.282 -1.549 . . . . 0.0 112.387 0.172 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.475 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 74.35 141.89 0.71 Allowed Glycine 0 C--N 1.333 0.377 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.534 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.3 124.33 20.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.762 0.315 . . . . 0.0 110.625 179.501 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -147.33 -178.99 6.53 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.185 -179.665 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -108.69 122.12 46.46 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.452 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.9 t -109.27 158.78 9.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.341 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.7 m -107.04 154.75 20.66 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.414 0.626 . . . . 0.0 111.81 -179.717 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.8 mt -125.34 171.9 13.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 114.698 -1.137 . . . . 0.0 109.308 -179.475 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.158 0 CA-C-O 118.384 -1.231 . . . . 0.0 111.978 179.59 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.405 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 19.9 m . . . . . 0 C--O 1.233 0.185 0 CA-C-O 120.314 0.102 . . . . 0.0 110.785 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.5 pt -132.38 146.36 33.11 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.392 0 N-CA-C 113.74 1.015 . . . . 0.0 113.74 -179.794 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.448 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 35.2 ttm180 -88.65 96.12 10.52 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 176.265 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.455 HG22 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.11 141.33 15.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 120.415 -0.514 . . . . 0.0 109.851 -178.165 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.8 tt0 -93.67 11.01 30.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.49 -178.677 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 46.2 ptt85 -98.39 -169.9 1.87 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.159 179.714 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.466 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.23 176.82 29.49 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.497 -0.859 . . . . 0.0 112.764 -179.412 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -74.23 109.11 1.1 Allowed 'Cis proline' 0 C--N 1.347 0.453 0 C-N-CA 123.151 -1.604 . . . . 0.0 112.51 0.001 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.466 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 71.81 156.82 2.79 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.495 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.0 mpt_? -67.83 133.7 49.64 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 120.789 0.328 . . . . 0.0 110.695 179.445 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.425 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -168.31 -164.61 0.54 Allowed 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.954 -179.626 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.448 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -141.27 137.11 32.27 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.654 179.181 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.1 t -110.77 163.75 7.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.921 -179.362 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.8 m -108.91 131.59 54.88 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.811 0.815 . . . . 0.0 111.92 -179.895 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.2 mt -100.63 174.96 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 113.983 -1.462 . . . . 0.0 109.175 179.251 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.609 -1.106 . . . . 0.0 112.541 179.273 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.4 m . . . . . 0 C--O 1.232 0.167 0 CA-C-O 120.572 0.225 . . . . 0.0 110.619 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.0 pt -130.6 147.85 33.12 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.411 0 CA-C-O 121.112 0.482 . . . . 0.0 112.295 -179.878 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 75.7 ttt180 -89.64 100.26 13.1 Favored 'General case' 0 N--CA 1.445 -0.71 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 176.043 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -76.98 150.59 5.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-O 121.32 0.581 . . . . 0.0 111.854 -176.641 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 62.7 mt-30 -93.61 12.18 26.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.698 -179.811 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -98.1 177.05 5.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.967 -179.174 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.438 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -104.25 -178.88 25.17 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.629 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -74.08 108.4 1.0 Allowed 'Cis proline' 0 C--N 1.345 0.36 0 C-N-CA 123.278 -1.551 . . . . 0.0 112.254 0.02 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.438 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 74.31 148.53 1.49 Allowed Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.346 -179.814 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.474 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -59.79 145.71 44.34 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.823 0.344 . . . . 0.0 110.885 179.806 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -164.74 -177.19 4.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.928 0.394 . . . . 0.0 111.202 -179.565 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -117.22 123.52 46.83 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.287 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 m -113.2 155.92 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.026 178.619 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 42.9 m -99.86 159.46 15.06 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.153 0.502 . . . . 0.0 111.316 -179.633 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -142.09 154.5 18.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.179 -178.69 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.261 0 CA-C-O 118.424 -1.209 . . . . 0.0 113.729 178.696 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.435 ' HB3' ' O ' ' A' ' 18' ' ' VAL . 24.0 m . . . . . 0 N--CA 1.452 -0.347 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.8 pt -128.45 146.59 33.66 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.352 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -179.414 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.458 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 53.9 ttp180 -95.83 92.86 6.74 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 176.257 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -75.99 154.72 5.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.577 -177.379 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.0 pt20 -97.05 12.03 34.04 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.211 -179.363 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -97.44 -178.75 4.25 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.648 -179.345 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.02 -179.56 30.24 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.447 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -77.86 107.76 1.06 Allowed 'Cis proline' 0 C--N 1.346 0.418 0 C-N-CA 123.098 -1.626 . . . . 0.0 112.403 0.028 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.26 153.22 5.53 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.214 -179.865 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 40.1 mmt-85 -66.17 119.93 12.33 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.69 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.84 -179.13 6.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.157 0.504 . . . . 0.0 111.75 -179.458 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.458 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -114.23 125.77 54.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.995 -179.996 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.435 ' O ' ' HB3' ' A' ' 6' ' ' SER . 5.6 t -110.05 162.99 7.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.705 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.433 HG21 ' N ' ' A' ' 20' ' ' ILE . 53.7 m -107.03 158.23 17.2 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.937 -0.305 . . . . 0.0 111.751 -179.464 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.433 ' N ' HG21 ' A' ' 19' ' ' THR . 2.6 mm -99.93 157.29 3.95 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.258 179.68 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.314 -1.27 . . . . 0.0 112.352 179.804 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.45 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.7 m . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 . . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.409 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 4.9 pt -131.28 147.82 32.85 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 N-CA-C 113.701 1.0 . . . . 0.0 113.701 -178.874 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.481 ' N ' ' HD2' ' A' ' 8' ' ' ARG . 2.2 mpt_? -86.94 99.72 12.07 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 176.012 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.475 HG22 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.85 143.3 12.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 C-N-CA 120.3 -0.56 . . . . 0.0 110.922 -177.452 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.1 pp0? -85.77 11.89 10.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.342 -179.724 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 78.9 ttt180 -98.04 158.7 15.39 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.89 -179.64 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.73 -170.64 30.16 Favored Glycine 0 N--CA 1.452 -0.27 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.268 179.811 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -83.46 115.96 3.99 Favored 'Cis proline' 0 N--CA 1.462 -0.348 0 C-N-CA 123.091 -1.629 . . . . 0.0 112.592 0.084 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.26 117.43 3.93 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.539 179.747 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.464 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -59.45 121.17 10.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.099 0.476 . . . . 0.0 110.975 179.71 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.405 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -155.18 -168.93 3.01 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.419 -179.498 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.45 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -136.25 145.74 45.93 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.654 179.626 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.7 t -112.44 160.95 11.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.182 -179.711 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 52.0 m -119.93 112.99 19.88 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.132 179.814 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -110.59 -179.41 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.015 178.983 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.618 -1.101 . . . . 0.0 112.276 179.705 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.1 m . . . . . 0 N--CA 1.455 -0.219 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.8 pt -130.64 148.94 33.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 N-CA-C 112.729 0.641 . . . . 0.0 112.729 -179.127 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 57.3 ttp85 -94.8 94.22 7.94 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 175.994 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -76.47 153.92 5.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.125 0.488 . . . . 0.0 111.606 -176.569 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . 0.412 ' HA ' ' HD2' ' A' ' 15' ' ' ARG . 62.4 mt-30 -97.14 11.38 36.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.672 -0.695 . . . . 0.0 111.19 -179.523 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.96 159.44 14.93 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.823 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.92 -171.05 32.63 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.765 -179.091 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.76 113.81 2.85 Favored 'Cis proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.977 -1.676 . . . . 0.0 112.62 0.349 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.87 138.26 5.31 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.61 179.859 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.412 ' HD2' ' HA ' ' A' ' 10' ' ' GLN . 55.5 mmt-85 -74.86 125.41 28.76 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.416 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -151.84 -176.01 5.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.19 0.519 . . . . 0.0 112.006 -179.144 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -106.99 125.1 50.57 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.088 179.885 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 6.0 t -113.69 162.93 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 178.919 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 52.9 m -103.36 151.26 22.95 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.07 0.462 . . . . 0.0 111.439 -179.827 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 8.2 mt -109.0 164.01 5.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.283 -179.781 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.978 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.015 179.636 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 m . . . . . 0 CA--C 1.528 0.107 0 CA-C-O 120.527 0.203 . . . . 0.0 110.806 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.0 pt -131.13 150.12 34.15 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.346 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 179.347 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 17.4 ptt85 -97.14 93.9 6.83 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 176.327 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.453 HG22 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.04 144.26 11.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.799 -177.072 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 19.8 tt0 -91.88 7.02 43.95 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.984 0.421 . . . . 0.0 110.966 -179.232 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.405 ' NH2' HG23 ' A' ' 9' ' ' ILE . 15.5 ptt85 -99.14 178.56 4.88 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.701 179.492 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.41 -177.91 32.77 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.523 -179.524 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.46 108.52 1.14 Allowed 'Cis proline' 0 C--N 1.342 0.225 0 C-N-CA 123.405 -1.498 . . . . 0.0 112.561 0.237 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 128.34 0.91 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.936 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.461 ' C ' ' HD2' ' A' ' 15' ' ' ARG . 3.1 tmm_? -65.56 113.65 4.35 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.439 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.424 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -149.02 -169.58 3.41 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.517 0.675 . . . . 0.0 111.89 -179.239 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -107.49 128.18 54.27 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.058 -0.973 . . . . 0.0 111.113 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.4 m -117.44 153.7 19.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.094 178.738 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.3 m -94.08 158.71 15.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.476 0.655 . . . . 0.0 111.861 -179.048 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 3.1 mt -141.31 160.62 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-N 114.735 -1.121 . . . . 0.0 109.552 -179.447 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.996 0 CA-C-O 118.365 -1.241 . . . . 0.0 112.448 179.403 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.437 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 9.5 m . . . . . 0 N--CA 1.455 -0.177 0 CA-C-O 120.625 0.25 . . . . 0.0 111.421 . . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.415 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 1.5 pt -132.12 148.3 32.14 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -179.809 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.422 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 28.3 ptt-85 -80.92 104.45 11.43 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 176.114 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.439 HG21 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.63 158.77 5.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 C-N-CA 120.039 -0.664 . . . . 0.0 110.622 -177.736 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -99.68 12.31 36.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.819 -178.988 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.406 HH11 ' HD3' ' A' ' 11' ' ' ARG . 49.2 mtt180 -97.61 161.86 13.57 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.805 0.336 . . . . 0.0 110.76 -179.738 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.79 -175.37 30.83 Favored Glycine 0 N--CA 1.452 -0.267 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.564 -179.69 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.62 119.43 6.3 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.978 -1.676 . . . . 0.0 112.412 -0.167 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.77 144.63 6.1 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.186 -179.772 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.5 mpt_? -77.44 117.2 18.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.041 0.448 . . . . 0.0 111.05 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -136.52 -173.03 3.3 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.823 179.639 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.415 ' HB2' ' C ' ' A' ' 7' ' ' ILE . 0.4 OUTLIER -130.7 143.62 50.87 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.048 0.451 . . . . 0.0 110.956 179.608 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 6' ' ' SER . 25.8 m -112.43 163.81 9.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.991 -179.542 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.4 m -120.3 123.72 43.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.297 -179.739 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.458 ' N ' ' CD1' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -114.59 157.05 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 C-N-CA 123.031 0.532 . . . . 0.0 110.798 179.275 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.201 -1.333 . . . . 0.0 112.177 179.933 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.529 0.171 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 . . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.1 pt -130.59 151.77 36.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.437 0 CA-C-O 121.312 0.577 . . . . 0.0 112.356 179.932 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.465 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 4.7 ptm85 -96.61 99.29 10.93 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 176.282 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -77.79 156.56 5.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.242 0.544 . . . . 0.0 111.955 -176.744 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -94.77 12.56 27.52 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.073 179.075 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.2 ttt180 -97.03 -168.32 1.68 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.71 -179.335 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.483 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -107.45 176.43 20.9 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.442 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -73.02 108.71 0.97 Allowed 'Cis proline' 0 CA--C 1.53 0.288 0 C-N-CA 123.311 -1.537 . . . . 0.0 112.369 0.038 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.483 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 65.57 173.61 4.46 Favored Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.673 -179.937 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.445 HH21 ' NE ' ' A' ' 8' ' ' ARG . 16.1 tpt180 -69.33 115.14 8.25 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.766 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.04 -177.94 5.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.172 0.51 . . . . 0.0 111.52 -179.26 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.465 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -115.44 132.02 56.75 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.053 179.887 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.1 m -121.98 161.63 22.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.74 -0.663 . . . . 0.0 109.819 178.838 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 41.5 m -96.7 155.67 16.67 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.015 0.436 . . . . 0.0 111.06 -179.631 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 20.7 mt -121.27 165.52 16.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.458 179.584 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.086 0 CA-C-O 118.202 -1.332 . . . . 0.0 111.982 179.917 . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 m . . . . . 0 C--O 1.231 0.125 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.7 pt -131.15 145.96 34.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 113.551 0.945 . . . . 0.0 113.551 -179.411 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.421 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 76.7 mtp180 -82.31 92.67 7.0 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 176.431 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.458 HG12 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.71 148.49 6.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.043 0.449 . . . . 0.0 110.92 -177.524 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -101.15 9.7 41.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.16 0.505 . . . . 0.0 109.884 179.05 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 64.5 mtp180 -99.86 -168.8 1.65 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.754 -179.269 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.7 -176.4 19.67 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 121.197 -0.525 . . . . 0.0 112.047 179.803 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -83.01 113.51 2.95 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.487 -1.464 . . . . 0.0 112.357 -0.075 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.11 128.31 6.03 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.219 -179.836 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 13.9 mmt180 -70.95 96.93 1.35 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.856 0.36 . . . . 0.0 110.728 -179.881 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.458 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -155.27 179.31 9.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.351 -179.842 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.421 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -103.79 147.35 27.38 Favored 'General case' 0 C--N 1.325 -0.5 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.646 179.851 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 31.3 m -119.18 165.52 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.136 -179.809 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 94.0 m -98.48 153.6 18.49 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.116 0.484 . . . . 0.0 111.03 179.835 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.8 mt -114.24 163.78 11.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.328 -179.237 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.208 -1.329 . . . . 0.0 112.001 179.827 . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.6 m . . . . . 0 N--CA 1.453 -0.314 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 . . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.0 pt -131.48 146.72 33.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -178.269 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.402 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -92.26 93.07 8.47 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 176.175 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -75.31 148.15 7.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.02 0.438 . . . . 0.0 111.026 -176.697 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 69.9 mt-30 -100.16 11.83 38.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.028 -179.384 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -97.78 -169.3 1.81 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.493 -0.322 . . . . 0.0 110.187 -179.864 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.14 -177.17 19.16 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.429 179.772 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -79.55 104.98 0.64 Allowed 'Cis proline' 0 C--N 1.344 0.314 0 C-N-CA 123.485 -1.465 . . . . 0.0 112.143 -0.117 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.49 145.46 13.76 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.97 179.883 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 26.3 mtt180 -78.11 137.29 38.13 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 110.523 -0.177 . . . . 0.0 110.523 179.813 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -168.53 -173.73 2.01 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-O 121.22 0.533 . . . . 0.0 111.227 -179.782 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.402 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -111.97 120.59 42.41 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.359 179.504 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.1 t -110.03 160.5 9.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.313 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 46.2 m -98.51 158.8 15.37 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.889 0.376 . . . . 0.0 110.158 179.356 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.1 mt -119.33 161.58 18.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.527 179.76 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.135 0 CA-C-O 118.455 -1.192 . . . . 0.0 112.22 179.958 . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.48 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 12.3 m . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.534 0.207 . . . . 0.0 111.216 . . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.9 pt -132.64 149.52 32.17 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.343 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -179.956 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.453 ' H ' ' HD3' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -90.1 105.45 17.82 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 175.514 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.516 HD11 HG22 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -78.57 156.52 4.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 C-N-CA 120.501 -0.479 . . . . 0.0 111.281 -177.436 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . 0.512 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 10.2 mp0 -94.72 10.28 35.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.48 179.904 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -99.67 179.59 4.49 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.858 -179.808 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.15 -176.61 30.41 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.186 179.859 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -76.57 107.68 1.01 Allowed 'Cis proline' 0 N--CA 1.464 -0.242 0 C-N-CA 123.246 -1.564 . . . . 0.0 112.521 0.052 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.21 151.54 7.23 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.835 179.674 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 16.5 mmm180 -60.13 109.97 1.1 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.71 0.29 . . . . 0.0 110.64 179.417 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.06 -177.07 4.93 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.439 -179.937 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.48 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -135.46 146.03 47.78 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.478 179.447 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.0 t -112.99 160.66 12.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.168 -179.495 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.408 ' CB ' ' HG ' ' A' ' 6' ' ' SER . 83.9 m -126.88 114.83 18.4 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.449 179.633 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.407 ' CD1' ' N ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -112.47 161.99 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.762 179.729 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.281 -1.289 . . . . 0.0 112.32 -179.996 . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 16.0 m . . . . . 0 N--CA 1.452 -0.332 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 . . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.4 pt -124.07 150.72 28.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 113.237 0.829 . . . . 0.0 113.237 -178.203 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.434 ' HD2' ' O ' ' A' ' 16' ' ' ALA . 14.6 tpt180 -92.22 94.37 9.15 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 176.197 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.422 HD11 HG22 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -76.28 148.53 7.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.912 -177.084 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 33.5 mt-30 -97.4 11.51 36.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.188 -179.569 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -98.34 -174.9 2.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.116 179.827 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.427 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.94 175.7 27.7 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.569 -179.763 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -76.46 109.46 1.36 Allowed 'Cis proline' 0 C--N 1.346 0.411 0 C-N-CA 123.247 -1.564 . . . . 0.0 112.438 -0.02 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.427 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 69.52 168.1 5.99 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.292 -179.743 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.439 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 4.8 mpt_? -80.11 134.27 36.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 110.547 179.662 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.434 ' O ' ' HD2' ' A' ' 8' ' ' ARG . . . -160.95 178.95 8.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.0 -179.751 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -109.85 124.08 50.71 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.917 179.739 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 m -114.28 140.01 37.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.399 179.117 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.7 m -101.48 142.15 33.29 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.857 -179.598 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.475 ' N ' ' CD1' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -112.36 161.14 11.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.986 179.788 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.287 -1.285 . . . . 0.0 112.029 179.985 . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.477 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 14.8 m . . . . . 0 N--CA 1.454 -0.232 0 CA-C-O 120.566 0.222 . . . . 0.0 110.937 . . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.43 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 2.2 pt -131.9 147.58 32.39 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -179.52 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.533 ' HB3' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -85.74 100.59 12.12 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 176.155 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.54 158.16 4.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.561 -0.456 . . . . 0.0 110.777 -177.815 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . 0.425 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 13.1 mp0 -100.89 10.17 41.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.86 0.362 . . . . 0.0 110.463 179.249 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 74.2 ttt180 -99.02 165.0 11.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.519 -179.527 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.82 -175.13 33.65 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.205 -179.976 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -74.81 115.83 3.64 Favored 'Cis proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.132 -1.612 . . . . 0.0 112.553 0.314 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.67 124.14 1.01 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.974 -0.632 . . . . 0.0 112.481 179.765 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.3 mtt85 -61.58 98.84 0.1 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.848 0.356 . . . . 0.0 110.418 179.656 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -131.0 -178.91 5.03 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.582 -179.636 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.442 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.3 OUTLIER -117.38 145.28 44.18 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.593 179.765 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.6 t -114.81 161.19 13.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.256 -179.475 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 86.9 m -120.69 109.06 14.75 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.081 179.568 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -104.44 171.37 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 CA-C-O 120.816 0.341 . . . . 0.0 111.387 -179.813 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.464 -1.187 . . . . 0.0 112.544 179.714 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 25.1 ttp-105 . . . . . 0 N--CA 1.488 1.426 0 N-CA-C 110.462 -0.199 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 62.0 tttp -147.66 152.57 38.08 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.123 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 88.2 p -142.35 156.79 45.26 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.168 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.8 pt -132.01 147.61 32.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 112.113 0.412 . . . . 0.0 112.113 179.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.483 ' O ' ' CD ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -91.19 91.6 8.3 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 176.118 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.408 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.59 150.51 6.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.613 -176.776 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 22.5 mp0 -89.0 12.52 15.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.621 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -96.88 177.94 5.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.32 -179.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.48 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.97 178.2 29.4 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.966 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -73.37 108.26 0.95 Allowed 'Cis proline' 0 C--N 1.344 0.326 0 C-N-CA 123.337 -1.526 . . . . 0.0 112.279 0.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.48 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 67.41 156.36 0.62 Allowed Glycine 0 C--N 1.333 0.391 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.422 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -60.27 126.04 25.96 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.766 0.317 . . . . 0.0 110.502 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.408 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -149.18 177.84 9.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.887 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.4 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -109.67 120.09 41.4 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.674 179.553 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.1 m -109.27 152.8 11.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.759 178.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.6 m -89.44 156.37 18.71 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.957 0.408 . . . . 0.0 111.24 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 8.3 mt -120.63 163.06 18.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.022 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.503 -1.165 . . . . 0.0 112.075 179.978 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 . . . . . 0 N--CA 1.485 1.289 0 N-CA-C 110.518 -0.178 . . . . 0.0 110.518 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.616 ' HD3' ' N ' ' A' ' 6' ' ' SER . 2.2 tmtp? -138.33 149.91 46.08 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.616 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 14.7 m -140.5 140.76 35.34 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.849 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.473 ' O ' ' HB2' ' A' ' 17' ' ' PHE . 1.6 pt -131.43 146.05 34.26 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.567 0 N-CA-C 113.696 0.998 . . . . 0.0 113.696 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -78.8 102.24 8.04 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 176.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 16' ' ' ALA . 1.8 pt -77.54 151.28 5.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.657 -177.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -100.95 10.49 41.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.464 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 36.0 ptt180 -109.25 -178.31 3.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.827 0.346 . . . . 0.0 111.017 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.54 -172.64 30.78 Favored Glycine 0 C--N 1.329 0.187 0 C-N-CA 121.108 -0.568 . . . . 0.0 112.308 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.98 117.66 5.33 Favored 'Cis proline' 0 N--CA 1.462 -0.349 0 C-N-CA 123.34 -1.525 . . . . 0.0 112.407 0.143 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 145.64 4.73 Favored Glycine 0 C--N 1.33 0.221 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.293 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.493 ' C ' ' HD2' ' A' ' 15' ' ' ARG . 4.8 ppt_? -66.72 128.8 37.66 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.427 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -169.52 -166.47 0.6 Allowed 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 121.199 0.523 . . . . 0.0 110.593 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.507 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.1 OUTLIER -137.62 152.57 49.5 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.367 179.572 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.5 m -115.75 154.9 17.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.972 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 86.3 m -113.74 110.71 20.61 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.359 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.493 HG13 ' HB3' ' A' ' 5' ' ' LYS . 7.8 pt -100.22 173.06 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.674 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.711 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.242 -1.31 . . . . 0.0 112.287 179.744 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 86.4 mtm180 . . . . . 0 N--CA 1.485 1.298 0 CA-C-O 120.56 0.219 . . . . 0.0 110.789 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.537 ' HD3' ' N ' ' A' ' 6' ' ' SER . 5.3 tmtm? -100.03 147.19 25.89 Favored 'General case' 0 C--O 1.223 -0.34 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.537 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 50.6 m -140.67 154.61 46.46 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.236 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.8 pt -130.95 152.04 36.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.318 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -179.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.484 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 22.8 ttm180 -94.97 104.32 16.2 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 175.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -77.37 144.29 11.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 C-N-CA 119.845 -0.742 . . . . 0.0 110.791 -177.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.1 tp-100 -93.88 12.46 25.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.426 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.3 mtt-85 -97.47 173.46 7.16 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.332 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.74 -179.83 30.52 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.1 108.63 1.14 Allowed 'Cis proline' 0 C--N 1.345 0.381 0 C-N-CA 123.34 -1.525 . . . . 0.0 112.256 0.039 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.54 152.18 3.48 Favored Glycine 0 C--N 1.332 0.335 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.467 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.462 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -62.34 152.64 33.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.875 0.369 . . . . 0.0 111.096 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -170.17 178.54 3.81 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.998 0.428 . . . . 0.0 111.152 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.484 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.6 OUTLIER -120.56 129.7 53.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.0 179.718 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 6.2 t -120.85 159.92 22.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.8 m -102.77 156.11 17.86 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.204 0.526 . . . . 0.0 111.316 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 8.7 mt -118.1 164.73 14.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.177 -0.92 . . . . 0.0 109.816 -179.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.999 0 CA-C-O 118.416 -1.214 . . . . 0.0 111.977 179.789 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 . . . . . 0 N--CA 1.484 1.262 0 CA-C-O 120.632 0.253 . . . . 0.0 110.799 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.471 ' HD2' ' H ' ' A' ' 6' ' ' SER . 0.0 OUTLIER -141.85 147.97 38.06 Favored 'General case' 0 C--O 1.211 -0.959 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.577 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.471 ' H ' ' HD2' ' A' ' 5' ' ' LYS . 17.4 m -141.07 151.66 44.18 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 118.762 0.71 . . . . 0.0 110.588 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.438 ' O ' ' HB2' ' A' ' 17' ' ' PHE . 2.9 pt -132.42 146.04 33.59 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.501 0 N-CA-C 113.933 1.086 . . . . 0.0 113.933 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.489 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 48.7 mtt85 -86.9 108.92 19.0 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 175.249 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.438 HG12 ' O ' ' A' ' 16' ' ' ALA . 1.3 pt -77.76 157.66 5.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.714 -177.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -100.57 11.0 40.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.598 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 5.3 ttm180 -98.95 -170.13 1.88 Allowed 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -108.95 179.35 21.13 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.155 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.56 112.42 2.34 Favored 'Cis proline' 0 C--N 1.344 0.297 0 C-N-CA 122.971 -1.679 . . . . 0.0 112.44 0.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.5 155.4 6.13 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.353 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.2 ttp85 -62.28 88.22 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.222 0.534 . . . . 0.0 110.293 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.438 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -101.58 -170.81 1.88 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.883 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.489 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -148.74 149.98 32.34 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.38 179.574 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.4 t -121.92 162.23 21.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.72 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 89.6 m -111.01 126.95 55.34 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.761 0.791 . . . . 0.0 112.05 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.5 mt -103.22 156.49 5.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.901 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.49 -1.172 . . . . 0.0 113.043 179.037 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.486 1.355 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.544 ' HD3' ' N ' ' A' ' 6' ' ' SER . 5.7 tmtm? -124.44 139.6 53.74 Favored 'General case' 0 C--O 1.222 -0.372 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.544 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 16.4 m -142.53 151.3 41.47 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.048 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.407 ' HA ' HH21 ' A' ' 8' ' ' ARG . 3.4 pt -132.0 148.67 32.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -179.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.564 ' HE ' ' N ' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -88.14 102.64 14.98 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 175.586 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.448 HG22 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.48 142.23 14.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 120.154 -0.618 . . . . 0.0 110.751 -177.379 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.65 11.47 24.28 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.805 -178.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -98.28 175.28 6.12 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.734 0.302 . . . . 0.0 110.646 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.49 -177.04 31.34 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.272 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 81.0 Cg_endo -78.87 110.4 1.84 Allowed 'Cis proline' 0 C--N 1.343 0.284 0 C-N-CA 123.062 -1.641 . . . . 0.0 112.796 0.181 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.06 141.57 4.93 Favored Glycine 0 C--N 1.331 0.299 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.663 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.462 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -60.14 142.47 54.22 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.956 0.407 . . . . 0.0 111.156 179.83 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.41 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -170.28 -168.12 0.69 Allowed 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.113 0.483 . . . . 0.0 110.624 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.428 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -144.56 145.48 31.84 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.486 179.12 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 t -125.61 162.32 28.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.243 -179.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 98.0 m -100.39 152.27 20.54 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.042 0.449 . . . . 0.0 110.8 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.0 mt -114.47 163.86 11.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.573 -179.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.527 -1.151 . . . . 0.0 112.002 179.889 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 33.3 ttt180 . . . . . 0 N--CA 1.486 1.337 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.9 tttp -58.79 147.7 32.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.962 0.41 . . . . 0.0 111.677 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 64.9 m -142.94 150.86 40.3 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.55 178.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.6 pt -131.41 148.44 32.72 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.36 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 -179.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 65.4 mtt85 -85.06 99.06 10.78 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 176.063 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.431 HD11 HG22 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.59 151.63 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.846 0.355 . . . . 0.0 111.18 -177.23 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -95.09 8.41 43.07 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.392 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 16.4 ptp180 -99.72 -175.89 3.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.458 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.34 -177.73 31.48 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.392 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.79 114.2 3.09 Favored 'Cis proline' 0 C--N 1.343 0.279 0 C-N-CA 123.381 -1.508 . . . . 0.0 112.532 0.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.59 161.81 8.6 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.5 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.407 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 1.0 OUTLIER -78.35 122.9 26.37 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.148 0.499 . . . . 0.0 111.043 179.734 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.411 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -160.48 -165.16 1.37 Allowed 'General case' 0 CA--C 1.512 -0.495 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.614 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -135.28 143.96 46.53 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.102 0.477 . . . . 0.0 110.707 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 31.1 m -118.49 168.42 10.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.678 -179.294 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.6 m -96.4 152.22 18.81 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 120.979 0.419 . . . . 0.0 111.071 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 9.5 mt -107.85 163.71 5.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.376 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.12 0 CA-C-O 118.117 -1.379 . . . . 0.0 111.827 179.871 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.438 ' HE ' HG21 ' A' ' 19' ' ' THR . 17.8 tpt180 . . . . . 0 N--CA 1.486 1.371 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.527 ' HD3' ' H ' ' A' ' 6' ' ' SER . 5.3 tmtt? -127.19 143.62 51.22 Favored 'General case' 0 C--O 1.218 -0.559 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.527 ' H ' ' HD3' ' A' ' 5' ' ' LYS . 15.9 m -141.59 142.4 33.47 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.01 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.433 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 2.4 pt -132.3 146.68 32.67 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.504 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.452 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 45.9 mtp85 -84.46 103.46 13.63 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.438 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.3 OUTLIER -78.01 153.83 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.188 -177.299 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.514 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 13.3 mp0 -92.61 13.21 20.61 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.241 -179.167 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 49.5 mtp85 -97.3 -176.06 3.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.921 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.76 177.35 30.42 Favored Glycine 0 C--N 1.332 0.323 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.409 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.96 135.9 38.66 Favored 'Cis proline' 0 C--N 1.344 0.317 0 C-N-CA 122.987 -1.672 . . . . 0.0 112.697 0.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 59.68 -104.34 0.55 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.112 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 8.0 ttp180 -160.07 134.11 7.31 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.438 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -159.79 -167.96 2.13 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.599 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.452 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -137.02 148.71 47.01 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.5 179.455 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.4 t -121.52 164.05 18.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.29 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.438 HG21 ' HE ' ' A' ' 4' ' ' ARG . 91.7 m -113.55 140.49 48.11 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.981 0.42 . . . . 0.0 111.238 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.462 ' N ' ' CD1' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -124.98 156.6 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.724 179.705 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.263 -1.299 . . . . 0.0 112.372 179.792 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 72.7 mtt85 . . . . . 0 N--CA 1.485 1.284 0 CA-C-O 120.581 0.229 . . . . 0.0 110.538 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 50.6 mtpt -128.69 154.14 46.61 Favored 'General case' 0 C--O 1.214 -0.778 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.4 m -143.93 142.95 31.03 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 178.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.404 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 8.5 pt -131.85 147.35 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 113.564 0.95 . . . . 0.0 113.564 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.576 ' H ' ' HD2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -85.02 101.91 12.78 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 106.325 -1.731 . . . . 0.0 106.325 175.235 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.434 HD11 HG22 ' A' ' 9' ' ' ILE . 0.1 OUTLIER -76.25 150.05 6.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.911 -176.404 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.439 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 17.7 mp0 -94.11 9.47 37.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.998 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 10.6 ptp180 -99.09 -173.62 2.54 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.908 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.35 -176.1 31.47 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.423 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -80.7 108.98 1.36 Allowed 'Cis proline' 0 CA--C 1.531 0.334 0 C-N-CA 122.886 -1.714 . . . . 0.0 112.597 0.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.23 169.77 38.0 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.682 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -71.36 123.79 23.1 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.742 0.306 . . . . 0.0 110.952 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.411 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -160.96 -169.32 2.33 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.243 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.434 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -145.36 141.15 28.23 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.942 178.994 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.5 t -115.5 163.95 12.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.398 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 92.6 m -100.07 158.37 15.89 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.292 0.567 . . . . 0.0 110.786 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -140.99 153.67 20.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.918 -178.762 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.443 -1.198 . . . . 0.0 112.153 179.688 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 120.616 0.246 . . . . 0.0 110.649 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' ILE . 1.7 mmmt -139.73 147.78 41.37 Favored 'General case' 0 C--O 1.219 -0.551 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.516 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.498 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.4 m -141.63 135.67 30.21 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.785 179.568 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 2.8 pt -132.48 147.85 31.91 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -86.67 102.93 14.66 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 175.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.455 HG21 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.78 153.63 5.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.859 -177.451 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 -99.02 10.96 40.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.363 -179.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -98.69 -177.03 3.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.751 0.31 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -108.76 -176.24 21.68 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.245 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -77.37 114.59 3.28 Favored 'Cis proline' 0 C--N 1.343 0.245 0 C-N-CA 122.93 -1.696 . . . . 0.0 112.337 -0.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.91 147.35 6.92 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.109 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.9 mpt_? -77.56 127.01 31.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.996 0.426 . . . . 0.0 110.877 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.406 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -156.19 -169.0 2.91 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.888 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.498 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -133.88 142.18 47.68 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.977 0.418 . . . . 0.0 110.948 179.521 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.8 t -110.58 162.73 7.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.053 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 78.8 m -124.91 114.18 18.83 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.83 0.348 . . . . 0.0 111.379 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.429 ' N ' ' O ' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -100.42 179.65 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.774 178.893 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.739 -1.034 . . . . 0.0 113.103 -179.867 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 25.9 ptt180 . . . . . 0 N--CA 1.484 1.254 0 N-CA-C 110.543 -0.169 . . . . 0.0 110.543 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 tmmm? -156.12 153.69 29.73 Favored 'General case' 0 C--O 1.221 -0.419 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.3 m -142.96 156.71 44.92 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 120.868 -0.333 . . . . 0.0 111.084 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.409 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 3.4 pt -131.28 145.96 34.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 113.742 1.016 . . . . 0.0 113.742 -179.311 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.3 mtt-85 -83.56 95.64 8.38 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 176.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.443 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.1 OUTLIER -76.37 142.94 13.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.102 0.477 . . . . 0.0 111.19 -176.933 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 58.7 mm-40 -92.66 11.43 26.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.453 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -98.03 173.25 7.14 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.25 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.7 -175.46 30.95 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.723 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -80.65 119.66 6.6 Favored 'Cis proline' 0 C--N 1.347 0.453 0 C-N-CA 123.326 -1.531 . . . . 0.0 112.34 -0.066 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.67 166.61 41.65 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.548 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.42 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 1.7 mpt_? -89.18 134.99 33.81 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.736 0.303 . . . . 0.0 110.593 179.546 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.443 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -168.85 -166.63 0.67 Allowed 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.141 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.409 ' HB2' ' C ' ' A' ' 7' ' ' ILE . 0.4 OUTLIER -141.75 139.88 32.94 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.923 178.681 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 26.8 m -112.39 166.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.899 -179.258 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 83.3 m -98.89 156.48 16.87 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.171 0.51 . . . . 0.0 111.594 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 8.5 mt -120.21 167.17 13.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.195 -0.912 . . . . 0.0 109.945 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.911 0 CA-C-O 118.281 -1.288 . . . . 0.0 112.017 179.756 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 38.4 ptt180 . . . . . 0 N--CA 1.484 1.23 0 CA-C-O 120.637 0.256 . . . . 0.0 110.979 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 64.1 tttp -140.1 164.47 29.95 Favored 'General case' 0 C--O 1.217 -0.637 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.1 m -141.46 149.45 40.99 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.889 0.313 . . . . 0.0 110.568 178.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.6 pt -130.33 150.41 34.58 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.314 0 CA-C-O 121.022 0.439 . . . . 0.0 112.005 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.425 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 12.3 ptm180 -95.67 90.98 5.89 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 176.47 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.438 HD11 HG22 ' A' ' 9' ' ' ILE . 0.1 OUTLIER -76.92 144.35 11.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.131 -177.122 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -97.87 9.95 41.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.811 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.541 ' HD2' ' N ' ' A' ' 11' ' ' ARG . 2.1 mpt_? -101.84 -179.49 4.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.241 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -102.45 -178.86 27.23 Favored Glycine 0 CA--C 1.516 0.156 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.272 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.47 114.4 3.33 Favored 'Cis proline' 0 C--N 1.346 0.409 0 C-N-CA 123.538 -1.442 . . . . 0.0 111.985 0.055 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 87.5 147.38 12.36 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.394 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 20.2 mmt85 -99.96 122.22 42.54 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -169.76 -173.86 1.71 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.136 0.494 . . . . 0.0 110.991 -179.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.0 120.85 34.82 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.547 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.2 t -109.65 162.04 7.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.44 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 97.0 m -100.66 158.83 15.65 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.389 0.614 . . . . 0.0 111.802 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.2 mt -129.0 165.61 28.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.273 -179.309 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.192 179.139 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 22.7 mmt85 . . . . . 0 N--CA 1.485 1.305 0 CA-C-O 120.838 0.352 . . . . 0.0 111.448 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.618 ' HD3' ' N ' ' A' ' 6' ' ' SER . 7.5 tmtm? -120.53 151.07 39.88 Favored 'General case' 0 C--O 1.222 -0.395 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.618 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 39.3 m -137.01 141.28 42.52 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.055 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.0 pt -130.46 152.83 38.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.147 -179.571 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.457 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 32.9 ptt180 -95.79 93.36 7.03 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 176.407 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.455 HD11 HG22 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -76.3 148.02 7.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.06 0.457 . . . . 0.0 111.395 -176.872 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.539 HE21 HH21 ' A' ' 15' ' ' ARG . 0.4 OUTLIER -89.85 11.27 20.74 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.805 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 65.2 mtt85 -98.35 -173.54 2.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.352 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.44 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.79 178.19 29.63 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.68 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -75.39 108.06 1.01 Allowed 'Cis proline' 0 C--N 1.344 0.33 0 C-N-CA 123.449 -1.479 . . . . 0.0 112.268 -0.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.44 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 68.97 160.37 2.08 Favored Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.572 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.539 HH21 HE21 ' A' ' 10' ' ' GLN . 16.3 tpp85 -64.42 118.1 8.26 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.576 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -151.32 -178.55 6.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.249 0.547 . . . . 0.0 111.622 -179.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.457 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -111.01 130.0 55.73 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.44 179.567 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.5 m -119.11 142.34 34.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.705 179.206 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 68.1 m -100.11 115.28 29.43 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.479 -179.317 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.481 HG13 ' HB3' ' A' ' 5' ' ' LYS . 7.5 pt -102.19 148.25 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.781 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.187 179.02 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.623 -1.098 . . . . 0.0 112.314 -179.82 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 . . . . . 0 N--CA 1.486 1.327 0 N-CA-C 110.64 -0.133 . . . . 0.0 110.64 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.5 tttp -127.61 151.02 49.45 Favored 'General case' 0 C--O 1.216 -0.681 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.8 m -142.85 152.09 41.78 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 178.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.406 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 6.2 pt -131.45 145.07 35.78 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.561 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.465 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 14.4 ptt85 -90.43 98.44 11.78 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 175.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.422 HG21 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -78.17 147.04 7.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.963 0.411 . . . . 0.0 111.485 -176.853 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 21.8 mp0 -94.15 9.48 37.68 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.46 -179.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.3 ptt180 -99.21 -177.75 3.71 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.736 0.303 . . . . 0.0 110.744 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.15 -176.33 30.39 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.466 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -79.08 106.91 0.94 Allowed 'Cis proline' 0 C--N 1.345 0.361 0 C-N-CA 122.958 -1.684 . . . . 0.0 112.779 -0.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.24 148.28 10.12 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.402 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 18.3 mmt85 -65.71 131.79 47.2 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.688 0.28 . . . . 0.0 110.829 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -167.6 -173.45 2.19 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.033 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.465 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -136.36 138.65 41.84 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.38 179.301 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 t -110.28 162.5 7.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.252 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 99.1 m -104.62 152.37 22.53 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.487 0.66 . . . . 0.0 111.063 179.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.9 mt -114.9 166.79 8.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.776 -179.113 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.111 0 CA-C-O 118.458 -1.19 . . . . 0.0 112.305 179.722 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 44.1 mtt85 . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 120.615 0.245 . . . . 0.0 110.513 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.457 ' HB3' HG13 ' A' ' 20' ' ' ILE . 61.5 tttm -146.62 154.81 41.92 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 179.63 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.476 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 13.2 m -142.19 136.8 30.31 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.244 179.533 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.8 pt -132.35 148.23 31.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.369 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 82.3 mtm180 -87.08 98.53 11.34 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 175.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.42 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.71 141.96 14.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 120.231 -0.587 . . . . 0.0 110.731 -177.539 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -93.21 12.34 24.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.732 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 37.8 ptt180 -98.53 -175.7 3.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.395 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.79 177.98 29.5 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.496 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -78.99 109.34 1.44 Allowed 'Cis proline' 0 C--N 1.345 0.381 0 C-N-CA 123.223 -1.574 . . . . 0.0 112.506 0.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.12 157.84 21.47 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.723 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -74.08 135.32 42.97 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.586 0.232 . . . . 0.0 110.414 179.552 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.42 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -170.42 -168.13 0.68 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.052 0.453 . . . . 0.0 110.536 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.476 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.1 OUTLIER -139.02 145.48 39.68 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.26 179.129 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 t -119.53 161.46 18.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.455 -178.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 90.3 m -117.87 113.45 21.78 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.558 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.457 HG13 ' HB3' ' A' ' 5' ' ' LYS . 34.1 pt -102.24 163.36 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 C-N-CA 122.938 0.495 . . . . 0.0 111.606 -179.745 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.181 0 CA-C-O 117.986 -1.452 . . . . 0.0 113.359 178.791 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.7 tpt180 . . . . . 0 N--CA 1.483 1.224 0 CA-C-O 120.583 0.23 . . . . 0.0 110.561 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.571 ' HD3' ' N ' ' A' ' 6' ' ' SER . 6.0 tmtm? -119.92 142.83 48.37 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.571 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 14.2 m -140.39 136.89 33.56 Favored 'General case' 0 C--N 1.318 -0.786 0 C-N-CA 121.167 -0.213 . . . . 0.0 110.652 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.2 pt -130.9 150.44 34.61 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.437 ' H ' ' HD3' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -89.11 99.82 12.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 176.382 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.433 HG22 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -78.7 144.12 11.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.506 -0.478 . . . . 0.0 111.446 -177.542 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 44.9 mt-30 -83.57 11.5 7.05 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.837 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -98.52 -175.07 2.98 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.352 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -102.18 -178.12 27.65 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.288 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.66 107.62 1.0 Allowed 'Cis proline' 0 C--N 1.343 0.265 0 C-N-CA 123.103 -1.624 . . . . 0.0 112.412 0.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.99 155.33 6.55 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.385 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.404 ' H ' ' NE ' ' A' ' 15' ' ' ARG . 0.1 OUTLIER -62.31 111.41 1.98 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.911 0.386 . . . . 0.0 110.723 179.762 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.418 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -144.13 -172.76 3.84 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 115.806 -0.633 . . . . 0.0 109.95 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.486 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -136.17 142.69 44.18 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.526 179.278 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.0 t -111.64 161.26 10.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.26 -179.262 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 71.8 m -118.32 111.0 18.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.579 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.405 ' CD1' ' N ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -109.02 178.28 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.931 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.758 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.438 -1.201 . . . . 0.0 112.165 179.69 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 28.1 ptt180 . . . . . 0 N--CA 1.484 1.229 0 CA-C-O 120.392 0.139 . . . . 0.0 110.819 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -86.49 147.16 26.1 Favored 'General case' 0 C--O 1.219 -0.544 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.928 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.4 m -143.0 145.05 32.57 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.483 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 pt -130.98 149.79 33.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -179.014 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.418 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 7.4 ptm180 -93.32 92.3 7.62 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 176.024 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.441 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.57 147.26 7.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.39 -176.63 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -95.17 11.12 33.41 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.25 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -98.26 -174.72 2.91 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.454 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -100.24 177.74 28.81 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.485 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.98 108.69 1.08 Allowed 'Cis proline' 0 C--N 1.344 0.31 0 C-N-CA 123.096 -1.626 . . . . 0.0 112.264 -0.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.454 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 72.47 150.67 1.19 Allowed Glycine 0 C--N 1.333 0.363 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.347 -179.601 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.408 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 1.3 mpt_? -73.34 133.26 43.79 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.344 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.441 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -164.88 -175.29 3.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.19 0.519 . . . . 0.0 111.31 -179.695 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.418 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -106.74 119.05 38.28 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.793 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.4 m -110.02 154.78 11.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.977 179.078 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 98.8 m -105.53 154.44 20.37 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.417 0.627 . . . . 0.0 111.933 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -130.42 147.26 33.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.505 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.4 -1.222 . . . . 0.0 112.482 179.702 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 35.8 ptt180 . . . . . 0 N--CA 1.485 1.292 0 CA-C-O 120.806 0.336 . . . . 0.0 110.863 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -90.68 162.33 14.97 Favored 'General case' 0 C--O 1.215 -0.737 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.5 m -144.55 150.47 37.57 Favored 'General case' 0 C--N 1.321 -0.666 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.102 179.021 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.9 pt -131.38 148.28 32.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 121.135 0.493 . . . . 0.0 112.219 179.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.436 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 38.9 ttt180 -93.8 98.09 10.85 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 176.419 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.459 ' O ' ' HD3' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -75.6 149.21 6.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 C-N-CA 120.766 -0.373 . . . . 0.0 110.558 -177.328 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.426 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 53.7 tt0 -94.68 11.41 31.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.243 -179.089 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 5.5 ptp180 -98.48 178.29 5.07 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.461 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.98 -177.01 30.67 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.59 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -77.0 110.7 1.77 Allowed 'Cis proline' 0 C--N 1.343 0.285 0 C-N-CA 123.287 -1.547 . . . . 0.0 112.323 -0.015 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.61 156.22 9.25 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.473 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.459 ' HD3' ' O ' ' A' ' 9' ' ' ILE . 17.7 tpp85 -71.9 129.35 38.37 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 179.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -152.04 -176.58 5.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.308 0.575 . . . . 0.0 111.875 -179.464 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.436 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -119.34 128.15 53.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.601 179.706 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 m -116.5 150.51 18.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.155 178.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 97.0 m -96.1 159.32 15.02 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.518 0.675 . . . . 0.0 111.877 -179.282 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.4 mt -135.48 155.15 36.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 114.537 -1.21 . . . . 0.0 108.945 -179.355 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.302 -1.277 . . . . 0.0 112.559 179.618 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 80.7 mtm-85 . . . . . 0 N--CA 1.484 1.236 0 N-CA-C 110.41 -0.218 . . . . 0.0 110.41 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.565 ' HD2' ' N ' ' A' ' 6' ' ' SER . 5.2 tmmm? -112.63 148.78 33.9 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.565 ' N ' ' HD2' ' A' ' 5' ' ' LYS . 13.4 m -141.06 133.29 28.06 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.682 -0.236 . . . . 0.0 110.778 179.353 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.451 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 1.7 pt -131.79 148.39 32.4 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 N-CA-C 113.313 0.857 . . . . 0.0 113.313 -179.332 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.432 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 5.8 ptm180 -84.38 108.7 17.35 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 175.756 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.493 HG21 HD11 ' A' ' 9' ' ' ILE . 0.3 OUTLIER -78.16 152.2 5.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.671 -177.79 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -90.5 11.63 21.19 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.019 -179.382 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.5 mtp85 -98.02 174.89 6.33 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.457 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.4 179.45 32.04 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.65 -179.376 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_exo -70.3 137.8 47.08 Favored 'Cis proline' 0 C--N 1.342 0.196 0 C-N-CA 123.124 -1.615 . . . . 0.0 112.527 0.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.439 ' C ' ' HD2' ' A' ' 15' ' ' ARG . . . 55.75 -145.31 32.98 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.087 -179.838 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.439 ' HD2' ' C ' ' A' ' 14' ' ' GLY . 9.5 mpt_? -117.99 128.16 54.52 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.53 -175.97 5.21 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.55 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.451 ' HB2' ' C ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -139.83 148.79 42.64 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.975 179.746 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 6' ' ' SER . 9.1 t -117.68 161.74 16.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.103 -179.661 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 80.9 m -118.33 112.57 20.21 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.249 179.576 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.45 ' N ' ' CD1' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -117.52 152.69 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-O 120.9 0.381 . . . . 0.0 111.431 -179.728 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.528 -1.151 . . . . 0.0 112.139 -179.737 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 . . . . . 0 N--CA 1.484 1.255 0 CA-C-O 120.672 0.272 . . . . 0.0 110.77 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -148.85 166.44 28.52 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -141.51 149.87 41.44 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 117.857 0.298 . . . . 0.0 111.143 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.9 pt -131.02 146.11 34.44 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-O 121.152 0.501 . . . . 0.0 112.351 179.123 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 13.4 tpt180 -96.87 85.9 3.89 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 176.605 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.466 HD11 HG22 ' A' ' 9' ' ' ILE . 0.1 OUTLIER -77.31 144.5 11.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.827 -177.354 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 38.6 tt0 -96.52 7.01 47.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.187 0.518 . . . . 0.0 110.131 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -99.43 -177.03 3.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.536 179.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.84 -178.28 29.37 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.126 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -80.14 108.87 1.32 Allowed 'Cis proline' 0 C--N 1.345 0.352 0 C-N-CA 123.428 -1.488 . . . . 0.0 112.328 0.161 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.52 133.06 5.75 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.884 179.611 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -81.61 110.91 17.42 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.404 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -163.29 -168.86 1.81 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.267 0.556 . . . . 0.0 111.087 -179.238 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -97.79 128.19 44.26 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.758 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.5 t -109.13 162.69 6.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 178.876 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.2 m -104.22 160.1 15.15 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.561 0.696 . . . . 0.0 111.541 -179.48 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 9.1 mt -140.71 167.73 17.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.714 -179.557 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.324 -1.264 . . . . 0.0 112.846 179.924 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.511 ' N ' ' O ' ' A' ' 21' ' ' GLY . 13.8 tpt180 . . . . . 0 N--CA 1.484 1.236 0 CA-C-O 120.877 0.37 . . . . 0.0 110.585 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.469 ' HD3' ' H ' ' A' ' 6' ' ' SER . 5.9 tmtt? -123.99 147.17 48.0 Favored 'General case' 0 C--O 1.217 -0.647 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -179.748 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.469 ' H ' ' HD3' ' A' ' 5' ' ' LYS . 14.3 m -141.24 139.02 33.67 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.714 179.337 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.0 pt -130.96 149.37 33.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.5 ttp85 -91.95 92.03 8.13 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 176.112 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.431 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.32 145.07 10.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.135 0.493 . . . . 0.0 111.046 -177.034 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -91.92 11.84 23.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.053 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 10.1 mtp-105 -98.31 -168.02 1.59 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.628 -179.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.4 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -115.17 179.81 18.33 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.416 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -75.54 109.6 1.35 Allowed 'Cis proline' 0 C--N 1.344 0.336 0 C-N-CA 123.088 -1.63 . . . . 0.0 112.394 -0.023 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.4 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 82.29 133.32 1.77 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.227 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.444 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -77.97 116.61 18.59 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.786 0.327 . . . . 0.0 110.337 179.672 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.431 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -153.2 -172.22 4.17 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.289 0.566 . . . . 0.0 111.076 -179.343 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -96.55 120.85 37.63 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.062 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.7 m -109.63 148.27 13.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.169 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 65.0 m -113.58 131.46 56.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.128 0.49 . . . . 0.0 111.511 -179.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.445 HG13 ' HB3' ' A' ' 5' ' ' LYS . 4.7 pt -123.33 143.31 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 C-N-CA 123.83 0.852 . . . . 0.0 110.952 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.511 ' O ' ' N ' ' A' ' 4' ' ' ARG . . . . . . . . 0 C--O 1.248 1.029 0 CA-C-O 118.11 -1.383 . . . . 0.0 113.511 179.306 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 56.3 ttp180 . . . . . 0 N--CA 1.483 1.178 0 CA-C-O 120.841 0.353 . . . . 0.0 110.886 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.455 ' HD2' ' N ' ' A' ' 6' ' ' SER . 1.4 tmmt? -143.17 157.14 44.77 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.725 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.455 ' N ' ' HD2' ' A' ' 5' ' ' LYS . 14.5 m -142.1 145.9 34.8 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.21 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.9 pt -131.79 152.27 36.68 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.272 0 CA-C-O 121.257 0.551 . . . . 0.0 112.32 179.908 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.445 ' HD3' ' NH2' ' A' ' 15' ' ' ARG . 28.9 ttm105 -93.71 91.46 7.03 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 107.278 -1.378 . . . . 0.0 107.278 176.555 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.441 HD12 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.42 146.58 8.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.836 -177.717 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.459 ' H ' ' CD ' ' A' ' 10' ' ' GLN . 0.1 OUTLIER -98.95 9.54 43.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.906 -179.805 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -99.7 -169.94 1.82 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.224 179.926 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.17 174.2 27.21 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.455 -0.879 . . . . 0.0 112.404 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -81.65 108.13 1.2 Allowed 'Cis proline' 0 C--N 1.345 0.388 0 C-N-CA 123.152 -1.603 . . . . 0.0 112.777 0.132 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.03 137.02 0.66 Allowed Glycine 0 C--N 1.332 0.358 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.788 179.61 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.544 ' C ' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -66.02 130.98 45.12 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.388 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.441 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -170.22 -174.74 1.79 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.136 0.493 . . . . 0.0 111.007 -179.44 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -103.39 121.18 42.26 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.61 179.825 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 m -108.96 156.98 9.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.778 178.825 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 75.6 m -118.48 148.28 42.76 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.08 0.467 . . . . 0.0 112.157 -178.658 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.424 ' N ' ' CD1' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -124.97 177.75 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.187 179.119 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.157 0 CA-C-O 118.814 -0.992 . . . . 0.0 113.567 -179.761 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 66.9 mtp180 . . . . . 0 N--CA 1.485 1.295 0 N-CA-C 110.252 -0.277 . . . . 0.0 110.252 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.574 ' HD3' ' N ' ' A' ' 6' ' ' SER . 6.9 tmtm? -111.15 144.42 40.33 Favored 'General case' 0 C--O 1.222 -0.346 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.893 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.574 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 66.3 m -141.37 157.0 45.76 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 179.185 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 pt -130.99 148.13 33.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 -179.502 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 13.7 tpp180 -95.56 91.48 6.17 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 176.037 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -76.47 144.71 11.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.819 -177.237 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.419 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 46.4 tt0 -88.66 11.64 16.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.826 -179.485 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.0 mtp-105 -96.59 -176.04 3.49 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.207 -179.23 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.475 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -107.73 -179.54 22.15 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.849 -179.412 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -73.4 107.28 0.87 Allowed 'Cis proline' 0 C--N 1.343 0.288 0 C-N-CA 123.282 -1.549 . . . . 0.0 112.387 0.172 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.475 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 74.35 141.89 0.71 Allowed Glycine 0 C--N 1.333 0.377 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.534 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.3 124.33 20.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.762 0.315 . . . . 0.0 110.625 179.501 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -147.33 -178.99 6.53 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.185 -179.665 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -108.69 122.12 46.46 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.452 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.9 t -109.27 158.78 9.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.341 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.7 m -107.04 154.75 20.66 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.414 0.626 . . . . 0.0 111.81 -179.717 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.8 mt -125.34 171.9 13.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 114.698 -1.137 . . . . 0.0 109.308 -179.475 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.158 0 CA-C-O 118.384 -1.231 . . . . 0.0 111.978 179.59 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.448 ' HA ' ' C ' ' A' ' 21' ' ' GLY . 74.8 ttt180 . . . . . 0 N--CA 1.484 1.231 0 CA-C-O 120.873 0.368 . . . . 0.0 111.031 . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -151.51 158.56 43.76 Favored 'General case' 0 C--O 1.217 -0.651 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 178.912 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.405 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 19.9 m -143.22 147.48 34.92 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.785 179.675 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.5 pt -132.38 146.36 33.11 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.392 0 N-CA-C 113.74 1.015 . . . . 0.0 113.74 -179.794 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.448 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 35.2 ttm180 -88.65 96.12 10.52 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 176.265 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.455 HG22 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.11 141.33 15.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 120.415 -0.514 . . . . 0.0 109.851 -178.165 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.8 tt0 -93.67 11.01 30.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.49 -178.677 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 46.2 ptt85 -98.39 -169.9 1.87 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.159 179.714 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.466 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.23 176.82 29.49 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.497 -0.859 . . . . 0.0 112.764 -179.412 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -74.23 109.11 1.1 Allowed 'Cis proline' 0 C--N 1.347 0.453 0 C-N-CA 123.151 -1.604 . . . . 0.0 112.51 0.001 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.466 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 71.81 156.82 2.79 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.495 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.0 mpt_? -67.83 133.7 49.64 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 120.789 0.328 . . . . 0.0 110.695 179.445 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.425 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -168.31 -164.61 0.54 Allowed 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.954 -179.626 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.448 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -141.27 137.11 32.27 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.654 179.181 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.1 t -110.77 163.75 7.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.921 -179.362 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.8 m -108.91 131.59 54.88 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.811 0.815 . . . . 0.0 111.92 -179.895 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.2 mt -100.63 174.96 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 113.983 -1.462 . . . . 0.0 109.175 179.251 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.448 ' C ' ' HA ' ' A' ' 4' ' ' ARG . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.609 -1.106 . . . . 0.0 112.541 179.273 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 68.0 mtm180 . . . . . 0 N--CA 1.485 1.316 0 CA-C-O 121.209 0.528 . . . . 0.0 111.662 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -144.86 166.0 26.52 Favored 'General case' 0 C--O 1.213 -0.835 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.4 m -142.56 147.21 35.53 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 118.679 0.672 . . . . 0.0 110.619 179.37 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.0 pt -130.6 147.85 33.12 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.411 0 CA-C-O 121.112 0.482 . . . . 0.0 112.295 -179.878 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 75.7 ttt180 -89.64 100.26 13.1 Favored 'General case' 0 N--CA 1.445 -0.71 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 176.043 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -76.98 150.59 5.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-O 121.32 0.581 . . . . 0.0 111.854 -176.641 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 62.7 mt-30 -93.61 12.18 26.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.698 -179.811 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -98.1 177.05 5.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.967 -179.174 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.438 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -104.25 -178.88 25.17 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.629 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -74.08 108.4 1.0 Allowed 'Cis proline' 0 C--N 1.345 0.36 0 C-N-CA 123.278 -1.551 . . . . 0.0 112.254 0.02 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.438 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 74.31 148.53 1.49 Allowed Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.346 -179.814 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.474 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -59.79 145.71 44.34 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.823 0.344 . . . . 0.0 110.885 179.806 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -164.74 -177.19 4.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.928 0.394 . . . . 0.0 111.202 -179.565 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -117.22 123.52 46.83 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.287 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 m -113.2 155.92 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.026 178.619 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 42.9 m -99.86 159.46 15.06 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.153 0.502 . . . . 0.0 111.316 -179.633 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -142.09 154.5 18.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.179 -178.69 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.261 0 CA-C-O 118.424 -1.209 . . . . 0.0 113.729 178.696 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 35.7 ttm180 . . . . . 0 N--CA 1.486 1.367 0 N-CA-C 110.487 -0.19 . . . . 0.0 110.487 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.462 ' O ' HG12 ' A' ' 20' ' ' ILE . 0.7 OUTLIER -98.4 152.3 19.64 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.956 0.408 . . . . 0.0 111.277 -179.574 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.435 ' HB3' ' O ' ' A' ' 18' ' ' VAL . 24.0 m -142.76 157.13 44.94 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.388 178.61 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.8 pt -128.45 146.59 33.66 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.352 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -179.414 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.458 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 53.9 ttp180 -95.83 92.86 6.74 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 176.257 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -75.99 154.72 5.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.577 -177.379 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.0 pt20 -97.05 12.03 34.04 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.211 -179.363 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -97.44 -178.75 4.25 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.648 -179.345 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.02 -179.56 30.24 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.447 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -77.86 107.76 1.06 Allowed 'Cis proline' 0 C--N 1.346 0.418 0 C-N-CA 123.098 -1.626 . . . . 0.0 112.403 0.028 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.26 153.22 5.53 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.214 -179.865 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 40.1 mmt-85 -66.17 119.93 12.33 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.69 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.84 -179.13 6.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.157 0.504 . . . . 0.0 111.75 -179.458 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.458 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -114.23 125.77 54.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.995 -179.996 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.435 ' O ' ' HB3' ' A' ' 6' ' ' SER . 5.6 t -110.05 162.99 7.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.705 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.433 HG21 ' N ' ' A' ' 20' ' ' ILE . 53.7 m -107.03 158.23 17.2 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.937 -0.305 . . . . 0.0 111.751 -179.464 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.462 HG12 ' O ' ' A' ' 5' ' ' LYS . 2.6 mm -99.93 157.29 3.95 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.258 179.68 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.314 -1.27 . . . . 0.0 112.352 179.804 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? . . . . . 0 N--CA 1.484 1.266 0 CA-C-O 120.682 0.277 . . . . 0.0 110.475 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.438 ' NZ ' ' CB ' ' A' ' 5' ' ' LYS . 7.9 mtpm? -104.1 148.64 26.03 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.636 179.738 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.45 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.7 m -142.93 132.64 23.89 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.043 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.409 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 4.9 pt -131.28 147.82 32.85 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 N-CA-C 113.701 1.0 . . . . 0.0 113.701 -178.874 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.481 ' N ' ' HD2' ' A' ' 8' ' ' ARG . 2.2 mpt_? -86.94 99.72 12.07 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 176.012 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.475 HG22 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.85 143.3 12.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 C-N-CA 120.3 -0.56 . . . . 0.0 110.922 -177.452 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.1 pp0? -85.77 11.89 10.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.342 -179.724 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 78.9 ttt180 -98.04 158.7 15.39 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.89 -179.64 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.73 -170.64 30.16 Favored Glycine 0 N--CA 1.452 -0.27 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.268 179.811 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -83.46 115.96 3.99 Favored 'Cis proline' 0 N--CA 1.462 -0.348 0 C-N-CA 123.091 -1.629 . . . . 0.0 112.592 0.084 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.26 117.43 3.93 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.539 179.747 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.464 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -59.45 121.17 10.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.099 0.476 . . . . 0.0 110.975 179.71 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.405 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -155.18 -168.93 3.01 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.419 -179.498 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.45 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -136.25 145.74 45.93 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.654 179.626 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.7 t -112.44 160.95 11.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.182 -179.711 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 52.0 m -119.93 112.99 19.88 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.132 179.814 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -110.59 -179.41 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.015 178.983 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.618 -1.101 . . . . 0.0 112.276 179.705 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.417 ' C ' ' HD2' ' A' ' 4' ' ' ARG . 1.2 tmm_? . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.582 0.23 . . . . 0.0 110.638 . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -110.66 157.48 19.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.978 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.1 m -142.43 151.58 41.92 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.006 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.8 pt -130.64 148.94 33.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 N-CA-C 112.729 0.641 . . . . 0.0 112.729 -179.127 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 57.3 ttp85 -94.8 94.22 7.94 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 175.994 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -76.47 153.92 5.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.125 0.488 . . . . 0.0 111.606 -176.569 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.412 ' HA ' ' HD2' ' A' ' 15' ' ' ARG . 62.4 mt-30 -97.14 11.38 36.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.672 -0.695 . . . . 0.0 111.19 -179.523 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.96 159.44 14.93 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.823 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.92 -171.05 32.63 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.765 -179.091 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.76 113.81 2.85 Favored 'Cis proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.977 -1.676 . . . . 0.0 112.62 0.349 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.87 138.26 5.31 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.61 179.859 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.412 ' HD2' ' HA ' ' A' ' 10' ' ' GLN . 55.5 mmt-85 -74.86 125.41 28.76 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.416 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -151.84 -176.01 5.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.19 0.519 . . . . 0.0 112.006 -179.144 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -106.99 125.1 50.57 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.088 179.885 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 6.0 t -113.69 162.93 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 178.919 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 52.9 m -103.36 151.26 22.95 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.07 0.462 . . . . 0.0 111.439 -179.827 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 8.2 mt -109.0 164.01 5.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.283 -179.781 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.978 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.015 179.636 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 . . . . . 0 N--CA 1.484 1.268 0 CA-C-O 120.651 0.262 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.4 tmmm? -154.36 165.27 36.9 Favored 'General case' 0 C--O 1.214 -0.788 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 m -142.81 152.12 41.88 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 118.42 0.555 . . . . 0.0 110.806 179.995 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.0 pt -131.13 150.12 34.15 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.346 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 179.347 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 17.4 ptt85 -97.14 93.9 6.83 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 176.327 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.453 HG22 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.04 144.26 11.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.799 -177.072 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 19.8 tt0 -91.88 7.02 43.95 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.984 0.421 . . . . 0.0 110.966 -179.232 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.405 ' NH2' HG23 ' A' ' 9' ' ' ILE . 15.5 ptt85 -99.14 178.56 4.88 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.701 179.492 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.41 -177.91 32.77 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.523 -179.524 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.46 108.52 1.14 Allowed 'Cis proline' 0 C--N 1.342 0.225 0 C-N-CA 123.405 -1.498 . . . . 0.0 112.561 0.237 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 128.34 0.91 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.936 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.461 ' C ' ' HD2' ' A' ' 15' ' ' ARG . 3.1 tmm_? -65.56 113.65 4.35 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.439 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.424 ' O ' HD12 ' A' ' 9' ' ' ILE . . . -149.02 -169.58 3.41 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.517 0.675 . . . . 0.0 111.89 -179.239 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -107.49 128.18 54.27 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.058 -0.973 . . . . 0.0 111.113 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.4 m -117.44 153.7 19.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.094 178.738 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.3 m -94.08 158.71 15.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.476 0.655 . . . . 0.0 111.861 -179.048 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 3.1 mt -141.31 160.62 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-N 114.735 -1.121 . . . . 0.0 109.552 -179.447 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.996 0 CA-C-O 118.365 -1.241 . . . . 0.0 112.448 179.403 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.581 ' N ' ' NE ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.484 1.27 0 CA-C-O 120.69 0.281 . . . . 0.0 110.649 . . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.505 ' HD2' ' H ' ' A' ' 6' ' ' SER . 0.1 OUTLIER -107.12 145.9 31.92 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 178.726 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.505 ' H ' ' HD2' ' A' ' 5' ' ' LYS . 9.5 m -141.05 140.26 34.21 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.421 -179.874 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.415 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 1.5 pt -132.12 148.3 32.14 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -179.809 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.422 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 28.3 ptt-85 -80.92 104.45 11.43 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 176.114 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.439 HG21 HD11 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -77.63 158.77 5.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 C-N-CA 120.039 -0.664 . . . . 0.0 110.622 -177.736 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -99.68 12.31 36.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.819 -178.988 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.406 HH11 ' HD3' ' A' ' 11' ' ' ARG . 49.2 mtt180 -97.61 161.86 13.57 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.805 0.336 . . . . 0.0 110.76 -179.738 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.79 -175.37 30.83 Favored Glycine 0 N--CA 1.452 -0.267 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.564 -179.69 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.62 119.43 6.3 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.978 -1.676 . . . . 0.0 112.412 -0.167 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.77 144.63 6.1 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.186 -179.772 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.5 mpt_? -77.44 117.2 18.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.041 0.448 . . . . 0.0 111.05 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -136.52 -173.03 3.3 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.823 179.639 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.415 ' HB2' ' C ' ' A' ' 7' ' ' ILE . 0.4 OUTLIER -130.7 143.62 50.87 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.048 0.451 . . . . 0.0 110.956 179.608 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 6' ' ' SER . 25.8 m -112.43 163.81 9.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.991 -179.542 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.4 m -120.3 123.72 43.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.297 -179.739 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.458 ' N ' ' CD1' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -114.59 157.05 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 C-N-CA 123.031 0.532 . . . . 0.0 110.798 179.275 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.201 -1.333 . . . . 0.0 112.177 179.933 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.431 ' HG2' ' N ' ' A' ' 5' ' ' LYS . 11.6 ttp180 . . . . . 0 N--CA 1.487 1.411 0 N-CA-C 110.27 -0.27 . . . . 0.0 110.27 . . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.543 ' HD3' ' N ' ' A' ' 6' ' ' SER . 5.4 tmtm? -143.67 144.86 32.05 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.809 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.543 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 0.9 OUTLIER -139.21 152.27 47.22 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.772 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.1 pt -130.59 151.77 36.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.437 0 CA-C-O 121.312 0.577 . . . . 0.0 112.356 179.932 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.465 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 4.7 ptm85 -96.61 99.29 10.93 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 176.282 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -77.79 156.56 5.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.242 0.544 . . . . 0.0 111.955 -176.744 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -94.77 12.56 27.52 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.073 179.075 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.2 ttt180 -97.03 -168.32 1.68 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.71 -179.335 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.483 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -107.45 176.43 20.9 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.442 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -73.02 108.71 0.97 Allowed 'Cis proline' 0 CA--C 1.53 0.288 0 C-N-CA 123.311 -1.537 . . . . 0.0 112.369 0.038 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.483 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 65.57 173.61 4.46 Favored Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.673 -179.937 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.445 HH21 ' NE ' ' A' ' 8' ' ' ARG . 16.1 tpt180 -69.33 115.14 8.25 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.766 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.04 -177.94 5.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.172 0.51 . . . . 0.0 111.52 -179.26 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.465 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -115.44 132.02 56.75 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.053 179.887 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.1 m -121.98 161.63 22.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.74 -0.663 . . . . 0.0 109.819 178.838 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 41.5 m -96.7 155.67 16.67 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.015 0.436 . . . . 0.0 111.06 -179.631 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 20.7 mt -121.27 165.52 16.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.458 179.584 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.086 0 CA-C-O 118.202 -1.332 . . . . 0.0 111.982 179.917 . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.5 tpp85 . . . . . 0 N--CA 1.487 1.377 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -142.56 148.97 38.42 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 110.197 -0.297 . . . . 0.0 110.197 179.551 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 m -143.75 152.99 41.95 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.076 178.999 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.7 pt -131.15 145.96 34.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 113.551 0.945 . . . . 0.0 113.551 -179.411 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.421 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 76.7 mtp180 -82.31 92.67 7.0 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 176.431 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.458 HG12 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.71 148.49 6.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.043 0.449 . . . . 0.0 110.92 -177.524 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -101.15 9.7 41.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.16 0.505 . . . . 0.0 109.884 179.05 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 64.5 mtp180 -99.86 -168.8 1.65 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.754 -179.269 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.7 -176.4 19.67 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 121.197 -0.525 . . . . 0.0 112.047 179.803 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -83.01 113.51 2.95 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.487 -1.464 . . . . 0.0 112.357 -0.075 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.11 128.31 6.03 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.219 -179.836 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 13.9 mmt180 -70.95 96.93 1.35 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.856 0.36 . . . . 0.0 110.728 -179.881 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.458 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -155.27 179.31 9.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.351 -179.842 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.421 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -103.79 147.35 27.38 Favored 'General case' 0 C--N 1.325 -0.5 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.646 179.851 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 31.3 m -119.18 165.52 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.136 -179.809 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 94.0 m -98.48 153.6 18.49 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.116 0.484 . . . . 0.0 111.03 179.835 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.8 mt -114.24 163.78 11.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.328 -179.237 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.208 -1.329 . . . . 0.0 112.001 179.827 . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 82.1 mtt-85 . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 . . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -58.89 146.55 37.21 Favored 'General case' 0 C--O 1.222 -0.342 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.015 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.6 m -141.14 147.76 38.98 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.102 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.0 pt -131.48 146.72 33.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -178.269 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.402 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -92.26 93.07 8.47 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 176.175 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -75.31 148.15 7.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.02 0.438 . . . . 0.0 111.026 -176.697 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 69.9 mt-30 -100.16 11.83 38.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.028 -179.384 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -97.78 -169.3 1.81 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.493 -0.322 . . . . 0.0 110.187 -179.864 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.14 -177.17 19.16 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.429 179.772 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -79.55 104.98 0.64 Allowed 'Cis proline' 0 C--N 1.344 0.314 0 C-N-CA 123.485 -1.465 . . . . 0.0 112.143 -0.117 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.49 145.46 13.76 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.97 179.883 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 26.3 mtt180 -78.11 137.29 38.13 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 110.523 -0.177 . . . . 0.0 110.523 179.813 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -168.53 -173.73 2.01 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-O 121.22 0.533 . . . . 0.0 111.227 -179.782 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.402 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -111.97 120.59 42.41 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.359 179.504 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.1 t -110.03 160.5 9.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.313 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 46.2 m -98.51 158.8 15.37 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.889 0.376 . . . . 0.0 110.158 179.356 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.1 mt -119.33 161.58 18.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.527 179.76 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.135 0 CA-C-O 118.455 -1.192 . . . . 0.0 112.22 179.958 . . . . . . . . 0 0 . 1 . 033 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.469 ' C ' ' HD2' ' A' ' 4' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 120.437 0.161 . . . . 0.0 110.711 . . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.511 ' HD3' ' N ' ' A' ' 6' ' ' SER . 4.2 tmtm? -138.93 140.99 38.48 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.952 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.511 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 12.3 m -141.4 135.27 30.22 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.216 179.63 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.9 pt -132.64 149.52 32.17 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.343 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -179.956 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.453 ' H ' ' HD3' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -90.1 105.45 17.82 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 175.514 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.516 HD11 HG22 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -78.57 156.52 4.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 C-N-CA 120.501 -0.479 . . . . 0.0 111.281 -177.436 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.512 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 10.2 mp0 -94.72 10.28 35.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.48 179.904 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -99.67 179.59 4.49 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.858 -179.808 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.15 -176.61 30.41 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.186 179.859 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -76.57 107.68 1.01 Allowed 'Cis proline' 0 N--CA 1.464 -0.242 0 C-N-CA 123.246 -1.564 . . . . 0.0 112.521 0.052 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.21 151.54 7.23 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.835 179.674 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 16.5 mmm180 -60.13 109.97 1.1 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.71 0.29 . . . . 0.0 110.64 179.417 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.06 -177.07 4.93 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.439 -179.937 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.48 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -135.46 146.03 47.78 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.478 179.447 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.0 t -112.99 160.66 12.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.168 -179.495 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.408 ' CB ' ' HG ' ' A' ' 6' ' ' SER . 83.9 m -126.88 114.83 18.4 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.449 179.633 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.407 ' CD1' ' N ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -112.47 161.99 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.762 179.729 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.281 -1.289 . . . . 0.0 112.32 -179.996 . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.1 ptp85 . . . . . 0 N--CA 1.485 1.278 0 CA-C-O 120.426 0.155 . . . . 0.0 110.681 . . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -114.15 135.11 54.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.657 179.626 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 16.0 m -140.92 135.82 31.64 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.929 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.4 pt -124.07 150.72 28.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 113.237 0.829 . . . . 0.0 113.237 -178.203 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.434 ' HD2' ' O ' ' A' ' 16' ' ' ALA . 14.6 tpt180 -92.22 94.37 9.15 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 176.197 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.422 HD11 HG22 ' A' ' 9' ' ' ILE . 0.2 OUTLIER -76.28 148.53 7.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.912 -177.084 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 33.5 mt-30 -97.4 11.51 36.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.188 -179.569 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -98.34 -174.9 2.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.116 179.827 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.427 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.94 175.7 27.7 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.569 -179.763 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -76.46 109.46 1.36 Allowed 'Cis proline' 0 C--N 1.346 0.411 0 C-N-CA 123.247 -1.564 . . . . 0.0 112.438 -0.02 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.427 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 69.52 168.1 5.99 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.292 -179.743 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.439 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 4.8 mpt_? -80.11 134.27 36.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 110.547 179.662 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.434 ' O ' ' HD2' ' A' ' 8' ' ' ARG . . . -160.95 178.95 8.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.0 -179.751 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -109.85 124.08 50.71 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.917 179.739 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 m -114.28 140.01 37.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.399 179.117 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.7 m -101.48 142.15 33.29 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.857 -179.598 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.475 ' N ' ' CD1' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -112.36 161.14 11.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.986 179.788 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.287 -1.285 . . . . 0.0 112.029 179.985 . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.42 ' HA ' ' NE ' ' A' ' 4' ' ' ARG . 15.4 mmp_? . . . . . 0 N--CA 1.483 1.223 0 CA-C-O 120.729 0.3 . . . . 0.0 110.841 . . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 29.7 ttmt -126.35 149.14 49.38 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 178.653 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.477 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 14.8 m -141.55 132.8 26.48 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.937 179.268 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.43 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 2.2 pt -131.9 147.58 32.39 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -179.52 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.533 ' HB3' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -85.74 100.59 12.12 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 176.155 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.54 158.16 4.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.561 -0.456 . . . . 0.0 110.777 -177.815 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.425 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 13.1 mp0 -100.89 10.17 41.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.86 0.362 . . . . 0.0 110.463 179.249 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 74.2 ttt180 -99.02 165.0 11.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.519 -179.527 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.82 -175.13 33.65 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.205 -179.976 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -74.81 115.83 3.64 Favored 'Cis proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.132 -1.612 . . . . 0.0 112.553 0.314 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.67 124.14 1.01 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.974 -0.632 . . . . 0.0 112.481 179.765 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.3 mtt85 -61.58 98.84 0.1 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.848 0.356 . . . . 0.0 110.418 179.656 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -131.0 -178.91 5.03 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.582 -179.636 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.442 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.3 OUTLIER -117.38 145.28 44.18 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.593 179.765 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.6 t -114.81 161.19 13.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.256 -179.475 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 86.9 m -120.69 109.06 14.75 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.081 179.568 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -104.44 171.37 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 CA-C-O 120.816 0.341 . . . . 0.0 111.387 -179.813 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.464 -1.187 . . . . 0.0 112.544 179.714 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 88.2 p . . . . . 0 C--O 1.233 0.234 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.594 HG23 HD11 ' A' ' 20' ' ' ILE . 3.8 pt -132.01 147.61 32.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 112.113 0.412 . . . . 0.0 112.113 179.157 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.483 ' O ' ' CD ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -91.19 91.6 8.3 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 176.118 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.525 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.59 150.51 6.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.613 -176.776 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 22.5 mp0 -89.0 12.52 15.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.621 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -96.88 177.94 5.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.32 -179.523 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.501 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.97 178.2 29.4 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.966 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -73.37 108.26 0.95 Allowed 'Cis proline' 0 C--N 1.344 0.326 0 C-N-CA 123.337 -1.526 . . . . 0.0 112.279 0.07 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.501 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 67.41 156.36 0.62 Allowed Glycine 0 C--N 1.333 0.391 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.422 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -60.27 126.04 25.96 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.766 0.317 . . . . 0.0 110.502 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.525 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -149.18 177.84 9.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.887 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -109.67 120.09 41.4 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.674 179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.499 HG22 HG23 ' A' ' 9' ' ' ILE . 15.1 m -109.27 152.8 11.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.759 178.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.6 m -89.44 156.37 18.71 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.957 0.408 . . . . 0.0 111.24 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.594 HD11 HG23 ' A' ' 7' ' ' ILE . 8.3 mt -120.63 163.06 18.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.022 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.425 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.503 -1.165 . . . . 0.0 112.075 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.531 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 14.7 m . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.465 0.174 . . . . 0.0 110.849 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.488 ' O ' ' HB2' ' A' ' 17' ' ' PHE . 1.6 pt -131.43 146.05 34.26 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.567 0 N-CA-C 113.696 0.998 . . . . 0.0 113.696 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -78.8 102.24 8.04 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 176.119 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.555 HD13 HG13 ' A' ' 18' ' ' VAL . 1.8 pt -77.54 151.28 5.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.657 -177.754 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -100.95 10.49 41.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.464 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 36.0 ptt180 -109.25 -178.31 3.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.827 0.346 . . . . 0.0 111.017 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.54 -172.64 30.78 Favored Glycine 0 C--N 1.329 0.187 0 C-N-CA 121.108 -0.568 . . . . 0.0 112.308 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.98 117.66 5.33 Favored 'Cis proline' 0 N--CA 1.462 -0.349 0 C-N-CA 123.34 -1.525 . . . . 0.0 112.407 0.143 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 145.64 4.73 Favored Glycine 0 C--N 1.33 0.221 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.293 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.492 ' C ' ' HD2' ' A' ' 15' ' ' ARG . 4.8 ppt_? -66.72 128.8 37.66 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.44 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -169.52 -166.47 0.6 Allowed 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 121.199 0.523 . . . . 0.0 110.593 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.531 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.1 OUTLIER -137.62 152.57 49.5 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.367 179.572 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.555 HG13 HD13 ' A' ' 9' ' ' ILE . 19.5 m -115.75 154.9 17.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.972 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 86.3 m -113.74 110.71 20.61 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.359 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.8 pt -100.22 173.06 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.674 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.711 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.242 -1.31 . . . . 0.0 112.287 179.744 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.6 m . . . . . 0 CA--C 1.528 0.122 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.8 pt -130.95 152.04 36.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.318 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -179.369 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.498 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 22.8 ttm180 -94.97 104.32 16.2 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 175.714 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.47 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.37 144.29 11.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 C-N-CA 119.845 -0.742 . . . . 0.0 110.791 -177.554 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 46.3 tp60 -93.88 12.46 25.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.426 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.3 mtt-85 -97.47 173.46 7.16 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.332 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.415 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.74 -179.83 30.52 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.1 108.63 1.14 Allowed 'Cis proline' 0 C--N 1.345 0.381 0 C-N-CA 123.34 -1.525 . . . . 0.0 112.256 0.039 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.415 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 75.54 152.18 3.48 Favored Glycine 0 C--N 1.332 0.335 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.467 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.491 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -62.34 152.64 33.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.875 0.369 . . . . 0.0 111.096 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.47 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.17 178.54 3.81 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.998 0.428 . . . . 0.0 111.152 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.498 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.6 OUTLIER -120.56 129.7 53.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.0 179.718 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 6.2 t -120.85 159.92 22.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.8 m -102.77 156.11 17.86 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.204 0.526 . . . . 0.0 111.316 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.414 HG22 ' N ' ' A' ' 21' ' ' GLY . 8.7 mt -118.1 164.73 14.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.177 -0.92 . . . . 0.0 109.816 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.414 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 0.999 0 CA-C-O 118.416 -1.214 . . . . 0.0 111.977 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.449 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 17.4 m . . . . . 0 C--O 1.232 0.145 0 N-CA-C 110.588 -0.153 . . . . 0.0 110.588 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.447 ' O ' ' HB2' ' A' ' 17' ' ' PHE . 2.9 pt -132.42 146.04 33.59 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.501 0 N-CA-C 113.933 1.086 . . . . 0.0 113.933 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.509 ' HA ' ' HB2' ' A' ' 17' ' ' PHE . 48.7 mtt85 -86.9 108.92 19.0 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 175.249 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 16' ' ' ALA . 1.3 pt -77.76 157.66 5.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.714 -177.768 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -100.57 11.0 40.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.598 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 5.3 ttm180 -98.95 -170.13 1.88 Allowed 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -108.95 179.35 21.13 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.155 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.56 112.42 2.34 Favored 'Cis proline' 0 C--N 1.344 0.297 0 C-N-CA 122.971 -1.679 . . . . 0.0 112.44 0.013 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.5 155.4 6.13 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.353 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.2 ttp85 -62.28 88.22 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.222 0.534 . . . . 0.0 110.293 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.453 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -101.58 -170.81 1.88 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.883 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.509 ' HB2' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -148.74 149.98 32.34 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.38 179.574 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.412 HG12 ' N ' ' A' ' 19' ' ' THR . 5.4 t -121.92 162.23 21.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.72 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.412 ' N ' HG12 ' A' ' 18' ' ' VAL . 89.6 m -111.01 126.95 55.34 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.761 0.791 . . . . 0.0 112.05 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.5 mt -103.22 156.49 5.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.901 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.49 -1.172 . . . . 0.0 113.043 179.037 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 C--O 1.232 0.175 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.421 ' HA ' HH21 ' A' ' 8' ' ' ARG . 3.4 pt -132.0 148.67 32.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -179.239 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.61 ' HE ' ' H ' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -88.14 102.64 14.98 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 175.586 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.613 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.48 142.23 14.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 120.154 -0.618 . . . . 0.0 110.751 -177.379 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.65 11.47 24.28 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.805 -178.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -98.28 175.28 6.12 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.734 0.302 . . . . 0.0 110.646 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.49 -177.04 31.34 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.272 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 81.0 Cg_endo -78.87 110.4 1.84 Allowed 'Cis proline' 0 C--N 1.343 0.284 0 C-N-CA 123.062 -1.641 . . . . 0.0 112.796 0.181 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.06 141.57 4.93 Favored Glycine 0 C--N 1.331 0.299 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.663 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.491 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -60.14 142.47 54.22 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.956 0.407 . . . . 0.0 111.156 179.83 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.613 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.28 -168.12 0.69 Allowed 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.113 0.483 . . . . 0.0 110.624 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.446 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -144.56 145.48 31.84 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.486 179.12 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 t -125.61 162.32 28.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.243 -179.256 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 98.0 m -100.39 152.27 20.54 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.042 0.449 . . . . 0.0 110.8 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.423 HG22 ' N ' ' A' ' 21' ' ' GLY . 7.0 mt -114.47 163.86 11.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.573 -179.146 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.423 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.527 -1.151 . . . . 0.0 112.002 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 64.9 m . . . . . 0 CA--C 1.529 0.145 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.6 pt -131.41 148.44 32.72 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.36 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 -179.124 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 65.4 mtt85 -85.06 99.06 10.78 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 176.063 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.578 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.59 151.63 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.846 0.355 . . . . 0.0 111.18 -177.23 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -95.09 8.41 43.07 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.392 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 16.4 ptp180 -99.72 -175.89 3.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.458 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.34 -177.73 31.48 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.392 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.79 114.2 3.09 Favored 'Cis proline' 0 C--N 1.343 0.279 0 C-N-CA 123.381 -1.508 . . . . 0.0 112.532 0.132 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.59 161.81 8.6 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.5 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -78.35 122.9 26.37 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.148 0.499 . . . . 0.0 111.043 179.734 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.578 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -160.48 -165.16 1.37 Allowed 'General case' 0 CA--C 1.512 -0.495 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.614 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -135.28 143.96 46.53 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.102 0.477 . . . . 0.0 110.707 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.44 HG22 ' CG2' ' A' ' 9' ' ' ILE . 31.1 m -118.49 168.42 10.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.678 -179.294 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.6 m -96.4 152.22 18.81 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 120.979 0.419 . . . . 0.0 111.071 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.429 HG22 ' N ' ' A' ' 21' ' ' GLY . 9.5 mt -107.85 163.71 5.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.376 -179.53 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.429 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.25 1.12 0 CA-C-O 118.117 -1.379 . . . . 0.0 111.827 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.435 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.9 m . . . . . 0 C--O 1.23 0.053 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.583 HG12 HD11 ' A' ' 20' ' ' ILE . 2.4 pt -132.3 146.68 32.67 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.504 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.46 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 45.9 mtp85 -84.46 103.46 13.63 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.063 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.684 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.3 OUTLIER -78.01 153.83 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.188 -177.299 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.514 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 13.3 mp0 -92.61 13.21 20.61 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.241 -179.167 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 49.5 mtp85 -97.3 -176.06 3.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.921 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.76 177.35 30.42 Favored Glycine 0 C--N 1.332 0.323 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.409 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.96 135.9 38.66 Favored 'Cis proline' 0 C--N 1.344 0.317 0 C-N-CA 122.987 -1.672 . . . . 0.0 112.697 0.124 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 59.68 -104.34 0.55 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.112 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 8.0 ttp180 -160.07 134.11 7.31 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.684 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -159.79 -167.96 2.13 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.599 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.46 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -137.02 148.71 47.01 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.5 179.455 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.544 HG23 HD12 ' A' ' 9' ' ' ILE . 4.4 t -121.52 164.05 18.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.29 -179.241 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.479 ' C ' HD13 ' A' ' 20' ' ' ILE . 91.7 m -113.55 140.49 48.11 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.981 0.42 . . . . 0.0 111.238 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.641 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -124.98 156.6 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.724 179.705 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.263 -1.299 . . . . 0.0 112.372 179.792 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.4 m . . . . . 0 C--O 1.232 0.142 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.623 HG12 HD11 ' A' ' 20' ' ' ILE . 8.5 pt -131.85 147.35 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 113.564 0.95 . . . . 0.0 113.564 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.682 ' H ' ' HD2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -85.02 101.91 12.78 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 106.325 -1.731 . . . . 0.0 106.325 175.235 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.489 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.1 OUTLIER -76.25 150.05 6.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.911 -176.404 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.439 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 17.7 mp0 -94.11 9.47 37.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.998 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 10.6 ptp180 -99.09 -173.62 2.54 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.908 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.35 -176.1 31.47 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.423 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -80.7 108.98 1.36 Allowed 'Cis proline' 0 CA--C 1.531 0.334 0 C-N-CA 122.886 -1.714 . . . . 0.0 112.597 0.128 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.23 169.77 38.0 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.682 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -71.36 123.79 23.1 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.742 0.306 . . . . 0.0 110.952 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.489 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -160.96 -169.32 2.33 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.243 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.443 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -145.36 141.15 28.23 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.942 178.994 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.427 HG12 ' N ' ' A' ' 19' ' ' THR . 5.5 t -115.5 163.95 12.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.398 -178.705 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.427 ' N ' HG12 ' A' ' 18' ' ' VAL . 92.6 m -100.07 158.37 15.89 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.292 0.567 . . . . 0.0 110.786 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.623 HD11 HG12 ' A' ' 7' ' ' ILE . 1.0 OUTLIER -140.99 153.67 20.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.918 -178.762 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.443 -1.198 . . . . 0.0 112.153 179.688 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.523 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.4 m . . . . . 0 N--CA 1.456 -0.137 0 CA-C-O 120.573 0.225 . . . . 0.0 110.785 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 2.8 pt -132.48 147.85 31.91 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -86.67 102.93 14.66 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 175.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.641 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.78 153.63 5.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.859 -177.451 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.406 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 17.3 tt0 -99.02 10.96 40.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.363 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -98.69 -177.03 3.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.751 0.31 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -108.76 -176.24 21.68 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.245 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -77.37 114.59 3.28 Favored 'Cis proline' 0 C--N 1.343 0.245 0 C-N-CA 122.93 -1.696 . . . . 0.0 112.337 -0.152 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.91 147.35 6.92 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.109 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.9 mpt_? -77.56 127.01 31.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.996 0.426 . . . . 0.0 110.877 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.641 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -156.19 -169.0 2.91 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.888 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.523 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -133.88 142.18 47.68 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.977 0.418 . . . . 0.0 110.948 179.521 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.544 HG23 HD12 ' A' ' 9' ' ' ILE . 3.8 t -110.58 162.73 7.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.053 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.448 HG23 ' OG ' ' A' ' 6' ' ' SER . 78.8 m -124.91 114.18 18.83 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.83 0.348 . . . . 0.0 111.379 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.599 HD13 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -100.42 179.65 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.774 178.893 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.739 -1.034 . . . . 0.0 113.103 -179.867 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.3 m . . . . . 0 CA--C 1.529 0.172 0 CA-C-O 120.373 0.13 . . . . 0.0 111.084 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.43 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 3.4 pt -131.28 145.96 34.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 113.742 1.016 . . . . 0.0 113.742 -179.311 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.3 mtt-85 -83.56 95.64 8.38 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 176.468 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.538 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.1 OUTLIER -76.37 142.94 13.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.102 0.477 . . . . 0.0 111.19 -176.933 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 58.7 mm-40 -92.66 11.43 26.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.453 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -98.03 173.25 7.14 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.25 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.7 -175.46 30.95 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.723 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -80.65 119.66 6.6 Favored 'Cis proline' 0 C--N 1.347 0.453 0 C-N-CA 123.326 -1.531 . . . . 0.0 112.34 -0.066 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.67 166.61 41.65 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.548 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.439 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 1.7 mpt_? -89.18 134.99 33.81 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.736 0.303 . . . . 0.0 110.593 179.546 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.538 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -168.85 -166.63 0.67 Allowed 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.141 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.43 ' HA ' ' O ' ' A' ' 7' ' ' ILE . 0.4 OUTLIER -141.75 139.88 32.94 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.923 178.681 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.47 HG22 ' CG2' ' A' ' 9' ' ' ILE . 26.8 m -112.39 166.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.899 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 83.3 m -98.89 156.48 16.87 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.171 0.51 . . . . 0.0 111.594 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.409 HG22 ' N ' ' A' ' 21' ' ' GLY . 8.5 mt -120.21 167.17 13.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.195 -0.912 . . . . 0.0 109.945 -179.126 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.409 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.247 0.911 0 CA-C-O 118.281 -1.288 . . . . 0.0 112.017 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.1 m . . . . . 0 N--CA 1.462 0.135 0 CA-C-O 120.584 0.231 . . . . 0.0 110.568 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.504 HG23 HD11 ' A' ' 20' ' ' ILE . 3.6 pt -130.33 150.41 34.58 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.314 0 CA-C-O 121.022 0.439 . . . . 0.0 112.005 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 12.3 ptm180 -95.67 90.98 5.89 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 176.47 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.868 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -76.92 144.35 11.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.131 -177.122 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -97.87 9.95 41.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.811 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.559 ' HD2' ' N ' ' A' ' 11' ' ' ARG . 2.1 mpt_? -101.84 -179.49 4.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.241 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -102.45 -178.86 27.23 Favored Glycine 0 CA--C 1.516 0.156 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.272 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.47 114.4 3.33 Favored 'Cis proline' 0 C--N 1.346 0.409 0 C-N-CA 123.538 -1.442 . . . . 0.0 111.985 0.055 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 87.5 147.38 12.36 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.394 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 20.2 mmt85 -99.96 122.22 42.54 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.481 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -169.76 -173.86 1.71 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.136 0.494 . . . . 0.0 110.991 -179.305 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.0 120.85 34.82 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.547 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.868 HG23 HD12 ' A' ' 9' ' ' ILE . 5.2 t -109.65 162.04 7.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.44 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.417 ' N ' HG12 ' A' ' 18' ' ' VAL . 97.0 m -100.66 158.83 15.65 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.389 0.614 . . . . 0.0 111.802 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.504 HD11 HG23 ' A' ' 7' ' ' ILE . 6.2 mt -129.0 165.61 28.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.273 -179.309 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.192 179.139 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.3 m . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.795 0.331 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.0 pt -130.46 152.83 38.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.147 -179.571 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.464 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 32.9 ptt180 -95.79 93.36 7.03 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 176.407 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.485 HG23 HG22 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -76.3 148.02 7.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.06 0.457 . . . . 0.0 111.395 -176.872 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -89.85 11.27 20.74 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.805 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 65.2 mtt85 -98.35 -173.54 2.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.352 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.459 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.79 178.19 29.63 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.68 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -75.39 108.06 1.01 Allowed 'Cis proline' 0 C--N 1.344 0.33 0 C-N-CA 123.449 -1.479 . . . . 0.0 112.268 -0.051 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.459 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 68.97 160.37 2.08 Favored Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.572 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 16.3 tpp85 -64.42 118.1 8.26 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.576 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.431 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -151.32 -178.55 6.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.249 0.547 . . . . 0.0 111.622 -179.563 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -111.01 130.0 55.73 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.44 179.567 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.485 HG22 HG23 ' A' ' 9' ' ' ILE . 16.5 m -119.11 142.34 34.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.705 179.206 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 68.1 m -100.11 115.28 29.43 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.479 -179.317 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.5 pt -102.19 148.25 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.781 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.187 179.02 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.623 -1.098 . . . . 0.0 112.314 -179.82 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.8 m . . . . . 0 C--O 1.231 0.098 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 6.2 pt -131.45 145.07 35.78 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.561 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.47 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 14.4 ptt85 -90.43 98.44 11.78 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 175.831 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.636 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -78.17 147.04 7.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.963 0.411 . . . . 0.0 111.485 -176.853 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 21.8 mp0 -94.15 9.48 37.68 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.46 -179.762 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.412 HH11 ' HD3' ' A' ' 11' ' ' ARG . 11.3 ptt180 -99.21 -177.75 3.71 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.736 0.303 . . . . 0.0 110.744 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.15 -176.33 30.39 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.466 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -79.08 106.91 0.94 Allowed 'Cis proline' 0 C--N 1.345 0.361 0 C-N-CA 122.958 -1.684 . . . . 0.0 112.779 -0.034 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.24 148.28 10.12 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.402 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 18.3 mmt85 -65.71 131.79 47.2 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.688 0.28 . . . . 0.0 110.829 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.636 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -167.6 -173.45 2.19 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.033 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.47 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -136.36 138.65 41.84 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.38 179.301 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.541 HG23 HD12 ' A' ' 9' ' ' ILE . 2.6 t -110.28 162.5 7.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.252 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 99.1 m -104.62 152.37 22.53 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.487 0.66 . . . . 0.0 111.063 179.747 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.406 HG22 ' H ' ' A' ' 21' ' ' GLY . 6.9 mt -114.9 166.79 8.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.776 -179.113 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.406 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.25 1.111 0 CA-C-O 118.458 -1.19 . . . . 0.0 112.305 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.5 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 13.2 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.707 0.289 . . . . 0.0 111.244 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.424 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 2.8 pt -132.35 148.23 31.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.369 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -179.671 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.426 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 82.3 mtm180 -87.08 98.53 11.34 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 175.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.657 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.71 141.96 14.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 120.231 -0.587 . . . . 0.0 110.731 -177.539 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -93.21 12.34 24.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.732 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 37.8 ptt180 -98.53 -175.7 3.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.395 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.79 177.98 29.5 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.496 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -78.99 109.34 1.44 Allowed 'Cis proline' 0 C--N 1.345 0.381 0 C-N-CA 123.223 -1.574 . . . . 0.0 112.506 0.107 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.12 157.84 21.47 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.723 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -74.08 135.32 42.97 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.586 0.232 . . . . 0.0 110.414 179.552 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.657 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.42 -168.13 0.68 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.052 0.453 . . . . 0.0 110.536 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.5 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.1 OUTLIER -139.02 145.48 39.68 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.26 179.129 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.4 t -119.53 161.46 18.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.455 -178.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 90.3 m -117.87 113.45 21.78 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.558 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 34.1 pt -102.24 163.36 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 C-N-CA 122.938 0.495 . . . . 0.0 111.606 -179.745 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.181 0 CA-C-O 117.986 -1.452 . . . . 0.0 113.359 178.791 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.511 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 14.2 m . . . . . 0 N--CA 1.456 -0.145 0 CA-C-O 120.522 0.201 . . . . 0.0 110.652 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.606 HG12 HD11 ' A' ' 20' ' ' ILE . 1.2 pt -130.9 150.44 34.61 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -179.517 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.521 ' H ' ' HD3' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -89.11 99.82 12.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 176.382 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.588 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -78.7 144.12 11.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.506 -0.478 . . . . 0.0 111.446 -177.542 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 44.9 mt-30 -83.57 11.5 7.05 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.837 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.447 ' H ' HG12 ' A' ' 9' ' ' ILE . 94.2 mtt180 -98.52 -175.07 2.98 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.352 -179.667 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.412 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -102.18 -178.12 27.65 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.288 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.66 107.62 1.0 Allowed 'Cis proline' 0 C--N 1.343 0.265 0 C-N-CA 123.103 -1.624 . . . . 0.0 112.412 0.003 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.412 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 76.99 155.33 6.55 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.385 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.457 ' NE ' ' H ' ' A' ' 15' ' ' ARG . 0.1 OUTLIER -62.31 111.41 1.98 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.911 0.386 . . . . 0.0 110.723 179.762 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.588 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -144.13 -172.76 3.84 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 115.806 -0.633 . . . . 0.0 109.95 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.511 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -136.17 142.69 44.18 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.526 179.278 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.0 t -111.64 161.26 10.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.26 -179.262 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 71.8 m -118.32 111.0 18.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.579 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.606 HD11 HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -109.02 178.28 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.931 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.758 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.438 -1.201 . . . . 0.0 112.165 179.69 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.4 m . . . . . 0 N--CA 1.456 -0.142 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 pt -130.98 149.79 33.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -179.014 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.424 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 7.4 ptm180 -93.32 92.3 7.62 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 176.024 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.538 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.57 147.26 7.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.39 -176.63 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -95.17 11.12 33.41 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.25 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -98.26 -174.72 2.91 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.473 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -100.24 177.74 28.81 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.485 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.98 108.69 1.08 Allowed 'Cis proline' 0 C--N 1.344 0.31 0 C-N-CA 123.096 -1.626 . . . . 0.0 112.264 -0.111 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.473 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 72.47 150.67 1.19 Allowed Glycine 0 C--N 1.333 0.363 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.347 -179.601 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.427 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 1.3 mpt_? -73.34 133.26 43.79 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.344 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.538 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -164.88 -175.29 3.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.19 0.519 . . . . 0.0 111.31 -179.695 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -106.74 119.05 38.28 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.793 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.489 HG22 HG23 ' A' ' 9' ' ' ILE . 17.4 m -110.02 154.78 11.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.977 179.078 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 98.8 m -105.53 154.44 20.37 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.417 0.627 . . . . 0.0 111.933 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -130.42 147.26 33.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.505 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.4 -1.222 . . . . 0.0 112.482 179.702 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.5 m . . . . . 0 CA--C 1.529 0.142 0 CA-C-O 120.62 0.248 . . . . 0.0 111.102 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.58 HG12 HD11 ' A' ' 20' ' ' ILE . 3.9 pt -131.38 148.28 32.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 121.135 0.493 . . . . 0.0 112.219 179.38 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.452 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 38.9 ttt180 -93.8 98.09 10.85 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 176.419 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.488 ' O ' ' HD3' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -75.6 149.21 6.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 C-N-CA 120.766 -0.373 . . . . 0.0 110.558 -177.328 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.435 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 53.7 tt0 -94.68 11.41 31.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.243 -179.089 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.416 ' HG2' ' CG1' ' A' ' 9' ' ' ILE . 5.5 ptp180 -98.48 178.29 5.07 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.461 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.98 -177.01 30.67 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.59 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -77.0 110.7 1.77 Allowed 'Cis proline' 0 C--N 1.343 0.285 0 C-N-CA 123.287 -1.547 . . . . 0.0 112.323 -0.015 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.61 156.22 9.25 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.473 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.488 ' HD3' ' O ' ' A' ' 9' ' ' ILE . 17.7 tpp85 -71.9 129.35 38.37 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 179.621 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.425 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -152.04 -176.58 5.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.308 0.575 . . . . 0.0 111.875 -179.464 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.452 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -119.34 128.15 53.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.601 179.706 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.478 HG22 HG23 ' A' ' 9' ' ' ILE . 16.9 m -116.5 150.51 18.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.155 178.727 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 97.0 m -96.1 159.32 15.02 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.518 0.675 . . . . 0.0 111.877 -179.282 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.58 HD11 HG12 ' A' ' 7' ' ' ILE . 2.4 mt -135.48 155.15 36.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 114.537 -1.21 . . . . 0.0 108.945 -179.355 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.302 -1.277 . . . . 0.0 112.559 179.618 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 13.4 m . . . . . 0 N--CA 1.456 -0.172 0 CA-C-O 120.539 0.209 . . . . 0.0 110.778 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.51 HG12 HD11 ' A' ' 20' ' ' ILE . 1.7 pt -131.79 148.39 32.4 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 N-CA-C 113.313 0.857 . . . . 0.0 113.313 -179.332 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.435 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 5.8 ptm180 -84.38 108.7 17.35 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 175.756 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.628 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.3 OUTLIER -78.16 152.2 5.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.671 -177.79 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -90.5 11.63 21.19 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.019 -179.382 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.5 mtp85 -98.02 174.89 6.33 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.457 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.4 179.45 32.04 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.65 -179.376 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_exo -70.3 137.8 47.08 Favored 'Cis proline' 0 C--N 1.342 0.196 0 C-N-CA 123.124 -1.615 . . . . 0.0 112.527 0.241 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.45 ' C ' ' HD2' ' A' ' 15' ' ' ARG . . . 55.75 -145.31 32.98 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.087 -179.838 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.45 ' HD2' ' C ' ' A' ' 14' ' ' GLY . 9.5 mpt_? -117.99 128.16 54.52 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.628 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -149.53 -175.97 5.21 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.55 -179.434 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.469 ' HB2' ' C ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -139.83 148.79 42.64 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.975 179.746 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 6' ' ' SER . 9.1 t -117.68 161.74 16.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.103 -179.661 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.423 ' N ' HG12 ' A' ' 18' ' ' VAL . 80.9 m -118.33 112.57 20.21 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.249 179.576 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.667 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -117.52 152.69 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-O 120.9 0.381 . . . . 0.0 111.431 -179.728 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.528 -1.151 . . . . 0.0 112.139 -179.737 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.645 0.259 . . . . 0.0 111.143 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.456 HG12 HD11 ' A' ' 20' ' ' ILE . 5.9 pt -131.02 146.11 34.44 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-O 121.152 0.501 . . . . 0.0 112.351 179.123 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 13.4 tpt180 -96.87 85.9 3.89 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 176.605 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.79 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -77.31 144.5 11.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.827 -177.354 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 38.6 tt0 -96.52 7.01 47.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.187 0.518 . . . . 0.0 110.131 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -99.43 -177.03 3.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.536 179.78 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.84 -178.28 29.37 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.126 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -80.14 108.87 1.32 Allowed 'Cis proline' 0 C--N 1.345 0.352 0 C-N-CA 123.428 -1.488 . . . . 0.0 112.328 0.161 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.52 133.06 5.75 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.884 179.611 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -81.61 110.91 17.42 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.497 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -163.29 -168.86 1.81 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.267 0.556 . . . . 0.0 111.087 -179.238 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -97.79 128.19 44.26 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.758 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.79 HG23 HD12 ' A' ' 9' ' ' ILE . 11.5 t -109.13 162.69 6.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 178.876 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.442 ' N ' HG12 ' A' ' 18' ' ' VAL . 9.2 m -104.22 160.1 15.15 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.561 0.696 . . . . 0.0 111.541 -179.48 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.456 HD11 HG12 ' A' ' 7' ' ' ILE . 9.1 mt -140.71 167.73 17.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.714 -179.557 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.406 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.324 -1.264 . . . . 0.0 112.846 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.3 m . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.642 0.258 . . . . 0.0 110.714 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.0 pt -130.96 149.37 33.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.5 ttp85 -91.95 92.03 8.13 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 176.112 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.58 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.32 145.07 10.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.135 0.493 . . . . 0.0 111.046 -177.034 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -91.92 11.84 23.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.053 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 10.1 mtp-105 -98.31 -168.02 1.59 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.628 -179.345 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.416 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -115.17 179.81 18.33 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.416 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -75.54 109.6 1.35 Allowed 'Cis proline' 0 C--N 1.344 0.336 0 C-N-CA 123.088 -1.63 . . . . 0.0 112.394 -0.023 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.416 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 82.29 133.32 1.77 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.227 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.43 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -77.97 116.61 18.59 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.786 0.327 . . . . 0.0 110.337 179.672 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.58 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -153.2 -172.22 4.17 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.289 0.566 . . . . 0.0 111.076 -179.343 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -96.55 120.85 37.63 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.062 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.51 HG22 HG23 ' A' ' 9' ' ' ILE . 12.7 m -109.63 148.27 13.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.169 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 65.0 m -113.58 131.46 56.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.128 0.49 . . . . 0.0 111.511 -179.346 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 pt -123.33 143.31 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 C-N-CA 123.83 0.852 . . . . 0.0 110.952 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.029 0 CA-C-O 118.11 -1.383 . . . . 0.0 113.511 179.306 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.5 m . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.691 0.282 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.9 pt -131.79 152.27 36.68 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.272 0 CA-C-O 121.257 0.551 . . . . 0.0 112.32 179.908 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.447 ' HD3' ' NH2' ' A' ' 15' ' ' ARG . 28.9 ttm105 -93.71 91.46 7.03 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 107.278 -1.378 . . . . 0.0 107.278 176.555 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.54 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.42 146.58 8.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.836 -177.717 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.54 ' H ' ' CD ' ' A' ' 10' ' ' GLN . 0.1 OUTLIER -98.95 9.54 43.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.906 -179.805 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -99.7 -169.94 1.82 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.224 179.926 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.17 174.2 27.21 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.455 -0.879 . . . . 0.0 112.404 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -81.65 108.13 1.2 Allowed 'Cis proline' 0 C--N 1.345 0.388 0 C-N-CA 123.152 -1.603 . . . . 0.0 112.777 0.132 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.03 137.02 0.66 Allowed Glycine 0 C--N 1.332 0.358 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.788 179.61 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.543 ' C ' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -66.02 130.98 45.12 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.388 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.54 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.22 -174.74 1.79 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.136 0.493 . . . . 0.0 111.007 -179.44 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -103.39 121.18 42.26 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.61 179.825 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.462 HG22 HG23 ' A' ' 9' ' ' ILE . 16.9 m -108.96 156.98 9.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.778 178.825 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.485 ' C ' HD13 ' A' ' 20' ' ' ILE . 75.6 m -118.48 148.28 42.76 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.08 0.467 . . . . 0.0 112.157 -178.658 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.599 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -124.97 177.75 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.187 179.119 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.157 0 CA-C-O 118.814 -0.992 . . . . 0.0 113.567 -179.761 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.3 m . . . . . 0 N--CA 1.462 0.13 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 pt -130.99 148.13 33.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 -179.502 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 13.7 tpp180 -95.56 91.48 6.17 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 176.037 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.465 HD12 HG23 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -76.47 144.71 11.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.819 -177.237 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.43 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 46.4 tt0 -88.66 11.64 16.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.826 -179.485 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.0 mtp-105 -96.59 -176.04 3.49 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.207 -179.23 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.494 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -107.73 -179.54 22.15 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.849 -179.412 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -73.4 107.28 0.87 Allowed 'Cis proline' 0 C--N 1.343 0.288 0 C-N-CA 123.282 -1.549 . . . . 0.0 112.387 0.172 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.494 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 74.35 141.89 0.71 Allowed Glycine 0 C--N 1.333 0.377 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.534 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.3 124.33 20.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.762 0.315 . . . . 0.0 110.625 179.501 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.426 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -147.33 -178.99 6.53 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.185 -179.665 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -108.69 122.12 46.46 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.452 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.465 HG23 HD12 ' A' ' 9' ' ' ILE . 3.9 t -109.27 158.78 9.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.341 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.7 m -107.04 154.75 20.66 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.414 0.626 . . . . 0.0 111.81 -179.717 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.493 HG22 ' H ' ' A' ' 21' ' ' GLY . 6.8 mt -125.34 171.9 13.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 114.698 -1.137 . . . . 0.0 109.308 -179.475 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.493 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.251 1.158 0 CA-C-O 118.384 -1.231 . . . . 0.0 111.978 179.59 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.428 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 19.9 m . . . . . 0 C--O 1.233 0.185 0 CA-C-O 120.314 0.102 . . . . 0.0 110.785 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.471 HG12 HD11 ' A' ' 20' ' ' ILE . 4.5 pt -132.38 146.36 33.11 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.392 0 N-CA-C 113.74 1.015 . . . . 0.0 113.74 -179.794 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.465 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 35.2 ttm180 -88.65 96.12 10.52 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 176.265 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.611 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.11 141.33 15.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 120.415 -0.514 . . . . 0.0 109.851 -178.165 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.8 tt0 -93.67 11.01 30.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.49 -178.677 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 46.2 ptt85 -98.39 -169.9 1.87 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.159 179.714 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.486 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.23 176.82 29.49 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.497 -0.859 . . . . 0.0 112.764 -179.412 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -74.23 109.11 1.1 Allowed 'Cis proline' 0 C--N 1.347 0.453 0 C-N-CA 123.151 -1.604 . . . . 0.0 112.51 0.001 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.486 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 71.81 156.82 2.79 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.495 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.0 mpt_? -67.83 133.7 49.64 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 120.789 0.328 . . . . 0.0 110.695 179.445 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.611 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -168.31 -164.61 0.54 Allowed 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.954 -179.626 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.465 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -141.27 137.11 32.27 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.654 179.181 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.529 HG23 HD12 ' A' ' 9' ' ' ILE . 4.1 t -110.77 163.75 7.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.921 -179.362 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.403 ' N ' HG12 ' A' ' 18' ' ' VAL . 53.8 m -108.91 131.59 54.88 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.811 0.815 . . . . 0.0 111.92 -179.895 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.545 HG22 ' H ' ' A' ' 21' ' ' GLY . 4.2 mt -100.63 174.96 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 113.983 -1.462 . . . . 0.0 109.175 179.251 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.545 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.609 -1.106 . . . . 0.0 112.541 179.273 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.4 m . . . . . 0 C--O 1.232 0.167 0 CA-C-O 120.572 0.225 . . . . 0.0 110.619 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.616 HG12 HD11 ' A' ' 20' ' ' ILE . 6.0 pt -130.6 147.85 33.12 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.411 0 CA-C-O 121.112 0.482 . . . . 0.0 112.295 -179.878 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.4 ' HA ' ' O ' ' A' ' 16' ' ' ALA . 75.7 ttt180 -89.64 100.26 13.1 Favored 'General case' 0 N--CA 1.445 -0.71 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 176.043 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.557 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.98 150.59 5.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-O 121.32 0.581 . . . . 0.0 111.854 -176.641 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 62.7 mt-30 -93.61 12.18 26.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.698 -179.811 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -98.1 177.05 5.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.967 -179.174 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.453 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -104.25 -178.88 25.17 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.629 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -74.08 108.4 1.0 Allowed 'Cis proline' 0 C--N 1.345 0.36 0 C-N-CA 123.278 -1.551 . . . . 0.0 112.254 0.02 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.453 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 74.31 148.53 1.49 Allowed Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.346 -179.814 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.502 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -59.79 145.71 44.34 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.823 0.344 . . . . 0.0 110.885 179.806 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.557 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -164.74 -177.19 4.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.928 0.394 . . . . 0.0 111.202 -179.565 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -117.22 123.52 46.83 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.287 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.516 HG22 HG23 ' A' ' 9' ' ' ILE . 20.2 m -113.2 155.92 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.026 178.619 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 42.9 m -99.86 159.46 15.06 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.153 0.502 . . . . 0.0 111.316 -179.633 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.616 HD11 HG12 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -142.09 154.5 18.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.179 -178.69 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.261 0 CA-C-O 118.424 -1.209 . . . . 0.0 113.729 178.696 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 24.0 m . . . . . 0 N--CA 1.452 -0.347 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.8 pt -128.45 146.59 33.66 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.352 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -179.414 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.473 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 53.9 ttp180 -95.83 92.86 6.74 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 176.257 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.452 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -75.99 154.72 5.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.577 -177.379 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.0 pt20 -97.05 12.03 34.04 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.211 -179.363 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.418 ' H ' HG12 ' A' ' 9' ' ' ILE . 97.7 mtt180 -97.44 -178.75 4.25 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.648 -179.345 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.02 -179.56 30.24 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.447 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -77.86 107.76 1.06 Allowed 'Cis proline' 0 C--N 1.346 0.418 0 C-N-CA 123.098 -1.626 . . . . 0.0 112.403 0.028 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.26 153.22 5.53 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.214 -179.865 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 40.1 mmt-85 -66.17 119.93 12.33 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.69 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.84 -179.13 6.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.157 0.504 . . . . 0.0 111.75 -179.458 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.473 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -114.23 125.77 54.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.995 -179.996 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.452 HG23 HD12 ' A' ' 9' ' ' ILE . 5.6 t -110.05 162.99 7.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.705 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 6' ' ' SER . 53.7 m -107.03 158.23 17.2 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.937 -0.305 . . . . 0.0 111.751 -179.464 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.6 mm -99.93 157.29 3.95 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.258 179.68 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.314 -1.27 . . . . 0.0 112.352 179.804 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.475 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.7 m . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 . . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.423 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 4.9 pt -131.28 147.82 32.85 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 N-CA-C 113.701 1.0 . . . . 0.0 113.701 -178.874 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.492 ' N ' ' HD2' ' A' ' 8' ' ' ARG . 2.2 mpt_? -86.94 99.72 12.07 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 176.012 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.581 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.85 143.3 12.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 C-N-CA 120.3 -0.56 . . . . 0.0 110.922 -177.452 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -85.77 11.89 10.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.342 -179.724 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.422 ' H ' HG12 ' A' ' 9' ' ' ILE . 78.9 ttt180 -98.04 158.7 15.39 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.89 -179.64 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.4 ' N ' ' HG2' ' A' ' 11' ' ' ARG . . . -99.73 -170.64 30.16 Favored Glycine 0 N--CA 1.452 -0.27 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.268 179.811 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -83.46 115.96 3.99 Favored 'Cis proline' 0 N--CA 1.462 -0.348 0 C-N-CA 123.091 -1.629 . . . . 0.0 112.592 0.084 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.26 117.43 3.93 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.539 179.747 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.456 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -59.45 121.17 10.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.099 0.476 . . . . 0.0 110.975 179.71 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.581 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -155.18 -168.93 3.01 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.419 -179.498 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.475 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -136.25 145.74 45.93 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.654 179.626 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.7 t -112.44 160.95 11.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.182 -179.711 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 52.0 m -119.93 112.99 19.88 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.132 179.814 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.582 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.1 OUTLIER -110.59 -179.41 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.015 178.983 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.618 -1.101 . . . . 0.0 112.276 179.705 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.1 m . . . . . 0 N--CA 1.455 -0.219 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.681 HG23 HD11 ' A' ' 20' ' ' ILE . 4.8 pt -130.64 148.94 33.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 N-CA-C 112.729 0.641 . . . . 0.0 112.729 -179.127 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 57.3 ttp85 -94.8 94.22 7.94 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 175.994 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.674 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -76.47 153.92 5.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.125 0.488 . . . . 0.0 111.606 -176.569 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.439 ' HA ' ' HD2' ' A' ' 15' ' ' ARG . 62.4 mt-30 -97.14 11.38 36.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.672 -0.695 . . . . 0.0 111.19 -179.523 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.96 159.44 14.93 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.823 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.92 -171.05 32.63 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.765 -179.091 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.76 113.81 2.85 Favored 'Cis proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.977 -1.676 . . . . 0.0 112.62 0.349 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.87 138.26 5.31 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.61 179.859 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.439 ' HD2' ' HA ' ' A' ' 10' ' ' GLN . 55.5 mmt-85 -74.86 125.41 28.76 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.416 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.433 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -151.84 -176.01 5.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.19 0.519 . . . . 0.0 112.006 -179.144 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -106.99 125.1 50.57 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.088 179.885 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.674 HG23 HD12 ' A' ' 9' ' ' ILE . 6.0 t -113.69 162.93 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 178.919 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.409 ' N ' HG12 ' A' ' 18' ' ' VAL . 52.9 m -103.36 151.26 22.95 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.07 0.462 . . . . 0.0 111.439 -179.827 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.681 HD11 HG23 ' A' ' 7' ' ' ILE . 8.2 mt -109.0 164.01 5.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.283 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.44 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 0.978 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.015 179.636 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 m . . . . . 0 CA--C 1.528 0.107 0 CA-C-O 120.527 0.203 . . . . 0.0 110.806 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.706 HG12 HD11 ' A' ' 20' ' ' ILE . 6.0 pt -131.13 150.12 34.15 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.346 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 179.347 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.405 ' O ' ' HG3' ' A' ' 8' ' ' ARG . 17.4 ptt85 -97.14 93.9 6.83 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 176.327 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.52 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.04 144.26 11.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.799 -177.072 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 19.8 tt0 -91.88 7.02 43.95 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.984 0.421 . . . . 0.0 110.966 -179.232 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.404 ' NH1' HG13 ' A' ' 9' ' ' ILE . 15.5 ptt85 -99.14 178.56 4.88 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.701 179.492 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.41 -177.91 32.77 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.523 -179.524 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.46 108.52 1.14 Allowed 'Cis proline' 0 C--N 1.342 0.225 0 C-N-CA 123.405 -1.498 . . . . 0.0 112.561 0.237 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 128.34 0.91 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.936 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.455 ' C ' ' HD2' ' A' ' 15' ' ' ARG . 3.1 tmm_? -65.56 113.65 4.35 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.439 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.52 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -149.02 -169.58 3.41 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.517 0.675 . . . . 0.0 111.89 -179.239 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -107.49 128.18 54.27 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.058 -0.973 . . . . 0.0 111.113 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.448 HG22 HG23 ' A' ' 9' ' ' ILE . 16.4 m -117.44 153.7 19.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.094 178.738 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.405 HG22 ' N ' ' A' ' 20' ' ' ILE . 57.3 m -94.08 158.71 15.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.476 0.655 . . . . 0.0 111.861 -179.048 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.706 HD11 HG12 ' A' ' 7' ' ' ILE . 3.1 mt -141.31 160.62 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-N 114.735 -1.121 . . . . 0.0 109.552 -179.447 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.996 0 CA-C-O 118.365 -1.241 . . . . 0.0 112.448 179.403 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.454 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 9.5 m . . . . . 0 N--CA 1.455 -0.177 0 CA-C-O 120.625 0.25 . . . . 0.0 111.421 . . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 1.5 pt -132.12 148.3 32.14 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -179.809 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.438 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 28.3 ptt-85 -80.92 104.45 11.43 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 176.114 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.662 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.63 158.77 5.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 C-N-CA 120.039 -0.664 . . . . 0.0 110.622 -177.736 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -99.68 12.31 36.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.819 -178.988 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.422 HH11 ' HD3' ' A' ' 11' ' ' ARG . 49.2 mtt180 -97.61 161.86 13.57 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.805 0.336 . . . . 0.0 110.76 -179.738 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.79 -175.37 30.83 Favored Glycine 0 N--CA 1.452 -0.267 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.564 -179.69 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.62 119.43 6.3 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.978 -1.676 . . . . 0.0 112.412 -0.167 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.77 144.63 6.1 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.186 -179.772 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.5 mpt_? -77.44 117.2 18.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.041 0.448 . . . . 0.0 111.05 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.662 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -136.52 -173.03 3.3 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.823 179.639 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 7' ' ' ILE . 0.4 OUTLIER -130.7 143.62 50.87 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.048 0.451 . . . . 0.0 110.956 179.608 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.579 HG13 HD12 ' A' ' 9' ' ' ILE . 25.8 m -112.43 163.81 9.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.991 -179.542 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.4 m -120.3 123.72 43.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.297 -179.739 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.67 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -114.59 157.05 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 C-N-CA 123.031 0.532 . . . . 0.0 110.798 179.275 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.201 -1.333 . . . . 0.0 112.177 179.933 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.529 0.171 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 . . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.551 HG23 HD11 ' A' ' 20' ' ' ILE . 3.1 pt -130.59 151.77 36.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.437 0 CA-C-O 121.312 0.577 . . . . 0.0 112.356 179.932 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.473 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 4.7 ptm85 -96.61 99.29 10.93 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 176.282 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.601 HD13 ' H ' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -77.79 156.56 5.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.242 0.544 . . . . 0.0 111.955 -176.744 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -94.77 12.56 27.52 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.073 179.075 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.2 ttt180 -97.03 -168.32 1.68 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.71 -179.335 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.503 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -107.45 176.43 20.9 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.442 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -73.02 108.71 0.97 Allowed 'Cis proline' 0 CA--C 1.53 0.288 0 C-N-CA 123.311 -1.537 . . . . 0.0 112.369 0.038 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.503 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 65.57 173.61 4.46 Favored Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.673 -179.937 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.459 HH21 ' NE ' ' A' ' 8' ' ' ARG . 16.1 tpt180 -69.33 115.14 8.25 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.766 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.04 -177.94 5.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.172 0.51 . . . . 0.0 111.52 -179.26 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.473 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -115.44 132.02 56.75 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.053 179.887 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.452 HG22 HG23 ' A' ' 9' ' ' ILE . 19.1 m -121.98 161.63 22.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.74 -0.663 . . . . 0.0 109.819 178.838 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 41.5 m -96.7 155.67 16.67 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.015 0.436 . . . . 0.0 111.06 -179.631 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.551 HD11 HG23 ' A' ' 7' ' ' ILE . 20.7 mt -121.27 165.52 16.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.458 179.584 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.478 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.249 1.086 0 CA-C-O 118.202 -1.332 . . . . 0.0 111.982 179.917 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 m . . . . . 0 C--O 1.231 0.125 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.417 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 3.7 pt -131.15 145.96 34.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 113.551 0.945 . . . . 0.0 113.551 -179.411 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.428 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 76.7 mtp180 -82.31 92.67 7.0 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 176.431 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.573 HD13 HG13 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -77.71 148.49 6.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.043 0.449 . . . . 0.0 110.92 -177.524 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -101.15 9.7 41.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.16 0.505 . . . . 0.0 109.884 179.05 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 64.5 mtp180 -99.86 -168.8 1.65 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.754 -179.269 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.7 -176.4 19.67 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 121.197 -0.525 . . . . 0.0 112.047 179.803 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -83.01 113.51 2.95 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.487 -1.464 . . . . 0.0 112.357 -0.075 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.11 128.31 6.03 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.219 -179.836 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 13.9 mmt180 -70.95 96.93 1.35 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.856 0.36 . . . . 0.0 110.728 -179.881 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.449 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -155.27 179.31 9.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.351 -179.842 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.428 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -103.79 147.35 27.38 Favored 'General case' 0 C--N 1.325 -0.5 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.646 179.851 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.573 HG13 HD13 ' A' ' 9' ' ' ILE . 31.3 m -119.18 165.52 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.136 -179.809 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 94.0 m -98.48 153.6 18.49 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.116 0.484 . . . . 0.0 111.03 179.835 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.8 mt -114.24 163.78 11.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.328 -179.237 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.208 -1.329 . . . . 0.0 112.001 179.827 . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.6 m . . . . . 0 N--CA 1.453 -0.314 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 . . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.68 HG23 HD11 ' A' ' 20' ' ' ILE . 8.0 pt -131.48 146.72 33.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -178.269 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -92.26 93.07 8.47 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 176.175 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.564 HD12 HG23 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -75.31 148.15 7.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.02 0.438 . . . . 0.0 111.026 -176.697 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 69.9 mt-30 -100.16 11.83 38.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.028 -179.384 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -97.78 -169.3 1.81 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.493 -0.322 . . . . 0.0 110.187 -179.864 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.14 -177.17 19.16 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.429 179.772 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -79.55 104.98 0.64 Allowed 'Cis proline' 0 C--N 1.344 0.314 0 C-N-CA 123.485 -1.465 . . . . 0.0 112.143 -0.117 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.49 145.46 13.76 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.97 179.883 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 26.3 mtt180 -78.11 137.29 38.13 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 110.523 -0.177 . . . . 0.0 110.523 179.813 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.439 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -168.53 -173.73 2.01 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-O 121.22 0.533 . . . . 0.0 111.227 -179.782 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -111.97 120.59 42.41 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.359 179.504 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.564 HG23 HD12 ' A' ' 9' ' ' ILE . 4.1 t -110.03 160.5 9.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.313 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 46.2 m -98.51 158.8 15.37 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.889 0.376 . . . . 0.0 110.158 179.356 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.68 HD11 HG23 ' A' ' 7' ' ' ILE . 7.1 mt -119.33 161.58 18.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.527 179.76 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.135 0 CA-C-O 118.455 -1.192 . . . . 0.0 112.22 179.958 . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.52 ' OG ' HG23 ' A' ' 19' ' ' THR . 12.3 m . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.534 0.207 . . . . 0.0 111.216 . . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.9 pt -132.64 149.52 32.17 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.343 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -179.956 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.556 ' H ' ' HD3' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -90.1 105.45 17.82 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 175.514 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.584 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -78.57 156.52 4.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 C-N-CA 120.501 -0.479 . . . . 0.0 111.281 -177.436 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.512 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 10.2 mp0 -94.72 10.28 35.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.48 179.904 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -99.67 179.59 4.49 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.858 -179.808 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.15 -176.61 30.41 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.186 179.859 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -76.57 107.68 1.01 Allowed 'Cis proline' 0 N--CA 1.464 -0.242 0 C-N-CA 123.246 -1.564 . . . . 0.0 112.521 0.052 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.21 151.54 7.23 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.835 179.674 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 16.5 mmm180 -60.13 109.97 1.1 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.71 0.29 . . . . 0.0 110.64 179.417 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.584 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -141.06 -177.07 4.93 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.439 -179.937 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.501 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -135.46 146.03 47.78 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.478 179.447 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.0 t -112.99 160.66 12.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.168 -179.495 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.52 HG23 ' OG ' ' A' ' 6' ' ' SER . 83.9 m -126.88 114.83 18.4 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.449 179.633 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.611 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -112.47 161.99 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.762 179.729 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.281 -1.289 . . . . 0.0 112.32 -179.996 . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 16.0 m . . . . . 0 N--CA 1.452 -0.332 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 . . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.4 pt -124.07 150.72 28.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 113.237 0.829 . . . . 0.0 113.237 -178.203 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.453 ' HD2' ' O ' ' A' ' 16' ' ' ALA . 14.6 tpt180 -92.22 94.37 9.15 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 176.197 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.474 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.28 148.53 7.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.912 -177.084 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 33.5 mt-30 -97.4 11.51 36.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.188 -179.569 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -98.34 -174.9 2.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.116 179.827 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.446 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.94 175.7 27.7 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.569 -179.763 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -76.46 109.46 1.36 Allowed 'Cis proline' 0 C--N 1.346 0.411 0 C-N-CA 123.247 -1.564 . . . . 0.0 112.438 -0.02 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.446 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 69.52 168.1 5.99 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.292 -179.743 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.454 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 4.8 mpt_? -80.11 134.27 36.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 110.547 179.662 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.474 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -160.95 178.95 8.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.0 -179.751 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -109.85 124.08 50.71 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.917 179.739 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.462 HG22 HG23 ' A' ' 9' ' ' ILE . 12.9 m -114.28 140.01 37.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.399 179.117 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.7 m -101.48 142.15 33.29 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.857 -179.598 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.675 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -112.36 161.14 11.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.986 179.788 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.287 -1.285 . . . . 0.0 112.029 179.985 . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.499 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 14.8 m . . . . . 0 N--CA 1.454 -0.232 0 CA-C-O 120.566 0.222 . . . . 0.0 110.937 . . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 2.2 pt -131.9 147.58 32.39 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -179.52 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.568 ' HB3' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -85.74 100.59 12.12 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 176.155 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.474 ' CD1' HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -78.54 158.16 4.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.561 -0.456 . . . . 0.0 110.777 -177.815 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.425 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 13.1 mp0 -100.89 10.17 41.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.86 0.362 . . . . 0.0 110.463 179.249 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 74.2 ttt180 -99.02 165.0 11.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.519 -179.527 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.82 -175.13 33.65 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.205 -179.976 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -74.81 115.83 3.64 Favored 'Cis proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.132 -1.612 . . . . 0.0 112.553 0.314 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.67 124.14 1.01 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.974 -0.632 . . . . 0.0 112.481 179.765 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.3 mtt85 -61.58 98.84 0.1 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.848 0.356 . . . . 0.0 110.418 179.656 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -131.0 -178.91 5.03 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.582 -179.636 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.465 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.3 OUTLIER -117.38 145.28 44.18 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.593 179.765 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.6 t -114.81 161.19 13.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.256 -179.475 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 86.9 m -120.69 109.06 14.75 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.081 179.568 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.582 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -104.44 171.37 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 CA-C-O 120.816 0.341 . . . . 0.0 111.387 -179.813 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.464 -1.187 . . . . 0.0 112.544 179.714 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 25.1 ttp-105 . . . . . 0 N--CA 1.488 1.426 0 N-CA-C 110.462 -0.199 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 62.0 tttp -147.66 152.57 38.08 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.123 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 88.2 p -142.35 156.79 45.26 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.168 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.594 HG23 HD11 ' A' ' 20' ' ' ILE . 3.8 pt -132.01 147.61 32.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 112.113 0.412 . . . . 0.0 112.113 179.157 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.483 ' O ' ' CD ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -91.19 91.6 8.3 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 176.118 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.525 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.59 150.51 6.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.613 -176.776 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 22.5 mp0 -89.0 12.52 15.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.621 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -96.88 177.94 5.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.32 -179.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.501 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.97 178.2 29.4 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.966 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -73.37 108.26 0.95 Allowed 'Cis proline' 0 C--N 1.344 0.326 0 C-N-CA 123.337 -1.526 . . . . 0.0 112.279 0.07 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.501 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 67.41 156.36 0.62 Allowed Glycine 0 C--N 1.333 0.391 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.422 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -60.27 126.04 25.96 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.766 0.317 . . . . 0.0 110.502 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.525 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -149.18 177.84 9.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.887 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -109.67 120.09 41.4 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.674 179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.499 HG22 HG23 ' A' ' 9' ' ' ILE . 15.1 m -109.27 152.8 11.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.759 178.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.6 m -89.44 156.37 18.71 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.957 0.408 . . . . 0.0 111.24 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.594 HD11 HG23 ' A' ' 7' ' ' ILE . 8.3 mt -120.63 163.06 18.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.022 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.425 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.503 -1.165 . . . . 0.0 112.075 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 . . . . . 0 N--CA 1.485 1.289 0 N-CA-C 110.518 -0.178 . . . . 0.0 110.518 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.635 ' HD3' ' N ' ' A' ' 6' ' ' SER . 2.2 tmtp? -138.33 149.91 46.08 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.635 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 14.7 m -140.5 140.76 35.34 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.849 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.536 HG23 ' HE2' ' A' ' 5' ' ' LYS . 1.6 pt -131.43 146.05 34.26 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.567 0 N-CA-C 113.696 0.998 . . . . 0.0 113.696 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -78.8 102.24 8.04 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 176.119 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.555 HD13 HG13 ' A' ' 18' ' ' VAL . 1.8 pt -77.54 151.28 5.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.657 -177.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -100.95 10.49 41.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.464 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 36.0 ptt180 -109.25 -178.31 3.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.827 0.346 . . . . 0.0 111.017 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.54 -172.64 30.78 Favored Glycine 0 C--N 1.329 0.187 0 C-N-CA 121.108 -0.568 . . . . 0.0 112.308 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.98 117.66 5.33 Favored 'Cis proline' 0 N--CA 1.462 -0.349 0 C-N-CA 123.34 -1.525 . . . . 0.0 112.407 0.143 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 145.64 4.73 Favored Glycine 0 C--N 1.33 0.221 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.293 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.492 ' C ' ' HD2' ' A' ' 15' ' ' ARG . 4.8 ppt_? -66.72 128.8 37.66 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.44 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -169.52 -166.47 0.6 Allowed 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 121.199 0.523 . . . . 0.0 110.593 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.531 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.1 OUTLIER -137.62 152.57 49.5 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.367 179.572 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.555 HG13 HD13 ' A' ' 9' ' ' ILE . 19.5 m -115.75 154.9 17.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.972 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 86.3 m -113.74 110.71 20.61 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.359 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.509 HG13 ' HB3' ' A' ' 5' ' ' LYS . 7.8 pt -100.22 173.06 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.674 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.711 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.242 -1.31 . . . . 0.0 112.287 179.744 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 86.4 mtm180 . . . . . 0 N--CA 1.485 1.298 0 CA-C-O 120.56 0.219 . . . . 0.0 110.789 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.563 ' HD3' ' N ' ' A' ' 6' ' ' SER . 5.3 tmtm? -100.03 147.19 25.89 Favored 'General case' 0 C--O 1.223 -0.34 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.563 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 50.6 m -140.67 154.61 46.46 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.236 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.8 pt -130.95 152.04 36.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.318 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -179.369 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.498 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 22.8 ttm180 -94.97 104.32 16.2 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 175.714 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.47 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.37 144.29 11.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 C-N-CA 119.845 -0.742 . . . . 0.0 110.791 -177.554 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 46.3 tp60 -93.88 12.46 25.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.426 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.3 mtt-85 -97.47 173.46 7.16 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.332 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.415 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.74 -179.83 30.52 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.1 108.63 1.14 Allowed 'Cis proline' 0 C--N 1.345 0.381 0 C-N-CA 123.34 -1.525 . . . . 0.0 112.256 0.039 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.415 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 75.54 152.18 3.48 Favored Glycine 0 C--N 1.332 0.335 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.467 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.491 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -62.34 152.64 33.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.875 0.369 . . . . 0.0 111.096 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.47 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.17 178.54 3.81 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.998 0.428 . . . . 0.0 111.152 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.498 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.6 OUTLIER -120.56 129.7 53.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.0 179.718 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 6.2 t -120.85 159.92 22.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.8 m -102.77 156.11 17.86 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.204 0.526 . . . . 0.0 111.316 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.49 HD12 ' HD2' ' A' ' 5' ' ' LYS . 8.7 mt -118.1 164.73 14.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.177 -0.92 . . . . 0.0 109.816 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.414 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 0.999 0 CA-C-O 118.416 -1.214 . . . . 0.0 111.977 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 . . . . . 0 N--CA 1.484 1.262 0 CA-C-O 120.632 0.253 . . . . 0.0 110.799 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.457 ' HD2' ' H ' ' A' ' 6' ' ' SER . 0.0 OUTLIER -141.85 147.97 38.06 Favored 'General case' 0 C--O 1.211 -0.959 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.577 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.457 ' H ' ' HD2' ' A' ' 5' ' ' LYS . 17.4 m -141.07 151.66 44.18 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 118.762 0.71 . . . . 0.0 110.588 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.447 ' O ' ' HB2' ' A' ' 17' ' ' PHE . 2.9 pt -132.42 146.04 33.59 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.501 0 N-CA-C 113.933 1.086 . . . . 0.0 113.933 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.509 ' HA ' ' HB2' ' A' ' 17' ' ' PHE . 48.7 mtt85 -86.9 108.92 19.0 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 175.249 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 16' ' ' ALA . 1.3 pt -77.76 157.66 5.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.714 -177.768 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -100.57 11.0 40.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.598 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 5.3 ttm180 -98.95 -170.13 1.88 Allowed 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -108.95 179.35 21.13 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.155 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.56 112.42 2.34 Favored 'Cis proline' 0 C--N 1.344 0.297 0 C-N-CA 122.971 -1.679 . . . . 0.0 112.44 0.013 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.5 155.4 6.13 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.353 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.2 ttp85 -62.28 88.22 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.222 0.534 . . . . 0.0 110.293 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.453 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -101.58 -170.81 1.88 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.883 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.509 ' HB2' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -148.74 149.98 32.34 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.38 179.574 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.412 HG12 ' N ' ' A' ' 19' ' ' THR . 5.4 t -121.92 162.23 21.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.72 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.412 ' N ' HG12 ' A' ' 18' ' ' VAL . 89.6 m -111.01 126.95 55.34 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.761 0.791 . . . . 0.0 112.05 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.5 mt -103.22 156.49 5.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.901 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.49 -1.172 . . . . 0.0 113.043 179.037 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.486 1.355 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.57 ' HD3' ' N ' ' A' ' 6' ' ' SER . 5.7 tmtm? -124.44 139.6 53.74 Favored 'General case' 0 C--O 1.222 -0.372 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.57 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 16.4 m -142.53 151.3 41.47 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.048 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.421 ' HA ' HH21 ' A' ' 8' ' ' ARG . 3.4 pt -132.0 148.67 32.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -179.239 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.61 ' HE ' ' H ' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -88.14 102.64 14.98 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 175.586 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.613 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.48 142.23 14.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 120.154 -0.618 . . . . 0.0 110.751 -177.379 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.65 11.47 24.28 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.805 -178.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -98.28 175.28 6.12 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.734 0.302 . . . . 0.0 110.646 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.49 -177.04 31.34 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.272 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 81.0 Cg_endo -78.87 110.4 1.84 Allowed 'Cis proline' 0 C--N 1.343 0.284 0 C-N-CA 123.062 -1.641 . . . . 0.0 112.796 0.181 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.06 141.57 4.93 Favored Glycine 0 C--N 1.331 0.299 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.663 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.491 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -60.14 142.47 54.22 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.956 0.407 . . . . 0.0 111.156 179.83 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.613 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.28 -168.12 0.69 Allowed 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.113 0.483 . . . . 0.0 110.624 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.446 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -144.56 145.48 31.84 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.486 179.12 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 t -125.61 162.32 28.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.243 -179.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 98.0 m -100.39 152.27 20.54 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.042 0.449 . . . . 0.0 110.8 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.423 HG22 ' N ' ' A' ' 21' ' ' GLY . 7.0 mt -114.47 163.86 11.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.573 -179.146 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.423 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.527 -1.151 . . . . 0.0 112.002 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 33.3 ttt180 . . . . . 0 N--CA 1.486 1.337 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.9 tttp -58.79 147.7 32.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.962 0.41 . . . . 0.0 111.677 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 64.9 m -142.94 150.86 40.3 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.55 178.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.6 pt -131.41 148.44 32.72 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.36 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 -179.124 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 65.4 mtt85 -85.06 99.06 10.78 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 176.063 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.578 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.59 151.63 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.846 0.355 . . . . 0.0 111.18 -177.23 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -95.09 8.41 43.07 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.392 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 16.4 ptp180 -99.72 -175.89 3.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.458 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.34 -177.73 31.48 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.392 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.79 114.2 3.09 Favored 'Cis proline' 0 C--N 1.343 0.279 0 C-N-CA 123.381 -1.508 . . . . 0.0 112.532 0.132 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.59 161.81 8.6 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.5 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -78.35 122.9 26.37 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.148 0.499 . . . . 0.0 111.043 179.734 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.578 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -160.48 -165.16 1.37 Allowed 'General case' 0 CA--C 1.512 -0.495 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.614 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -135.28 143.96 46.53 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.102 0.477 . . . . 0.0 110.707 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.44 HG22 ' CG2' ' A' ' 9' ' ' ILE . 31.1 m -118.49 168.42 10.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.678 -179.294 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.6 m -96.4 152.22 18.81 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 120.979 0.419 . . . . 0.0 111.071 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.429 HG22 ' N ' ' A' ' 21' ' ' GLY . 9.5 mt -107.85 163.71 5.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.376 -179.53 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.429 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.25 1.12 0 CA-C-O 118.117 -1.379 . . . . 0.0 111.827 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.616 ' HE ' HG22 ' A' ' 19' ' ' THR . 17.8 tpt180 . . . . . 0 N--CA 1.486 1.371 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.545 ' HD3' ' H ' ' A' ' 6' ' ' SER . 5.3 tmtt? -127.19 143.62 51.22 Favored 'General case' 0 C--O 1.218 -0.559 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.545 ' H ' ' HD3' ' A' ' 5' ' ' LYS . 15.9 m -141.59 142.4 33.47 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.01 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.583 HG12 HD11 ' A' ' 20' ' ' ILE . 2.4 pt -132.3 146.68 32.67 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.504 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.46 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 45.9 mtp85 -84.46 103.46 13.63 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.063 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.684 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.3 OUTLIER -78.01 153.83 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.188 -177.299 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.514 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 13.3 mp0 -92.61 13.21 20.61 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.241 -179.167 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 49.5 mtp85 -97.3 -176.06 3.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.921 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.76 177.35 30.42 Favored Glycine 0 C--N 1.332 0.323 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.409 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.96 135.9 38.66 Favored 'Cis proline' 0 C--N 1.344 0.317 0 C-N-CA 122.987 -1.672 . . . . 0.0 112.697 0.124 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 59.68 -104.34 0.55 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.112 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 8.0 ttp180 -160.07 134.11 7.31 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.684 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -159.79 -167.96 2.13 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.599 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.46 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -137.02 148.71 47.01 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.5 179.455 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.544 HG23 HD12 ' A' ' 9' ' ' ILE . 4.4 t -121.52 164.05 18.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.29 -179.241 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.616 HG22 ' HE ' ' A' ' 4' ' ' ARG . 91.7 m -113.55 140.49 48.11 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.981 0.42 . . . . 0.0 111.238 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.641 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -124.98 156.6 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.724 179.705 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.263 -1.299 . . . . 0.0 112.372 179.792 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 72.7 mtt85 . . . . . 0 N--CA 1.485 1.284 0 CA-C-O 120.581 0.229 . . . . 0.0 110.538 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 50.6 mtpt -128.69 154.14 46.61 Favored 'General case' 0 C--O 1.214 -0.778 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.224 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.4 m -143.93 142.95 31.03 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 178.598 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.623 HG12 HD11 ' A' ' 20' ' ' ILE . 8.5 pt -131.85 147.35 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 113.564 0.95 . . . . 0.0 113.564 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.682 ' H ' ' HD2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -85.02 101.91 12.78 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 106.325 -1.731 . . . . 0.0 106.325 175.235 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.489 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.1 OUTLIER -76.25 150.05 6.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.911 -176.404 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.439 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 17.7 mp0 -94.11 9.47 37.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.998 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 10.6 ptp180 -99.09 -173.62 2.54 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.908 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.35 -176.1 31.47 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.423 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -80.7 108.98 1.36 Allowed 'Cis proline' 0 CA--C 1.531 0.334 0 C-N-CA 122.886 -1.714 . . . . 0.0 112.597 0.128 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.23 169.77 38.0 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.682 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -71.36 123.79 23.1 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.742 0.306 . . . . 0.0 110.952 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.489 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -160.96 -169.32 2.33 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.243 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.443 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -145.36 141.15 28.23 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.942 178.994 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.427 HG12 ' N ' ' A' ' 19' ' ' THR . 5.5 t -115.5 163.95 12.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.398 -178.705 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.427 ' N ' HG12 ' A' ' 18' ' ' VAL . 92.6 m -100.07 158.37 15.89 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.292 0.567 . . . . 0.0 110.786 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.623 HD11 HG12 ' A' ' 7' ' ' ILE . 1.0 OUTLIER -140.99 153.67 20.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.918 -178.762 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.443 -1.198 . . . . 0.0 112.153 179.688 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.413 ' HA ' ' C ' ' A' ' 21' ' ' GLY . 96.4 mtt180 . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 120.616 0.246 . . . . 0.0 110.649 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' ILE . 1.7 mmmt -139.73 147.78 41.37 Favored 'General case' 0 C--O 1.219 -0.551 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.516 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.523 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.4 m -141.63 135.67 30.21 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.785 179.568 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 2.8 pt -132.48 147.85 31.91 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -86.67 102.93 14.66 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 175.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.641 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.78 153.63 5.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.859 -177.451 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.406 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 17.3 tt0 -99.02 10.96 40.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.363 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -98.69 -177.03 3.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.751 0.31 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -108.76 -176.24 21.68 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.245 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -77.37 114.59 3.28 Favored 'Cis proline' 0 C--N 1.343 0.245 0 C-N-CA 122.93 -1.696 . . . . 0.0 112.337 -0.152 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.91 147.35 6.92 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.109 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.9 mpt_? -77.56 127.01 31.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.996 0.426 . . . . 0.0 110.877 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.641 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -156.19 -169.0 2.91 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.888 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.523 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -133.88 142.18 47.68 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.977 0.418 . . . . 0.0 110.948 179.521 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.544 HG23 HD12 ' A' ' 9' ' ' ILE . 3.8 t -110.58 162.73 7.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.053 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.448 HG23 ' OG ' ' A' ' 6' ' ' SER . 78.8 m -124.91 114.18 18.83 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.83 0.348 . . . . 0.0 111.379 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.599 HD13 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -100.42 179.65 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.774 178.893 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.413 ' C ' ' HA ' ' A' ' 4' ' ' ARG . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.739 -1.034 . . . . 0.0 113.103 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 25.9 ptt180 . . . . . 0 N--CA 1.484 1.254 0 N-CA-C 110.543 -0.169 . . . . 0.0 110.543 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.544 ' CE ' HD12 ' A' ' 20' ' ' ILE . 2.0 tmmm? -156.12 153.69 29.73 Favored 'General case' 0 C--O 1.221 -0.419 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.433 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.3 m -142.96 156.71 44.92 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 120.868 -0.333 . . . . 0.0 111.084 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.43 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 3.4 pt -131.28 145.96 34.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 113.742 1.016 . . . . 0.0 113.742 -179.311 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.3 mtt-85 -83.56 95.64 8.38 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 176.468 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.538 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.1 OUTLIER -76.37 142.94 13.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.102 0.477 . . . . 0.0 111.19 -176.933 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 58.7 mm-40 -92.66 11.43 26.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.453 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -98.03 173.25 7.14 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.25 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.7 -175.46 30.95 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.723 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -80.65 119.66 6.6 Favored 'Cis proline' 0 C--N 1.347 0.453 0 C-N-CA 123.326 -1.531 . . . . 0.0 112.34 -0.066 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.67 166.61 41.65 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.548 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.439 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 1.7 mpt_? -89.18 134.99 33.81 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.736 0.303 . . . . 0.0 110.593 179.546 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.538 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -168.85 -166.63 0.67 Allowed 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.141 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.43 ' HA ' ' O ' ' A' ' 7' ' ' ILE . 0.4 OUTLIER -141.75 139.88 32.94 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.923 178.681 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.47 HG22 ' CG2' ' A' ' 9' ' ' ILE . 26.8 m -112.39 166.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.899 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 83.3 m -98.89 156.48 16.87 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.171 0.51 . . . . 0.0 111.594 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.544 HD12 ' CE ' ' A' ' 5' ' ' LYS . 8.5 mt -120.21 167.17 13.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.195 -0.912 . . . . 0.0 109.945 -179.126 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.409 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.247 0.911 0 CA-C-O 118.281 -1.288 . . . . 0.0 112.017 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 38.4 ptt180 . . . . . 0 N--CA 1.484 1.23 0 CA-C-O 120.637 0.256 . . . . 0.0 110.979 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 64.1 tttp -140.1 164.47 29.95 Favored 'General case' 0 C--O 1.217 -0.637 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.1 m -141.46 149.45 40.99 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.889 0.313 . . . . 0.0 110.568 178.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.504 HG23 HD11 ' A' ' 20' ' ' ILE . 3.6 pt -130.33 150.41 34.58 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.314 0 CA-C-O 121.022 0.439 . . . . 0.0 112.005 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 12.3 ptm180 -95.67 90.98 5.89 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 176.47 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.868 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -76.92 144.35 11.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.131 -177.122 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -97.87 9.95 41.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.811 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.559 ' HD2' ' N ' ' A' ' 11' ' ' ARG . 2.1 mpt_? -101.84 -179.49 4.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.241 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -102.45 -178.86 27.23 Favored Glycine 0 CA--C 1.516 0.156 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.272 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.47 114.4 3.33 Favored 'Cis proline' 0 C--N 1.346 0.409 0 C-N-CA 123.538 -1.442 . . . . 0.0 111.985 0.055 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 87.5 147.38 12.36 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.394 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 20.2 mmt85 -99.96 122.22 42.54 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.481 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -169.76 -173.86 1.71 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.136 0.494 . . . . 0.0 110.991 -179.305 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.0 120.85 34.82 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.547 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.868 HG23 HD12 ' A' ' 9' ' ' ILE . 5.2 t -109.65 162.04 7.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.44 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.417 ' N ' HG12 ' A' ' 18' ' ' VAL . 97.0 m -100.66 158.83 15.65 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.389 0.614 . . . . 0.0 111.802 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.504 HD11 HG23 ' A' ' 7' ' ' ILE . 6.2 mt -129.0 165.61 28.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.273 -179.309 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.192 179.139 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 22.7 mmt85 . . . . . 0 N--CA 1.485 1.305 0 CA-C-O 120.838 0.352 . . . . 0.0 111.448 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.642 ' HD3' ' N ' ' A' ' 6' ' ' SER . 7.5 tmtm? -120.53 151.07 39.88 Favored 'General case' 0 C--O 1.222 -0.395 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.642 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 39.3 m -137.01 141.28 42.52 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.055 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.0 pt -130.46 152.83 38.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.147 -179.571 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.464 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 32.9 ptt180 -95.79 93.36 7.03 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 176.407 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.485 HG23 HG22 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -76.3 148.02 7.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.06 0.457 . . . . 0.0 111.395 -176.872 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -89.85 11.27 20.74 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.805 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 65.2 mtt85 -98.35 -173.54 2.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.352 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.459 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.79 178.19 29.63 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.68 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -75.39 108.06 1.01 Allowed 'Cis proline' 0 C--N 1.344 0.33 0 C-N-CA 123.449 -1.479 . . . . 0.0 112.268 -0.051 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.459 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 68.97 160.37 2.08 Favored Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.572 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 16.3 tpp85 -64.42 118.1 8.26 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.576 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.431 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -151.32 -178.55 6.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.249 0.547 . . . . 0.0 111.622 -179.563 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -111.01 130.0 55.73 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.44 179.567 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.485 HG22 HG23 ' A' ' 9' ' ' ILE . 16.5 m -119.11 142.34 34.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.705 179.206 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 68.1 m -100.11 115.28 29.43 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.479 -179.317 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.491 HG13 ' HB3' ' A' ' 5' ' ' LYS . 7.5 pt -102.19 148.25 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.781 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.187 179.02 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.623 -1.098 . . . . 0.0 112.314 -179.82 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 . . . . . 0 N--CA 1.486 1.327 0 N-CA-C 110.64 -0.133 . . . . 0.0 110.64 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.5 tttp -127.61 151.02 49.45 Favored 'General case' 0 C--O 1.216 -0.681 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.8 m -142.85 152.09 41.78 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 178.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 6.2 pt -131.45 145.07 35.78 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.561 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.47 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 14.4 ptt85 -90.43 98.44 11.78 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 175.831 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.636 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -78.17 147.04 7.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.963 0.411 . . . . 0.0 111.485 -176.853 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 21.8 mp0 -94.15 9.48 37.68 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.46 -179.762 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.412 HH11 ' HD3' ' A' ' 11' ' ' ARG . 11.3 ptt180 -99.21 -177.75 3.71 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.736 0.303 . . . . 0.0 110.744 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.15 -176.33 30.39 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.466 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -79.08 106.91 0.94 Allowed 'Cis proline' 0 C--N 1.345 0.361 0 C-N-CA 122.958 -1.684 . . . . 0.0 112.779 -0.034 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.24 148.28 10.12 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.402 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 18.3 mmt85 -65.71 131.79 47.2 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.688 0.28 . . . . 0.0 110.829 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.636 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -167.6 -173.45 2.19 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.033 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.47 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -136.36 138.65 41.84 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.38 179.301 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.541 HG23 HD12 ' A' ' 9' ' ' ILE . 2.6 t -110.28 162.5 7.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.252 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 99.1 m -104.62 152.37 22.53 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.487 0.66 . . . . 0.0 111.063 179.747 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.406 HG22 ' H ' ' A' ' 21' ' ' GLY . 6.9 mt -114.9 166.79 8.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.776 -179.113 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.406 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.25 1.111 0 CA-C-O 118.458 -1.19 . . . . 0.0 112.305 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 44.1 mtt85 . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 120.615 0.245 . . . . 0.0 110.513 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.486 ' HB3' HG13 ' A' ' 20' ' ' ILE . 61.5 tttm -146.62 154.81 41.92 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 179.63 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.5 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 13.2 m -142.19 136.8 30.31 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.244 179.533 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.469 HG23 ' NZ ' ' A' ' 5' ' ' LYS . 2.8 pt -132.35 148.23 31.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.369 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -179.671 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.426 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 82.3 mtm180 -87.08 98.53 11.34 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 175.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.657 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.71 141.96 14.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 120.231 -0.587 . . . . 0.0 110.731 -177.539 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -93.21 12.34 24.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.732 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 37.8 ptt180 -98.53 -175.7 3.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.395 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.79 177.98 29.5 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.496 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -78.99 109.34 1.44 Allowed 'Cis proline' 0 C--N 1.345 0.381 0 C-N-CA 123.223 -1.574 . . . . 0.0 112.506 0.107 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.12 157.84 21.47 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.723 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -74.08 135.32 42.97 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.586 0.232 . . . . 0.0 110.414 179.552 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.657 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.42 -168.13 0.68 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.052 0.453 . . . . 0.0 110.536 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.5 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.1 OUTLIER -139.02 145.48 39.68 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.26 179.129 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.4 t -119.53 161.46 18.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.455 -178.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 90.3 m -117.87 113.45 21.78 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.558 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.486 HG13 ' HB3' ' A' ' 5' ' ' LYS . 34.1 pt -102.24 163.36 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 C-N-CA 122.938 0.495 . . . . 0.0 111.606 -179.745 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.181 0 CA-C-O 117.986 -1.452 . . . . 0.0 113.359 178.791 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.7 tpt180 . . . . . 0 N--CA 1.483 1.224 0 CA-C-O 120.583 0.23 . . . . 0.0 110.561 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.601 ' HD3' ' N ' ' A' ' 6' ' ' SER . 6.0 tmtm? -119.92 142.83 48.37 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.601 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 14.2 m -140.39 136.89 33.56 Favored 'General case' 0 C--N 1.318 -0.786 0 C-N-CA 121.167 -0.213 . . . . 0.0 110.652 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.606 HG12 HD11 ' A' ' 20' ' ' ILE . 1.2 pt -130.9 150.44 34.61 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -179.517 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.521 ' H ' ' HD3' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -89.11 99.82 12.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 176.382 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.588 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -78.7 144.12 11.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.506 -0.478 . . . . 0.0 111.446 -177.542 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 44.9 mt-30 -83.57 11.5 7.05 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.837 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.447 ' H ' HG12 ' A' ' 9' ' ' ILE . 94.2 mtt180 -98.52 -175.07 2.98 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.352 -179.667 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.412 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -102.18 -178.12 27.65 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.288 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.66 107.62 1.0 Allowed 'Cis proline' 0 C--N 1.343 0.265 0 C-N-CA 123.103 -1.624 . . . . 0.0 112.412 0.003 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.412 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 76.99 155.33 6.55 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.385 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.457 ' NE ' ' H ' ' A' ' 15' ' ' ARG . 0.1 OUTLIER -62.31 111.41 1.98 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.911 0.386 . . . . 0.0 110.723 179.762 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.588 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -144.13 -172.76 3.84 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 115.806 -0.633 . . . . 0.0 109.95 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.511 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -136.17 142.69 44.18 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.526 179.278 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.0 t -111.64 161.26 10.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.26 -179.262 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 71.8 m -118.32 111.0 18.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.579 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.606 HD11 HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -109.02 178.28 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.931 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.758 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.438 -1.201 . . . . 0.0 112.165 179.69 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.469 ' NE ' HG21 ' A' ' 19' ' ' THR . 28.1 ptt180 . . . . . 0 N--CA 1.484 1.229 0 CA-C-O 120.392 0.139 . . . . 0.0 110.819 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -86.49 147.16 26.1 Favored 'General case' 0 C--O 1.219 -0.544 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.928 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.4 m -143.0 145.05 32.57 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.483 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 pt -130.98 149.79 33.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -179.014 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.424 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 7.4 ptm180 -93.32 92.3 7.62 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 176.024 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.538 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.57 147.26 7.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.39 -176.63 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -95.17 11.12 33.41 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.25 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -98.26 -174.72 2.91 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.473 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -100.24 177.74 28.81 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.485 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.98 108.69 1.08 Allowed 'Cis proline' 0 C--N 1.344 0.31 0 C-N-CA 123.096 -1.626 . . . . 0.0 112.264 -0.111 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.473 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 72.47 150.67 1.19 Allowed Glycine 0 C--N 1.333 0.363 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.347 -179.601 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.427 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 1.3 mpt_? -73.34 133.26 43.79 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.344 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.538 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -164.88 -175.29 3.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.19 0.519 . . . . 0.0 111.31 -179.695 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -106.74 119.05 38.28 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.793 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.489 HG22 HG23 ' A' ' 9' ' ' ILE . 17.4 m -110.02 154.78 11.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.977 179.078 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.469 HG21 ' NE ' ' A' ' 4' ' ' ARG . 98.8 m -105.53 154.44 20.37 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.417 0.627 . . . . 0.0 111.933 -179.373 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -130.42 147.26 33.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.505 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.4 -1.222 . . . . 0.0 112.482 179.702 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 35.8 ptt180 . . . . . 0 N--CA 1.485 1.292 0 CA-C-O 120.806 0.336 . . . . 0.0 110.863 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.407 ' HG2' ' N ' ' A' ' 6' ' ' SER . 88.1 tttt -90.68 162.33 14.97 Favored 'General case' 0 C--O 1.215 -0.737 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.407 ' N ' ' HG2' ' A' ' 5' ' ' LYS . 66.5 m -144.55 150.47 37.57 Favored 'General case' 0 C--N 1.321 -0.666 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.102 179.021 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.58 HG12 HD11 ' A' ' 20' ' ' ILE . 3.9 pt -131.38 148.28 32.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 121.135 0.493 . . . . 0.0 112.219 179.38 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.452 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 38.9 ttt180 -93.8 98.09 10.85 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 176.419 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.488 ' O ' ' HD3' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -75.6 149.21 6.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 C-N-CA 120.766 -0.373 . . . . 0.0 110.558 -177.328 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.435 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 53.7 tt0 -94.68 11.41 31.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.243 -179.089 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.416 ' HG2' ' CG1' ' A' ' 9' ' ' ILE . 5.5 ptp180 -98.48 178.29 5.07 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.461 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.98 -177.01 30.67 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.59 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -77.0 110.7 1.77 Allowed 'Cis proline' 0 C--N 1.343 0.285 0 C-N-CA 123.287 -1.547 . . . . 0.0 112.323 -0.015 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.61 156.22 9.25 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.473 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.488 ' HD3' ' O ' ' A' ' 9' ' ' ILE . 17.7 tpp85 -71.9 129.35 38.37 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 179.621 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.425 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -152.04 -176.58 5.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.308 0.575 . . . . 0.0 111.875 -179.464 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.452 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -119.34 128.15 53.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.601 179.706 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.478 HG22 HG23 ' A' ' 9' ' ' ILE . 16.9 m -116.5 150.51 18.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.155 178.727 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 97.0 m -96.1 159.32 15.02 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.518 0.675 . . . . 0.0 111.877 -179.282 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.58 HD11 HG12 ' A' ' 7' ' ' ILE . 2.4 mt -135.48 155.15 36.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 114.537 -1.21 . . . . 0.0 108.945 -179.355 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.302 -1.277 . . . . 0.0 112.559 179.618 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 80.7 mtm-85 . . . . . 0 N--CA 1.484 1.236 0 N-CA-C 110.41 -0.218 . . . . 0.0 110.41 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.577 ' HD2' ' N ' ' A' ' 6' ' ' SER . 5.2 tmmm? -112.63 148.78 33.9 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.577 ' N ' ' HD2' ' A' ' 5' ' ' LYS . 13.4 m -141.06 133.29 28.06 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.682 -0.236 . . . . 0.0 110.778 179.353 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.51 HG12 HD11 ' A' ' 20' ' ' ILE . 1.7 pt -131.79 148.39 32.4 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 N-CA-C 113.313 0.857 . . . . 0.0 113.313 -179.332 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.435 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 5.8 ptm180 -84.38 108.7 17.35 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 175.756 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.628 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.3 OUTLIER -78.16 152.2 5.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.671 -177.79 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -90.5 11.63 21.19 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.019 -179.382 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.5 mtp85 -98.02 174.89 6.33 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.457 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.4 179.45 32.04 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.65 -179.376 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_exo -70.3 137.8 47.08 Favored 'Cis proline' 0 C--N 1.342 0.196 0 C-N-CA 123.124 -1.615 . . . . 0.0 112.527 0.241 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.45 ' C ' ' HD2' ' A' ' 15' ' ' ARG . . . 55.75 -145.31 32.98 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.087 -179.838 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.45 ' HD2' ' C ' ' A' ' 14' ' ' GLY . 9.5 mpt_? -117.99 128.16 54.52 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.628 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -149.53 -175.97 5.21 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.55 -179.434 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.469 ' HB2' ' C ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -139.83 148.79 42.64 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.975 179.746 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 6' ' ' SER . 9.1 t -117.68 161.74 16.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.103 -179.661 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.423 ' N ' HG12 ' A' ' 18' ' ' VAL . 80.9 m -118.33 112.57 20.21 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.249 179.576 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.667 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -117.52 152.69 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-O 120.9 0.381 . . . . 0.0 111.431 -179.728 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.528 -1.151 . . . . 0.0 112.139 -179.737 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 . . . . . 0 N--CA 1.484 1.255 0 CA-C-O 120.672 0.272 . . . . 0.0 110.77 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -148.85 166.44 28.52 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -141.51 149.87 41.44 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 117.857 0.298 . . . . 0.0 111.143 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.456 HG12 HD11 ' A' ' 20' ' ' ILE . 5.9 pt -131.02 146.11 34.44 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-O 121.152 0.501 . . . . 0.0 112.351 179.123 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 13.4 tpt180 -96.87 85.9 3.89 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 176.605 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.79 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -77.31 144.5 11.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.827 -177.354 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 38.6 tt0 -96.52 7.01 47.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.187 0.518 . . . . 0.0 110.131 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -99.43 -177.03 3.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.536 179.78 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.84 -178.28 29.37 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.126 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -80.14 108.87 1.32 Allowed 'Cis proline' 0 C--N 1.345 0.352 0 C-N-CA 123.428 -1.488 . . . . 0.0 112.328 0.161 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.52 133.06 5.75 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.884 179.611 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -81.61 110.91 17.42 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.497 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -163.29 -168.86 1.81 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.267 0.556 . . . . 0.0 111.087 -179.238 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -97.79 128.19 44.26 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.758 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.79 HG23 HD12 ' A' ' 9' ' ' ILE . 11.5 t -109.13 162.69 6.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 178.876 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.442 ' N ' HG12 ' A' ' 18' ' ' VAL . 9.2 m -104.22 160.1 15.15 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.561 0.696 . . . . 0.0 111.541 -179.48 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.456 HD11 HG12 ' A' ' 7' ' ' ILE . 9.1 mt -140.71 167.73 17.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.714 -179.557 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.406 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.324 -1.264 . . . . 0.0 112.846 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.511 ' N ' ' O ' ' A' ' 21' ' ' GLY . 13.8 tpt180 . . . . . 0 N--CA 1.484 1.236 0 CA-C-O 120.877 0.37 . . . . 0.0 110.585 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.487 ' HD3' ' H ' ' A' ' 6' ' ' SER . 5.9 tmtt? -123.99 147.17 48.0 Favored 'General case' 0 C--O 1.217 -0.647 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -179.748 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.487 ' H ' ' HD3' ' A' ' 5' ' ' LYS . 14.3 m -141.24 139.02 33.67 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.714 179.337 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.0 pt -130.96 149.37 33.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.5 ttp85 -91.95 92.03 8.13 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 176.112 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.58 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.32 145.07 10.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.135 0.493 . . . . 0.0 111.046 -177.034 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -91.92 11.84 23.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.053 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 10.1 mtp-105 -98.31 -168.02 1.59 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.628 -179.345 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.416 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -115.17 179.81 18.33 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.416 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -75.54 109.6 1.35 Allowed 'Cis proline' 0 C--N 1.344 0.336 0 C-N-CA 123.088 -1.63 . . . . 0.0 112.394 -0.023 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.416 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 82.29 133.32 1.77 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.227 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.43 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -77.97 116.61 18.59 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.786 0.327 . . . . 0.0 110.337 179.672 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.58 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -153.2 -172.22 4.17 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.289 0.566 . . . . 0.0 111.076 -179.343 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -96.55 120.85 37.63 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.062 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.51 HG22 HG23 ' A' ' 9' ' ' ILE . 12.7 m -109.63 148.27 13.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.169 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 65.0 m -113.58 131.46 56.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.128 0.49 . . . . 0.0 111.511 -179.346 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.472 HG13 ' HB3' ' A' ' 5' ' ' LYS . 4.7 pt -123.33 143.31 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 C-N-CA 123.83 0.852 . . . . 0.0 110.952 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.511 ' O ' ' N ' ' A' ' 4' ' ' ARG . . . . . . . . 0 C--O 1.248 1.029 0 CA-C-O 118.11 -1.383 . . . . 0.0 113.511 179.306 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 56.3 ttp180 . . . . . 0 N--CA 1.483 1.178 0 CA-C-O 120.841 0.353 . . . . 0.0 110.886 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.467 ' HD2' ' N ' ' A' ' 6' ' ' SER . 1.4 tmmt? -143.17 157.14 44.77 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.725 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.467 ' N ' ' HD2' ' A' ' 5' ' ' LYS . 14.5 m -142.1 145.9 34.8 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.21 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.9 pt -131.79 152.27 36.68 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.272 0 CA-C-O 121.257 0.551 . . . . 0.0 112.32 179.908 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.447 ' HD3' ' NH2' ' A' ' 15' ' ' ARG . 28.9 ttm105 -93.71 91.46 7.03 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 107.278 -1.378 . . . . 0.0 107.278 176.555 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.54 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.42 146.58 8.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.836 -177.717 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.54 ' H ' ' CD ' ' A' ' 10' ' ' GLN . 0.1 OUTLIER -98.95 9.54 43.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.906 -179.805 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -99.7 -169.94 1.82 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.224 179.926 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.17 174.2 27.21 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.455 -0.879 . . . . 0.0 112.404 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -81.65 108.13 1.2 Allowed 'Cis proline' 0 C--N 1.345 0.388 0 C-N-CA 123.152 -1.603 . . . . 0.0 112.777 0.132 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.03 137.02 0.66 Allowed Glycine 0 C--N 1.332 0.358 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.788 179.61 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.543 ' C ' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -66.02 130.98 45.12 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.388 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.54 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.22 -174.74 1.79 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.136 0.493 . . . . 0.0 111.007 -179.44 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -103.39 121.18 42.26 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.61 179.825 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.462 HG22 HG23 ' A' ' 9' ' ' ILE . 16.9 m -108.96 156.98 9.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.778 178.825 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.485 ' C ' HD13 ' A' ' 20' ' ' ILE . 75.6 m -118.48 148.28 42.76 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.08 0.467 . . . . 0.0 112.157 -178.658 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.599 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -124.97 177.75 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.187 179.119 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.157 0 CA-C-O 118.814 -0.992 . . . . 0.0 113.567 -179.761 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 66.9 mtp180 . . . . . 0 N--CA 1.485 1.295 0 N-CA-C 110.252 -0.277 . . . . 0.0 110.252 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.596 ' HD3' ' N ' ' A' ' 6' ' ' SER . 6.9 tmtm? -111.15 144.42 40.33 Favored 'General case' 0 C--O 1.222 -0.346 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.893 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.596 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 66.3 m -141.37 157.0 45.76 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 179.185 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 pt -130.99 148.13 33.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 -179.502 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 13.7 tpp180 -95.56 91.48 6.17 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 176.037 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.465 HD12 HG23 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -76.47 144.71 11.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.819 -177.237 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.43 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 46.4 tt0 -88.66 11.64 16.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.826 -179.485 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.0 mtp-105 -96.59 -176.04 3.49 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.207 -179.23 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.494 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -107.73 -179.54 22.15 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.849 -179.412 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -73.4 107.28 0.87 Allowed 'Cis proline' 0 C--N 1.343 0.288 0 C-N-CA 123.282 -1.549 . . . . 0.0 112.387 0.172 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.494 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 74.35 141.89 0.71 Allowed Glycine 0 C--N 1.333 0.377 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.534 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.3 124.33 20.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.762 0.315 . . . . 0.0 110.625 179.501 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.426 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -147.33 -178.99 6.53 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.185 -179.665 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -108.69 122.12 46.46 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.452 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.465 HG23 HD12 ' A' ' 9' ' ' ILE . 3.9 t -109.27 158.78 9.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.341 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.7 m -107.04 154.75 20.66 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.414 0.626 . . . . 0.0 111.81 -179.717 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.586 HD12 ' HD2' ' A' ' 5' ' ' LYS . 6.8 mt -125.34 171.9 13.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 114.698 -1.137 . . . . 0.0 109.308 -179.475 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.493 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.251 1.158 0 CA-C-O 118.384 -1.231 . . . . 0.0 111.978 179.59 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.465 ' HA ' ' C ' ' A' ' 21' ' ' GLY . 74.8 ttt180 . . . . . 0 N--CA 1.484 1.231 0 CA-C-O 120.873 0.368 . . . . 0.0 111.031 . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -151.51 158.56 43.76 Favored 'General case' 0 C--O 1.217 -0.651 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 178.912 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.428 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 19.9 m -143.22 147.48 34.92 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.785 179.675 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.471 HG12 HD11 ' A' ' 20' ' ' ILE . 4.5 pt -132.38 146.36 33.11 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.392 0 N-CA-C 113.74 1.015 . . . . 0.0 113.74 -179.794 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.465 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 35.2 ttm180 -88.65 96.12 10.52 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 176.265 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.611 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.11 141.33 15.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 120.415 -0.514 . . . . 0.0 109.851 -178.165 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.8 tt0 -93.67 11.01 30.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.49 -178.677 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 46.2 ptt85 -98.39 -169.9 1.87 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.159 179.714 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.486 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.23 176.82 29.49 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.497 -0.859 . . . . 0.0 112.764 -179.412 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -74.23 109.11 1.1 Allowed 'Cis proline' 0 C--N 1.347 0.453 0 C-N-CA 123.151 -1.604 . . . . 0.0 112.51 0.001 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.486 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 71.81 156.82 2.79 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.495 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.0 mpt_? -67.83 133.7 49.64 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 120.789 0.328 . . . . 0.0 110.695 179.445 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.611 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -168.31 -164.61 0.54 Allowed 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.954 -179.626 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.465 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -141.27 137.11 32.27 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.654 179.181 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.529 HG23 HD12 ' A' ' 9' ' ' ILE . 4.1 t -110.77 163.75 7.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.921 -179.362 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.403 ' N ' HG12 ' A' ' 18' ' ' VAL . 53.8 m -108.91 131.59 54.88 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.811 0.815 . . . . 0.0 111.92 -179.895 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.545 HG22 ' H ' ' A' ' 21' ' ' GLY . 4.2 mt -100.63 174.96 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 113.983 -1.462 . . . . 0.0 109.175 179.251 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.545 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.609 -1.106 . . . . 0.0 112.541 179.273 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 68.0 mtm180 . . . . . 0 N--CA 1.485 1.316 0 CA-C-O 121.209 0.528 . . . . 0.0 111.662 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -144.86 166.0 26.52 Favored 'General case' 0 C--O 1.213 -0.835 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.4 m -142.56 147.21 35.53 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 118.679 0.672 . . . . 0.0 110.619 179.37 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.616 HG12 HD11 ' A' ' 20' ' ' ILE . 6.0 pt -130.6 147.85 33.12 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.411 0 CA-C-O 121.112 0.482 . . . . 0.0 112.295 -179.878 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.4 ' HA ' ' O ' ' A' ' 16' ' ' ALA . 75.7 ttt180 -89.64 100.26 13.1 Favored 'General case' 0 N--CA 1.445 -0.71 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 176.043 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.557 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.98 150.59 5.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-O 121.32 0.581 . . . . 0.0 111.854 -176.641 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 62.7 mt-30 -93.61 12.18 26.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.698 -179.811 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -98.1 177.05 5.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.967 -179.174 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.453 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -104.25 -178.88 25.17 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.629 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -74.08 108.4 1.0 Allowed 'Cis proline' 0 C--N 1.345 0.36 0 C-N-CA 123.278 -1.551 . . . . 0.0 112.254 0.02 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.453 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 74.31 148.53 1.49 Allowed Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.346 -179.814 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.502 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -59.79 145.71 44.34 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.823 0.344 . . . . 0.0 110.885 179.806 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.557 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -164.74 -177.19 4.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.928 0.394 . . . . 0.0 111.202 -179.565 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -117.22 123.52 46.83 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.287 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.516 HG22 HG23 ' A' ' 9' ' ' ILE . 20.2 m -113.2 155.92 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.026 178.619 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 42.9 m -99.86 159.46 15.06 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.153 0.502 . . . . 0.0 111.316 -179.633 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.616 HD11 HG12 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -142.09 154.5 18.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.179 -178.69 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.261 0 CA-C-O 118.424 -1.209 . . . . 0.0 113.729 178.696 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 35.7 ttm180 . . . . . 0 N--CA 1.486 1.367 0 N-CA-C 110.487 -0.19 . . . . 0.0 110.487 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.476 ' O ' HG12 ' A' ' 20' ' ' ILE . 0.7 OUTLIER -98.4 152.3 19.64 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.956 0.408 . . . . 0.0 111.277 -179.574 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 24.0 m -142.76 157.13 44.94 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.388 178.61 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.8 pt -128.45 146.59 33.66 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.352 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -179.414 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.473 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 53.9 ttp180 -95.83 92.86 6.74 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 176.257 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.452 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -75.99 154.72 5.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.577 -177.379 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.0 pt20 -97.05 12.03 34.04 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.211 -179.363 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.418 ' H ' HG12 ' A' ' 9' ' ' ILE . 97.7 mtt180 -97.44 -178.75 4.25 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.648 -179.345 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.02 -179.56 30.24 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.447 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -77.86 107.76 1.06 Allowed 'Cis proline' 0 C--N 1.346 0.418 0 C-N-CA 123.098 -1.626 . . . . 0.0 112.403 0.028 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.26 153.22 5.53 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.214 -179.865 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 40.1 mmt-85 -66.17 119.93 12.33 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.69 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.84 -179.13 6.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.157 0.504 . . . . 0.0 111.75 -179.458 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.473 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -114.23 125.77 54.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.995 -179.996 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.452 HG23 HD12 ' A' ' 9' ' ' ILE . 5.6 t -110.05 162.99 7.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.705 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 6' ' ' SER . 53.7 m -107.03 158.23 17.2 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.937 -0.305 . . . . 0.0 111.751 -179.464 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.476 HG12 ' O ' ' A' ' 5' ' ' LYS . 2.6 mm -99.93 157.29 3.95 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.258 179.68 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.314 -1.27 . . . . 0.0 112.352 179.804 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? . . . . . 0 N--CA 1.484 1.266 0 CA-C-O 120.682 0.277 . . . . 0.0 110.475 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.438 ' NZ ' ' CB ' ' A' ' 5' ' ' LYS . 7.9 mtpm? -104.1 148.64 26.03 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.636 179.738 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.475 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.7 m -142.93 132.64 23.89 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.043 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.423 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 4.9 pt -131.28 147.82 32.85 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 N-CA-C 113.701 1.0 . . . . 0.0 113.701 -178.874 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.492 ' N ' ' HD2' ' A' ' 8' ' ' ARG . 2.2 mpt_? -86.94 99.72 12.07 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 176.012 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.581 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.85 143.3 12.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 C-N-CA 120.3 -0.56 . . . . 0.0 110.922 -177.452 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -85.77 11.89 10.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.342 -179.724 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.422 ' H ' HG12 ' A' ' 9' ' ' ILE . 78.9 ttt180 -98.04 158.7 15.39 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.89 -179.64 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.4 ' N ' ' HG2' ' A' ' 11' ' ' ARG . . . -99.73 -170.64 30.16 Favored Glycine 0 N--CA 1.452 -0.27 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.268 179.811 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -83.46 115.96 3.99 Favored 'Cis proline' 0 N--CA 1.462 -0.348 0 C-N-CA 123.091 -1.629 . . . . 0.0 112.592 0.084 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.26 117.43 3.93 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.539 179.747 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.456 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -59.45 121.17 10.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.099 0.476 . . . . 0.0 110.975 179.71 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.581 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -155.18 -168.93 3.01 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.419 -179.498 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.475 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -136.25 145.74 45.93 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.654 179.626 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.7 t -112.44 160.95 11.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.182 -179.711 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 52.0 m -119.93 112.99 19.88 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.132 179.814 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.582 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.1 OUTLIER -110.59 -179.41 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.015 178.983 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.618 -1.101 . . . . 0.0 112.276 179.705 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.41 ' C ' ' HD2' ' A' ' 4' ' ' ARG . 1.2 tmm_? . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.582 0.23 . . . . 0.0 110.638 . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -110.66 157.48 19.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.978 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.1 m -142.43 151.58 41.92 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.006 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.681 HG23 HD11 ' A' ' 20' ' ' ILE . 4.8 pt -130.64 148.94 33.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 N-CA-C 112.729 0.641 . . . . 0.0 112.729 -179.127 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 57.3 ttp85 -94.8 94.22 7.94 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 175.994 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.674 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -76.47 153.92 5.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.125 0.488 . . . . 0.0 111.606 -176.569 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.439 ' HA ' ' HD2' ' A' ' 15' ' ' ARG . 62.4 mt-30 -97.14 11.38 36.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.672 -0.695 . . . . 0.0 111.19 -179.523 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.96 159.44 14.93 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.823 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.92 -171.05 32.63 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.765 -179.091 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.76 113.81 2.85 Favored 'Cis proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.977 -1.676 . . . . 0.0 112.62 0.349 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.87 138.26 5.31 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.61 179.859 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.439 ' HD2' ' HA ' ' A' ' 10' ' ' GLN . 55.5 mmt-85 -74.86 125.41 28.76 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.416 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.433 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -151.84 -176.01 5.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.19 0.519 . . . . 0.0 112.006 -179.144 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -106.99 125.1 50.57 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.088 179.885 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.674 HG23 HD12 ' A' ' 9' ' ' ILE . 6.0 t -113.69 162.93 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 178.919 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.409 ' N ' HG12 ' A' ' 18' ' ' VAL . 52.9 m -103.36 151.26 22.95 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.07 0.462 . . . . 0.0 111.439 -179.827 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.681 HD11 HG23 ' A' ' 7' ' ' ILE . 8.2 mt -109.0 164.01 5.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.283 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.44 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 0.978 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.015 179.636 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 . . . . . 0 N--CA 1.484 1.268 0 CA-C-O 120.651 0.262 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.519 ' CE ' HD12 ' A' ' 20' ' ' ILE . 5.4 tmmm? -154.36 165.27 36.9 Favored 'General case' 0 C--O 1.214 -0.788 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 180.0 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.4 ' N ' ' HD2' ' A' ' 5' ' ' LYS . 15.5 m -142.81 152.12 41.88 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 118.42 0.555 . . . . 0.0 110.806 179.995 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.706 HG12 HD11 ' A' ' 20' ' ' ILE . 6.0 pt -131.13 150.12 34.15 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.346 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 179.347 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.405 ' O ' ' HG3' ' A' ' 8' ' ' ARG . 17.4 ptt85 -97.14 93.9 6.83 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 176.327 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.52 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.04 144.26 11.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.799 -177.072 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 19.8 tt0 -91.88 7.02 43.95 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.984 0.421 . . . . 0.0 110.966 -179.232 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.404 ' NH1' HG13 ' A' ' 9' ' ' ILE . 15.5 ptt85 -99.14 178.56 4.88 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.701 179.492 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.41 -177.91 32.77 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.523 -179.524 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.46 108.52 1.14 Allowed 'Cis proline' 0 C--N 1.342 0.225 0 C-N-CA 123.405 -1.498 . . . . 0.0 112.561 0.237 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 128.34 0.91 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.936 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.455 ' C ' ' HD2' ' A' ' 15' ' ' ARG . 3.1 tmm_? -65.56 113.65 4.35 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.439 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.52 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -149.02 -169.58 3.41 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.517 0.675 . . . . 0.0 111.89 -179.239 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -107.49 128.18 54.27 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.058 -0.973 . . . . 0.0 111.113 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.448 HG22 HG23 ' A' ' 9' ' ' ILE . 16.4 m -117.44 153.7 19.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.094 178.738 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.405 HG22 ' N ' ' A' ' 20' ' ' ILE . 57.3 m -94.08 158.71 15.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.476 0.655 . . . . 0.0 111.861 -179.048 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.706 HD11 HG12 ' A' ' 7' ' ' ILE . 3.1 mt -141.31 160.62 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-N 114.735 -1.121 . . . . 0.0 109.552 -179.447 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.996 0 CA-C-O 118.365 -1.241 . . . . 0.0 112.448 179.403 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.581 ' N ' ' NE ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.484 1.27 0 CA-C-O 120.69 0.281 . . . . 0.0 110.649 . . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.603 ' HE3' HG23 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -107.12 145.9 31.92 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 178.726 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.506 ' H ' ' HD2' ' A' ' 5' ' ' LYS . 9.5 m -141.05 140.26 34.21 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.421 -179.874 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.603 HG23 ' HE3' ' A' ' 5' ' ' LYS . 1.5 pt -132.12 148.3 32.14 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -179.809 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.438 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 28.3 ptt-85 -80.92 104.45 11.43 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 176.114 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.662 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.63 158.77 5.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 C-N-CA 120.039 -0.664 . . . . 0.0 110.622 -177.736 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -99.68 12.31 36.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.819 -178.988 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.422 HH11 ' HD3' ' A' ' 11' ' ' ARG . 49.2 mtt180 -97.61 161.86 13.57 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.805 0.336 . . . . 0.0 110.76 -179.738 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.79 -175.37 30.83 Favored Glycine 0 N--CA 1.452 -0.267 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.564 -179.69 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.62 119.43 6.3 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.978 -1.676 . . . . 0.0 112.412 -0.167 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.77 144.63 6.1 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.186 -179.772 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.5 mpt_? -77.44 117.2 18.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.041 0.448 . . . . 0.0 111.05 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.662 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -136.52 -173.03 3.3 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.823 179.639 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 7' ' ' ILE . 0.4 OUTLIER -130.7 143.62 50.87 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.048 0.451 . . . . 0.0 110.956 179.608 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.579 HG13 HD12 ' A' ' 9' ' ' ILE . 25.8 m -112.43 163.81 9.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.991 -179.542 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.4 m -120.3 123.72 43.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.297 -179.739 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.67 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -114.59 157.05 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 C-N-CA 123.031 0.532 . . . . 0.0 110.798 179.275 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.201 -1.333 . . . . 0.0 112.177 179.933 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.448 ' HG2' ' N ' ' A' ' 5' ' ' LYS . 11.6 ttp180 . . . . . 0 N--CA 1.487 1.411 0 N-CA-C 110.27 -0.27 . . . . 0.0 110.27 . . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.627 ' HD2' HD12 ' A' ' 20' ' ' ILE . 5.4 tmtm? -143.67 144.86 32.05 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.809 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.567 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 0.9 OUTLIER -139.21 152.27 47.22 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.772 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.551 HG23 HD11 ' A' ' 20' ' ' ILE . 3.1 pt -130.59 151.77 36.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.437 0 CA-C-O 121.312 0.577 . . . . 0.0 112.356 179.932 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.473 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 4.7 ptm85 -96.61 99.29 10.93 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 176.282 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.601 HD13 ' H ' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -77.79 156.56 5.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.242 0.544 . . . . 0.0 111.955 -176.744 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -94.77 12.56 27.52 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.073 179.075 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.2 ttt180 -97.03 -168.32 1.68 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.71 -179.335 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.503 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -107.45 176.43 20.9 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.442 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -73.02 108.71 0.97 Allowed 'Cis proline' 0 CA--C 1.53 0.288 0 C-N-CA 123.311 -1.537 . . . . 0.0 112.369 0.038 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.503 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 65.57 173.61 4.46 Favored Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.673 -179.937 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.459 HH21 ' NE ' ' A' ' 8' ' ' ARG . 16.1 tpt180 -69.33 115.14 8.25 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.766 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.04 -177.94 5.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.172 0.51 . . . . 0.0 111.52 -179.26 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.473 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -115.44 132.02 56.75 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.053 179.887 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.452 HG22 HG23 ' A' ' 9' ' ' ILE . 19.1 m -121.98 161.63 22.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.74 -0.663 . . . . 0.0 109.819 178.838 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 41.5 m -96.7 155.67 16.67 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.015 0.436 . . . . 0.0 111.06 -179.631 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.627 HD12 ' HD2' ' A' ' 5' ' ' LYS . 20.7 mt -121.27 165.52 16.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.458 179.584 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.478 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.249 1.086 0 CA-C-O 118.202 -1.332 . . . . 0.0 111.982 179.917 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.5 tpp85 . . . . . 0 N--CA 1.487 1.377 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -142.56 148.97 38.42 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 110.197 -0.297 . . . . 0.0 110.197 179.551 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 m -143.75 152.99 41.95 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.076 178.999 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.417 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 3.7 pt -131.15 145.96 34.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 113.551 0.945 . . . . 0.0 113.551 -179.411 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.428 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 76.7 mtp180 -82.31 92.67 7.0 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 176.431 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.573 HD13 HG13 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -77.71 148.49 6.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.043 0.449 . . . . 0.0 110.92 -177.524 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -101.15 9.7 41.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.16 0.505 . . . . 0.0 109.884 179.05 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 64.5 mtp180 -99.86 -168.8 1.65 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.754 -179.269 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.7 -176.4 19.67 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 121.197 -0.525 . . . . 0.0 112.047 179.803 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -83.01 113.51 2.95 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.487 -1.464 . . . . 0.0 112.357 -0.075 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.11 128.31 6.03 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.219 -179.836 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 13.9 mmt180 -70.95 96.93 1.35 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.856 0.36 . . . . 0.0 110.728 -179.881 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.449 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -155.27 179.31 9.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.351 -179.842 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.428 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -103.79 147.35 27.38 Favored 'General case' 0 C--N 1.325 -0.5 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.646 179.851 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.573 HG13 HD13 ' A' ' 9' ' ' ILE . 31.3 m -119.18 165.52 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.136 -179.809 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 94.0 m -98.48 153.6 18.49 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.116 0.484 . . . . 0.0 111.03 179.835 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.8 mt -114.24 163.78 11.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.328 -179.237 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.208 -1.329 . . . . 0.0 112.001 179.827 . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 82.1 mtt-85 . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 . . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.445 ' HB3' HD12 ' A' ' 20' ' ' ILE . 55.9 mtpt -58.89 146.55 37.21 Favored 'General case' 0 C--O 1.222 -0.342 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.015 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.6 m -141.14 147.76 38.98 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.102 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.68 HG23 HD11 ' A' ' 20' ' ' ILE . 8.0 pt -131.48 146.72 33.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -178.269 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -92.26 93.07 8.47 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 176.175 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.564 HD12 HG23 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -75.31 148.15 7.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.02 0.438 . . . . 0.0 111.026 -176.697 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 69.9 mt-30 -100.16 11.83 38.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.028 -179.384 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -97.78 -169.3 1.81 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.493 -0.322 . . . . 0.0 110.187 -179.864 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.14 -177.17 19.16 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.429 179.772 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -79.55 104.98 0.64 Allowed 'Cis proline' 0 C--N 1.344 0.314 0 C-N-CA 123.485 -1.465 . . . . 0.0 112.143 -0.117 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.49 145.46 13.76 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.97 179.883 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 26.3 mtt180 -78.11 137.29 38.13 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 110.523 -0.177 . . . . 0.0 110.523 179.813 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.439 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -168.53 -173.73 2.01 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-O 121.22 0.533 . . . . 0.0 111.227 -179.782 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -111.97 120.59 42.41 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.359 179.504 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.564 HG23 HD12 ' A' ' 9' ' ' ILE . 4.1 t -110.03 160.5 9.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.313 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 46.2 m -98.51 158.8 15.37 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.889 0.376 . . . . 0.0 110.158 179.356 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.68 HD11 HG23 ' A' ' 7' ' ' ILE . 7.1 mt -119.33 161.58 18.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.527 179.76 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.135 0 CA-C-O 118.455 -1.192 . . . . 0.0 112.22 179.958 . . . . . . . . 0 0 . 1 . 033 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.484 ' C ' ' HD2' ' A' ' 4' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 120.437 0.161 . . . . 0.0 110.711 . . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.535 ' HD3' ' N ' ' A' ' 6' ' ' SER . 4.2 tmtm? -138.93 140.99 38.48 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.952 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.535 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 12.3 m -141.4 135.27 30.22 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.216 179.63 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.9 pt -132.64 149.52 32.17 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.343 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -179.956 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.556 ' H ' ' HD3' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -90.1 105.45 17.82 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 175.514 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.584 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -78.57 156.52 4.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 C-N-CA 120.501 -0.479 . . . . 0.0 111.281 -177.436 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.512 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 10.2 mp0 -94.72 10.28 35.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.48 179.904 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -99.67 179.59 4.49 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.858 -179.808 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.15 -176.61 30.41 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.186 179.859 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -76.57 107.68 1.01 Allowed 'Cis proline' 0 N--CA 1.464 -0.242 0 C-N-CA 123.246 -1.564 . . . . 0.0 112.521 0.052 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.21 151.54 7.23 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.835 179.674 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 16.5 mmm180 -60.13 109.97 1.1 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.71 0.29 . . . . 0.0 110.64 179.417 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.584 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -141.06 -177.07 4.93 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.439 -179.937 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.501 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -135.46 146.03 47.78 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.478 179.447 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.0 t -112.99 160.66 12.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.168 -179.495 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.52 HG23 ' OG ' ' A' ' 6' ' ' SER . 83.9 m -126.88 114.83 18.4 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.449 179.633 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.611 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -112.47 161.99 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.762 179.729 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.281 -1.289 . . . . 0.0 112.32 -179.996 . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.1 ptp85 . . . . . 0 N--CA 1.485 1.278 0 CA-C-O 120.426 0.155 . . . . 0.0 110.681 . . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -114.15 135.11 54.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.657 179.626 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 16.0 m -140.92 135.82 31.64 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.929 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.4 pt -124.07 150.72 28.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 113.237 0.829 . . . . 0.0 113.237 -178.203 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.453 ' HD2' ' O ' ' A' ' 16' ' ' ALA . 14.6 tpt180 -92.22 94.37 9.15 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 176.197 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.474 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.28 148.53 7.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.912 -177.084 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 33.5 mt-30 -97.4 11.51 36.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.188 -179.569 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -98.34 -174.9 2.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.116 179.827 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.446 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.94 175.7 27.7 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.569 -179.763 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -76.46 109.46 1.36 Allowed 'Cis proline' 0 C--N 1.346 0.411 0 C-N-CA 123.247 -1.564 . . . . 0.0 112.438 -0.02 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.446 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 69.52 168.1 5.99 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.292 -179.743 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.454 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 4.8 mpt_? -80.11 134.27 36.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 110.547 179.662 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.474 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -160.95 178.95 8.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.0 -179.751 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -109.85 124.08 50.71 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.917 179.739 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.462 HG22 HG23 ' A' ' 9' ' ' ILE . 12.9 m -114.28 140.01 37.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.399 179.117 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.7 m -101.48 142.15 33.29 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.857 -179.598 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.675 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -112.36 161.14 11.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.986 179.788 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.287 -1.285 . . . . 0.0 112.029 179.985 . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.413 ' HA ' ' NE ' ' A' ' 4' ' ' ARG . 15.4 mmp_? . . . . . 0 N--CA 1.483 1.223 0 CA-C-O 120.729 0.3 . . . . 0.0 110.841 . . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 29.7 ttmt -126.35 149.14 49.38 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 178.653 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.499 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 14.8 m -141.55 132.8 26.48 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.937 179.268 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 2.2 pt -131.9 147.58 32.39 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -179.52 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.568 ' HB3' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -85.74 100.59 12.12 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 176.155 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.474 ' CD1' HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -78.54 158.16 4.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.561 -0.456 . . . . 0.0 110.777 -177.815 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.425 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 13.1 mp0 -100.89 10.17 41.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.86 0.362 . . . . 0.0 110.463 179.249 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 74.2 ttt180 -99.02 165.0 11.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.519 -179.527 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.82 -175.13 33.65 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.205 -179.976 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -74.81 115.83 3.64 Favored 'Cis proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.132 -1.612 . . . . 0.0 112.553 0.314 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.67 124.14 1.01 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.974 -0.632 . . . . 0.0 112.481 179.765 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.3 mtt85 -61.58 98.84 0.1 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.848 0.356 . . . . 0.0 110.418 179.656 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -131.0 -178.91 5.03 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.582 -179.636 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.465 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.3 OUTLIER -117.38 145.28 44.18 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.593 179.765 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.6 t -114.81 161.19 13.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.256 -179.475 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 86.9 m -120.69 109.06 14.75 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.081 179.568 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.582 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -104.44 171.37 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 CA-C-O 120.816 0.341 . . . . 0.0 111.387 -179.813 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.464 -1.187 . . . . 0.0 112.544 179.714 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 88.2 p . . . . . 0 C--O 1.233 0.234 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.594 HG23 HD11 ' A' ' 20' ' ' ILE . 3.8 pt -132.01 147.61 32.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 112.113 0.412 . . . . 0.0 112.113 179.157 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.483 ' O ' ' CD ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -91.19 91.6 8.3 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 176.118 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.525 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.59 150.51 6.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.613 -176.776 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 22.5 mp0 -89.0 12.52 15.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.621 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -96.88 177.94 5.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.32 -179.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.501 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.97 178.2 29.4 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.966 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -73.37 108.26 0.95 Allowed 'Cis proline' 0 C--N 1.344 0.326 0 C-N-CA 123.337 -1.526 . . . . 0.0 112.279 0.07 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.501 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 67.41 156.36 0.62 Allowed Glycine 0 C--N 1.333 0.391 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.422 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -60.27 126.04 25.96 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.766 0.317 . . . . 0.0 110.502 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.525 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -149.18 177.84 9.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.887 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -109.67 120.09 41.4 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.674 179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.499 HG22 HG23 ' A' ' 9' ' ' ILE . 15.1 m -109.27 152.8 11.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.759 178.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.6 m -89.44 156.37 18.71 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.957 0.408 . . . . 0.0 111.24 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.594 HD11 HG23 ' A' ' 7' ' ' ILE . 8.3 mt -120.63 163.06 18.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.022 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.425 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.503 -1.165 . . . . 0.0 112.075 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.531 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 14.7 m . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.465 0.174 . . . . 0.0 110.849 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.488 ' O ' ' HB2' ' A' ' 17' ' ' PHE . 1.6 pt -131.43 146.05 34.26 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.567 0 N-CA-C 113.696 0.998 . . . . 0.0 113.696 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -78.8 102.24 8.04 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 176.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.555 HD13 HG13 ' A' ' 18' ' ' VAL . 1.8 pt -77.54 151.28 5.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.657 -177.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -100.95 10.49 41.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.464 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 36.0 ptt180 -109.25 -178.31 3.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.827 0.346 . . . . 0.0 111.017 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.54 -172.64 30.78 Favored Glycine 0 C--N 1.329 0.187 0 C-N-CA 121.108 -0.568 . . . . 0.0 112.308 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.98 117.66 5.33 Favored 'Cis proline' 0 N--CA 1.462 -0.349 0 C-N-CA 123.34 -1.525 . . . . 0.0 112.407 0.143 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 145.64 4.73 Favored Glycine 0 C--N 1.33 0.221 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.293 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.492 ' C ' ' HD2' ' A' ' 15' ' ' ARG . 4.8 ppt_? -66.72 128.8 37.66 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.44 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -169.52 -166.47 0.6 Allowed 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 121.199 0.523 . . . . 0.0 110.593 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.531 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.1 OUTLIER -137.62 152.57 49.5 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.367 179.572 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.555 HG13 HD13 ' A' ' 9' ' ' ILE . 19.5 m -115.75 154.9 17.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.972 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 86.3 m -113.74 110.71 20.61 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.359 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.8 pt -100.22 173.06 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.674 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.711 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.242 -1.31 . . . . 0.0 112.287 179.744 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.6 m . . . . . 0 CA--C 1.528 0.122 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.8 pt -130.95 152.04 36.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.318 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -179.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.498 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 22.8 ttm180 -94.97 104.32 16.2 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 175.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.47 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.37 144.29 11.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 C-N-CA 119.845 -0.742 . . . . 0.0 110.791 -177.554 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.1 tp-100 -93.88 12.46 25.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.426 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.3 mtt-85 -97.47 173.46 7.16 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.332 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.415 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.74 -179.83 30.52 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.1 108.63 1.14 Allowed 'Cis proline' 0 C--N 1.345 0.381 0 C-N-CA 123.34 -1.525 . . . . 0.0 112.256 0.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.415 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 75.54 152.18 3.48 Favored Glycine 0 C--N 1.332 0.335 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.467 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.491 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -62.34 152.64 33.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.875 0.369 . . . . 0.0 111.096 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.47 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.17 178.54 3.81 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.998 0.428 . . . . 0.0 111.152 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.498 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.6 OUTLIER -120.56 129.7 53.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.0 179.718 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 6.2 t -120.85 159.92 22.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.8 m -102.77 156.11 17.86 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.204 0.526 . . . . 0.0 111.316 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.414 HG22 ' N ' ' A' ' 21' ' ' GLY . 8.7 mt -118.1 164.73 14.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.177 -0.92 . . . . 0.0 109.816 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.414 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 0.999 0 CA-C-O 118.416 -1.214 . . . . 0.0 111.977 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.449 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 17.4 m . . . . . 0 C--O 1.232 0.145 0 N-CA-C 110.588 -0.153 . . . . 0.0 110.588 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.447 ' O ' ' HB2' ' A' ' 17' ' ' PHE . 2.9 pt -132.42 146.04 33.59 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.501 0 N-CA-C 113.933 1.086 . . . . 0.0 113.933 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.509 ' HA ' ' HB2' ' A' ' 17' ' ' PHE . 48.7 mtt85 -86.9 108.92 19.0 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 175.249 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 16' ' ' ALA . 1.3 pt -77.76 157.66 5.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.714 -177.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -100.57 11.0 40.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.598 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 5.3 ttm180 -98.95 -170.13 1.88 Allowed 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -108.95 179.35 21.13 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.155 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.56 112.42 2.34 Favored 'Cis proline' 0 C--N 1.344 0.297 0 C-N-CA 122.971 -1.679 . . . . 0.0 112.44 0.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.5 155.4 6.13 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.353 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.2 ttp85 -62.28 88.22 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.222 0.534 . . . . 0.0 110.293 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.453 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -101.58 -170.81 1.88 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.883 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.509 ' HB2' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -148.74 149.98 32.34 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.38 179.574 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.412 HG12 ' N ' ' A' ' 19' ' ' THR . 5.4 t -121.92 162.23 21.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.72 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.412 ' N ' HG12 ' A' ' 18' ' ' VAL . 89.6 m -111.01 126.95 55.34 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.761 0.791 . . . . 0.0 112.05 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.5 mt -103.22 156.49 5.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.901 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.49 -1.172 . . . . 0.0 113.043 179.037 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 C--O 1.232 0.175 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.421 ' HA ' HH21 ' A' ' 8' ' ' ARG . 3.4 pt -132.0 148.67 32.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -179.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.61 ' HE ' ' H ' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -88.14 102.64 14.98 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 175.586 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.613 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.48 142.23 14.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 120.154 -0.618 . . . . 0.0 110.751 -177.379 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.65 11.47 24.28 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.805 -178.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -98.28 175.28 6.12 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.734 0.302 . . . . 0.0 110.646 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.49 -177.04 31.34 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.272 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 81.0 Cg_endo -78.87 110.4 1.84 Allowed 'Cis proline' 0 C--N 1.343 0.284 0 C-N-CA 123.062 -1.641 . . . . 0.0 112.796 0.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.06 141.57 4.93 Favored Glycine 0 C--N 1.331 0.299 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.663 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.491 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -60.14 142.47 54.22 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.956 0.407 . . . . 0.0 111.156 179.83 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.613 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.28 -168.12 0.69 Allowed 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.113 0.483 . . . . 0.0 110.624 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.446 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -144.56 145.48 31.84 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.486 179.12 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 t -125.61 162.32 28.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.243 -179.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 98.0 m -100.39 152.27 20.54 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.042 0.449 . . . . 0.0 110.8 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.423 HG22 ' N ' ' A' ' 21' ' ' GLY . 7.0 mt -114.47 163.86 11.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.573 -179.146 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.423 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.527 -1.151 . . . . 0.0 112.002 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 64.9 m . . . . . 0 CA--C 1.529 0.145 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.6 pt -131.41 148.44 32.72 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.36 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 -179.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 65.4 mtt85 -85.06 99.06 10.78 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 176.063 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.578 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.59 151.63 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.846 0.355 . . . . 0.0 111.18 -177.23 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -95.09 8.41 43.07 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.392 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 16.4 ptp180 -99.72 -175.89 3.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.458 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.34 -177.73 31.48 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.392 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.79 114.2 3.09 Favored 'Cis proline' 0 C--N 1.343 0.279 0 C-N-CA 123.381 -1.508 . . . . 0.0 112.532 0.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.59 161.81 8.6 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.5 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -78.35 122.9 26.37 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.148 0.499 . . . . 0.0 111.043 179.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.578 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -160.48 -165.16 1.37 Allowed 'General case' 0 CA--C 1.512 -0.495 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.614 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -135.28 143.96 46.53 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.102 0.477 . . . . 0.0 110.707 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.44 HG22 ' CG2' ' A' ' 9' ' ' ILE . 31.1 m -118.49 168.42 10.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.678 -179.294 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.6 m -96.4 152.22 18.81 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 120.979 0.419 . . . . 0.0 111.071 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.429 HG22 ' N ' ' A' ' 21' ' ' GLY . 9.5 mt -107.85 163.71 5.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.376 -179.53 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.429 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.25 1.12 0 CA-C-O 118.117 -1.379 . . . . 0.0 111.827 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.435 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.9 m . . . . . 0 C--O 1.23 0.053 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.583 HG12 HD11 ' A' ' 20' ' ' ILE . 2.4 pt -132.3 146.68 32.67 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.504 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.46 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 45.9 mtp85 -84.46 103.46 13.63 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.684 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.3 OUTLIER -78.01 153.83 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.188 -177.299 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.514 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 13.3 mp0 -92.61 13.21 20.61 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.241 -179.167 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 49.5 mtp85 -97.3 -176.06 3.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.921 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.76 177.35 30.42 Favored Glycine 0 C--N 1.332 0.323 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.409 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.96 135.9 38.66 Favored 'Cis proline' 0 C--N 1.344 0.317 0 C-N-CA 122.987 -1.672 . . . . 0.0 112.697 0.124 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 59.68 -104.34 0.55 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.112 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 8.0 ttp180 -160.07 134.11 7.31 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.684 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -159.79 -167.96 2.13 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.599 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.46 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -137.02 148.71 47.01 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.5 179.455 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.544 HG23 HD12 ' A' ' 9' ' ' ILE . 4.4 t -121.52 164.05 18.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.29 -179.241 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.479 ' C ' HD13 ' A' ' 20' ' ' ILE . 91.7 m -113.55 140.49 48.11 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.981 0.42 . . . . 0.0 111.238 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.641 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -124.98 156.6 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.724 179.705 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.263 -1.299 . . . . 0.0 112.372 179.792 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.4 m . . . . . 0 C--O 1.232 0.142 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.623 HG12 HD11 ' A' ' 20' ' ' ILE . 8.5 pt -131.85 147.35 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 113.564 0.95 . . . . 0.0 113.564 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.682 ' H ' ' HD2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -85.02 101.91 12.78 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 106.325 -1.731 . . . . 0.0 106.325 175.235 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.489 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.1 OUTLIER -76.25 150.05 6.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.911 -176.404 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.439 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 17.7 mp0 -94.11 9.47 37.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.998 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 10.6 ptp180 -99.09 -173.62 2.54 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.908 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.35 -176.1 31.47 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.423 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -80.7 108.98 1.36 Allowed 'Cis proline' 0 CA--C 1.531 0.334 0 C-N-CA 122.886 -1.714 . . . . 0.0 112.597 0.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.23 169.77 38.0 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.682 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -71.36 123.79 23.1 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.742 0.306 . . . . 0.0 110.952 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.489 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -160.96 -169.32 2.33 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.243 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.443 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -145.36 141.15 28.23 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.942 178.994 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.427 HG12 ' N ' ' A' ' 19' ' ' THR . 5.5 t -115.5 163.95 12.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.398 -178.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.427 ' N ' HG12 ' A' ' 18' ' ' VAL . 92.6 m -100.07 158.37 15.89 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.292 0.567 . . . . 0.0 110.786 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.623 HD11 HG12 ' A' ' 7' ' ' ILE . 1.0 OUTLIER -140.99 153.67 20.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.918 -178.762 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.443 -1.198 . . . . 0.0 112.153 179.688 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.523 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.4 m . . . . . 0 N--CA 1.456 -0.137 0 CA-C-O 120.573 0.225 . . . . 0.0 110.785 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 2.8 pt -132.48 147.85 31.91 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -86.67 102.93 14.66 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 175.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.641 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.78 153.63 5.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.859 -177.451 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.406 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 17.3 tt0 -99.02 10.96 40.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.363 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -98.69 -177.03 3.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.751 0.31 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -108.76 -176.24 21.68 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.245 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -77.37 114.59 3.28 Favored 'Cis proline' 0 C--N 1.343 0.245 0 C-N-CA 122.93 -1.696 . . . . 0.0 112.337 -0.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.91 147.35 6.92 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.109 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.9 mpt_? -77.56 127.01 31.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.996 0.426 . . . . 0.0 110.877 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.641 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -156.19 -169.0 2.91 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.888 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.523 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -133.88 142.18 47.68 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.977 0.418 . . . . 0.0 110.948 179.521 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.544 HG23 HD12 ' A' ' 9' ' ' ILE . 3.8 t -110.58 162.73 7.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.053 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.448 HG23 ' OG ' ' A' ' 6' ' ' SER . 78.8 m -124.91 114.18 18.83 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.83 0.348 . . . . 0.0 111.379 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.599 HD13 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -100.42 179.65 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.774 178.893 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.739 -1.034 . . . . 0.0 113.103 -179.867 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.3 m . . . . . 0 CA--C 1.529 0.172 0 CA-C-O 120.373 0.13 . . . . 0.0 111.084 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.43 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 3.4 pt -131.28 145.96 34.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 113.742 1.016 . . . . 0.0 113.742 -179.311 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.3 mtt-85 -83.56 95.64 8.38 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 176.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.538 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.1 OUTLIER -76.37 142.94 13.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.102 0.477 . . . . 0.0 111.19 -176.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 58.7 mm-40 -92.66 11.43 26.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.453 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -98.03 173.25 7.14 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.25 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.7 -175.46 30.95 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.723 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -80.65 119.66 6.6 Favored 'Cis proline' 0 C--N 1.347 0.453 0 C-N-CA 123.326 -1.531 . . . . 0.0 112.34 -0.066 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.67 166.61 41.65 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.548 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.439 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 1.7 mpt_? -89.18 134.99 33.81 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.736 0.303 . . . . 0.0 110.593 179.546 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.538 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -168.85 -166.63 0.67 Allowed 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.141 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.43 ' HA ' ' O ' ' A' ' 7' ' ' ILE . 0.4 OUTLIER -141.75 139.88 32.94 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.923 178.681 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.47 HG22 ' CG2' ' A' ' 9' ' ' ILE . 26.8 m -112.39 166.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.899 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 83.3 m -98.89 156.48 16.87 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.171 0.51 . . . . 0.0 111.594 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.409 HG22 ' N ' ' A' ' 21' ' ' GLY . 8.5 mt -120.21 167.17 13.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.195 -0.912 . . . . 0.0 109.945 -179.126 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.409 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.247 0.911 0 CA-C-O 118.281 -1.288 . . . . 0.0 112.017 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.1 m . . . . . 0 N--CA 1.462 0.135 0 CA-C-O 120.584 0.231 . . . . 0.0 110.568 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.504 HG23 HD11 ' A' ' 20' ' ' ILE . 3.6 pt -130.33 150.41 34.58 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.314 0 CA-C-O 121.022 0.439 . . . . 0.0 112.005 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 12.3 ptm180 -95.67 90.98 5.89 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 176.47 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.868 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -76.92 144.35 11.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.131 -177.122 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -97.87 9.95 41.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.811 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.559 ' HD2' ' N ' ' A' ' 11' ' ' ARG . 2.1 mpt_? -101.84 -179.49 4.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.241 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -102.45 -178.86 27.23 Favored Glycine 0 CA--C 1.516 0.156 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.272 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.47 114.4 3.33 Favored 'Cis proline' 0 C--N 1.346 0.409 0 C-N-CA 123.538 -1.442 . . . . 0.0 111.985 0.055 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 87.5 147.38 12.36 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.394 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 20.2 mmt85 -99.96 122.22 42.54 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.481 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -169.76 -173.86 1.71 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.136 0.494 . . . . 0.0 110.991 -179.305 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.0 120.85 34.82 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.547 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.868 HG23 HD12 ' A' ' 9' ' ' ILE . 5.2 t -109.65 162.04 7.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.417 ' N ' HG12 ' A' ' 18' ' ' VAL . 97.0 m -100.66 158.83 15.65 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.389 0.614 . . . . 0.0 111.802 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.504 HD11 HG23 ' A' ' 7' ' ' ILE . 6.2 mt -129.0 165.61 28.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.273 -179.309 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.192 179.139 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.3 m . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.795 0.331 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.0 pt -130.46 152.83 38.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.147 -179.571 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.464 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 32.9 ptt180 -95.79 93.36 7.03 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 176.407 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.485 HG23 HG22 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -76.3 148.02 7.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.06 0.457 . . . . 0.0 111.395 -176.872 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.573 HE21 HH21 ' A' ' 15' ' ' ARG . 0.4 OUTLIER -89.85 11.27 20.74 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.805 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 65.2 mtt85 -98.35 -173.54 2.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.352 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.459 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.79 178.19 29.63 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.68 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -75.39 108.06 1.01 Allowed 'Cis proline' 0 C--N 1.344 0.33 0 C-N-CA 123.449 -1.479 . . . . 0.0 112.268 -0.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.459 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 68.97 160.37 2.08 Favored Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.572 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.573 HH21 HE21 ' A' ' 10' ' ' GLN . 16.3 tpp85 -64.42 118.1 8.26 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.576 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.431 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -151.32 -178.55 6.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.249 0.547 . . . . 0.0 111.622 -179.563 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -111.01 130.0 55.73 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.44 179.567 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.485 HG22 HG23 ' A' ' 9' ' ' ILE . 16.5 m -119.11 142.34 34.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.705 179.206 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 68.1 m -100.11 115.28 29.43 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.479 -179.317 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.5 pt -102.19 148.25 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.781 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.187 179.02 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.623 -1.098 . . . . 0.0 112.314 -179.82 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.8 m . . . . . 0 C--O 1.231 0.098 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 6.2 pt -131.45 145.07 35.78 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.561 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.47 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 14.4 ptt85 -90.43 98.44 11.78 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 175.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.636 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -78.17 147.04 7.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.963 0.411 . . . . 0.0 111.485 -176.853 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 21.8 mp0 -94.15 9.48 37.68 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.46 -179.762 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.412 HH11 ' HD3' ' A' ' 11' ' ' ARG . 11.3 ptt180 -99.21 -177.75 3.71 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.736 0.303 . . . . 0.0 110.744 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.15 -176.33 30.39 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.466 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -79.08 106.91 0.94 Allowed 'Cis proline' 0 C--N 1.345 0.361 0 C-N-CA 122.958 -1.684 . . . . 0.0 112.779 -0.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.24 148.28 10.12 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.402 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 18.3 mmt85 -65.71 131.79 47.2 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.688 0.28 . . . . 0.0 110.829 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.636 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -167.6 -173.45 2.19 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.033 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.47 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -136.36 138.65 41.84 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.38 179.301 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.541 HG23 HD12 ' A' ' 9' ' ' ILE . 2.6 t -110.28 162.5 7.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.252 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 99.1 m -104.62 152.37 22.53 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.487 0.66 . . . . 0.0 111.063 179.747 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.406 HG22 ' H ' ' A' ' 21' ' ' GLY . 6.9 mt -114.9 166.79 8.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.776 -179.113 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.406 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.25 1.111 0 CA-C-O 118.458 -1.19 . . . . 0.0 112.305 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.5 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 13.2 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.707 0.289 . . . . 0.0 111.244 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.424 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 2.8 pt -132.35 148.23 31.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.369 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -179.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.426 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 82.3 mtm180 -87.08 98.53 11.34 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 175.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.657 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.71 141.96 14.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 120.231 -0.587 . . . . 0.0 110.731 -177.539 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -93.21 12.34 24.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.732 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 37.8 ptt180 -98.53 -175.7 3.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.395 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.79 177.98 29.5 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.496 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -78.99 109.34 1.44 Allowed 'Cis proline' 0 C--N 1.345 0.381 0 C-N-CA 123.223 -1.574 . . . . 0.0 112.506 0.107 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.12 157.84 21.47 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.723 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -74.08 135.32 42.97 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.586 0.232 . . . . 0.0 110.414 179.552 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.657 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.42 -168.13 0.68 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.052 0.453 . . . . 0.0 110.536 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.5 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.1 OUTLIER -139.02 145.48 39.68 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.26 179.129 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.4 t -119.53 161.46 18.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.455 -178.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 90.3 m -117.87 113.45 21.78 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.558 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 34.1 pt -102.24 163.36 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 C-N-CA 122.938 0.495 . . . . 0.0 111.606 -179.745 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.181 0 CA-C-O 117.986 -1.452 . . . . 0.0 113.359 178.791 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.511 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 14.2 m . . . . . 0 N--CA 1.456 -0.145 0 CA-C-O 120.522 0.201 . . . . 0.0 110.652 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.606 HG12 HD11 ' A' ' 20' ' ' ILE . 1.2 pt -130.9 150.44 34.61 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -179.517 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.521 ' H ' ' HD3' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -89.11 99.82 12.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 176.382 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.588 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -78.7 144.12 11.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.506 -0.478 . . . . 0.0 111.446 -177.542 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 44.9 mt-30 -83.57 11.5 7.05 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.837 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.447 ' H ' HG12 ' A' ' 9' ' ' ILE . 94.2 mtt180 -98.52 -175.07 2.98 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.352 -179.667 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.412 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -102.18 -178.12 27.65 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.288 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.66 107.62 1.0 Allowed 'Cis proline' 0 C--N 1.343 0.265 0 C-N-CA 123.103 -1.624 . . . . 0.0 112.412 0.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.412 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 76.99 155.33 6.55 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.385 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.457 ' NE ' ' H ' ' A' ' 15' ' ' ARG . 0.1 OUTLIER -62.31 111.41 1.98 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.911 0.386 . . . . 0.0 110.723 179.762 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.588 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -144.13 -172.76 3.84 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 115.806 -0.633 . . . . 0.0 109.95 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.511 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -136.17 142.69 44.18 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.526 179.278 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.0 t -111.64 161.26 10.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.26 -179.262 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 71.8 m -118.32 111.0 18.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.579 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.606 HD11 HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -109.02 178.28 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.931 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.758 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.438 -1.201 . . . . 0.0 112.165 179.69 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.4 m . . . . . 0 N--CA 1.456 -0.142 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 pt -130.98 149.79 33.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -179.014 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.424 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 7.4 ptm180 -93.32 92.3 7.62 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 176.024 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.538 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.57 147.26 7.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.39 -176.63 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -95.17 11.12 33.41 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.25 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -98.26 -174.72 2.91 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.473 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -100.24 177.74 28.81 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.485 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.98 108.69 1.08 Allowed 'Cis proline' 0 C--N 1.344 0.31 0 C-N-CA 123.096 -1.626 . . . . 0.0 112.264 -0.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.473 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 72.47 150.67 1.19 Allowed Glycine 0 C--N 1.333 0.363 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.347 -179.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.427 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 1.3 mpt_? -73.34 133.26 43.79 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.538 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -164.88 -175.29 3.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.19 0.519 . . . . 0.0 111.31 -179.695 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -106.74 119.05 38.28 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.793 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.489 HG22 HG23 ' A' ' 9' ' ' ILE . 17.4 m -110.02 154.78 11.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.977 179.078 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 98.8 m -105.53 154.44 20.37 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.417 0.627 . . . . 0.0 111.933 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -130.42 147.26 33.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.505 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.4 -1.222 . . . . 0.0 112.482 179.702 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.5 m . . . . . 0 CA--C 1.529 0.142 0 CA-C-O 120.62 0.248 . . . . 0.0 111.102 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.58 HG12 HD11 ' A' ' 20' ' ' ILE . 3.9 pt -131.38 148.28 32.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 121.135 0.493 . . . . 0.0 112.219 179.38 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.452 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 38.9 ttt180 -93.8 98.09 10.85 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 176.419 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.488 ' O ' ' HD3' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -75.6 149.21 6.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 C-N-CA 120.766 -0.373 . . . . 0.0 110.558 -177.328 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.435 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 53.7 tt0 -94.68 11.41 31.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.243 -179.089 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.416 ' HG2' ' CG1' ' A' ' 9' ' ' ILE . 5.5 ptp180 -98.48 178.29 5.07 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.461 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.98 -177.01 30.67 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.59 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -77.0 110.7 1.77 Allowed 'Cis proline' 0 C--N 1.343 0.285 0 C-N-CA 123.287 -1.547 . . . . 0.0 112.323 -0.015 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.61 156.22 9.25 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.473 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.488 ' HD3' ' O ' ' A' ' 9' ' ' ILE . 17.7 tpp85 -71.9 129.35 38.37 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 179.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.425 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -152.04 -176.58 5.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.308 0.575 . . . . 0.0 111.875 -179.464 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.452 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -119.34 128.15 53.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.601 179.706 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.478 HG22 HG23 ' A' ' 9' ' ' ILE . 16.9 m -116.5 150.51 18.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.155 178.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 97.0 m -96.1 159.32 15.02 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.518 0.675 . . . . 0.0 111.877 -179.282 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.58 HD11 HG12 ' A' ' 7' ' ' ILE . 2.4 mt -135.48 155.15 36.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 114.537 -1.21 . . . . 0.0 108.945 -179.355 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.302 -1.277 . . . . 0.0 112.559 179.618 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 13.4 m . . . . . 0 N--CA 1.456 -0.172 0 CA-C-O 120.539 0.209 . . . . 0.0 110.778 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.51 HG12 HD11 ' A' ' 20' ' ' ILE . 1.7 pt -131.79 148.39 32.4 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 N-CA-C 113.313 0.857 . . . . 0.0 113.313 -179.332 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.435 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 5.8 ptm180 -84.38 108.7 17.35 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 175.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.628 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.3 OUTLIER -78.16 152.2 5.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.671 -177.79 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -90.5 11.63 21.19 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.019 -179.382 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.5 mtp85 -98.02 174.89 6.33 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.457 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.4 179.45 32.04 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.65 -179.376 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_exo -70.3 137.8 47.08 Favored 'Cis proline' 0 C--N 1.342 0.196 0 C-N-CA 123.124 -1.615 . . . . 0.0 112.527 0.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.45 ' C ' ' HD2' ' A' ' 15' ' ' ARG . . . 55.75 -145.31 32.98 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.087 -179.838 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.45 ' HD2' ' C ' ' A' ' 14' ' ' GLY . 9.5 mpt_? -117.99 128.16 54.52 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.628 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -149.53 -175.97 5.21 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.55 -179.434 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.469 ' HB2' ' C ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -139.83 148.79 42.64 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.975 179.746 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 6' ' ' SER . 9.1 t -117.68 161.74 16.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.103 -179.661 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.423 ' N ' HG12 ' A' ' 18' ' ' VAL . 80.9 m -118.33 112.57 20.21 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.249 179.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.667 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -117.52 152.69 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-O 120.9 0.381 . . . . 0.0 111.431 -179.728 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.528 -1.151 . . . . 0.0 112.139 -179.737 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.645 0.259 . . . . 0.0 111.143 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.456 HG12 HD11 ' A' ' 20' ' ' ILE . 5.9 pt -131.02 146.11 34.44 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-O 121.152 0.501 . . . . 0.0 112.351 179.123 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 13.4 tpt180 -96.87 85.9 3.89 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 176.605 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.79 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -77.31 144.5 11.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.827 -177.354 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 38.6 tt0 -96.52 7.01 47.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.187 0.518 . . . . 0.0 110.131 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -99.43 -177.03 3.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.536 179.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.84 -178.28 29.37 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.126 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -80.14 108.87 1.32 Allowed 'Cis proline' 0 C--N 1.345 0.352 0 C-N-CA 123.428 -1.488 . . . . 0.0 112.328 0.161 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.52 133.06 5.75 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.884 179.611 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -81.61 110.91 17.42 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.497 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -163.29 -168.86 1.81 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.267 0.556 . . . . 0.0 111.087 -179.238 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -97.79 128.19 44.26 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.758 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.79 HG23 HD12 ' A' ' 9' ' ' ILE . 11.5 t -109.13 162.69 6.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 178.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.442 ' N ' HG12 ' A' ' 18' ' ' VAL . 9.2 m -104.22 160.1 15.15 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.561 0.696 . . . . 0.0 111.541 -179.48 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.456 HD11 HG12 ' A' ' 7' ' ' ILE . 9.1 mt -140.71 167.73 17.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.714 -179.557 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.406 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.324 -1.264 . . . . 0.0 112.846 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.3 m . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.642 0.258 . . . . 0.0 110.714 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.0 pt -130.96 149.37 33.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.5 ttp85 -91.95 92.03 8.13 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 176.112 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.58 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.32 145.07 10.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.135 0.493 . . . . 0.0 111.046 -177.034 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -91.92 11.84 23.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.053 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 10.1 mtp-105 -98.31 -168.02 1.59 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.628 -179.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.416 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -115.17 179.81 18.33 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.416 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -75.54 109.6 1.35 Allowed 'Cis proline' 0 C--N 1.344 0.336 0 C-N-CA 123.088 -1.63 . . . . 0.0 112.394 -0.023 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.416 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 82.29 133.32 1.77 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.227 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.43 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -77.97 116.61 18.59 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.786 0.327 . . . . 0.0 110.337 179.672 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.58 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -153.2 -172.22 4.17 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.289 0.566 . . . . 0.0 111.076 -179.343 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -96.55 120.85 37.63 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.062 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.51 HG22 HG23 ' A' ' 9' ' ' ILE . 12.7 m -109.63 148.27 13.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.169 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 65.0 m -113.58 131.46 56.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.128 0.49 . . . . 0.0 111.511 -179.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 pt -123.33 143.31 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 C-N-CA 123.83 0.852 . . . . 0.0 110.952 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.029 0 CA-C-O 118.11 -1.383 . . . . 0.0 113.511 179.306 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.5 m . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.691 0.282 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.9 pt -131.79 152.27 36.68 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.272 0 CA-C-O 121.257 0.551 . . . . 0.0 112.32 179.908 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.447 ' HD3' ' NH2' ' A' ' 15' ' ' ARG . 28.9 ttm105 -93.71 91.46 7.03 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 107.278 -1.378 . . . . 0.0 107.278 176.555 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.54 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.42 146.58 8.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.836 -177.717 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.54 ' H ' ' CD ' ' A' ' 10' ' ' GLN . 0.1 OUTLIER -98.95 9.54 43.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.906 -179.805 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -99.7 -169.94 1.82 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.224 179.926 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.17 174.2 27.21 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.455 -0.879 . . . . 0.0 112.404 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -81.65 108.13 1.2 Allowed 'Cis proline' 0 C--N 1.345 0.388 0 C-N-CA 123.152 -1.603 . . . . 0.0 112.777 0.132 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.03 137.02 0.66 Allowed Glycine 0 C--N 1.332 0.358 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.788 179.61 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.543 ' C ' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -66.02 130.98 45.12 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.388 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.54 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.22 -174.74 1.79 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.136 0.493 . . . . 0.0 111.007 -179.44 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -103.39 121.18 42.26 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.61 179.825 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.462 HG22 HG23 ' A' ' 9' ' ' ILE . 16.9 m -108.96 156.98 9.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.778 178.825 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.485 ' C ' HD13 ' A' ' 20' ' ' ILE . 75.6 m -118.48 148.28 42.76 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.08 0.467 . . . . 0.0 112.157 -178.658 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.599 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -124.97 177.75 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.187 179.119 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.157 0 CA-C-O 118.814 -0.992 . . . . 0.0 113.567 -179.761 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.3 m . . . . . 0 N--CA 1.462 0.13 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 pt -130.99 148.13 33.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 -179.502 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 13.7 tpp180 -95.56 91.48 6.17 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 176.037 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.465 HD12 HG23 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -76.47 144.71 11.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.819 -177.237 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.43 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 46.4 tt0 -88.66 11.64 16.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.826 -179.485 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.0 mtp-105 -96.59 -176.04 3.49 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.207 -179.23 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.494 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -107.73 -179.54 22.15 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.849 -179.412 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -73.4 107.28 0.87 Allowed 'Cis proline' 0 C--N 1.343 0.288 0 C-N-CA 123.282 -1.549 . . . . 0.0 112.387 0.172 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.494 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 74.35 141.89 0.71 Allowed Glycine 0 C--N 1.333 0.377 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.534 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.3 124.33 20.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.762 0.315 . . . . 0.0 110.625 179.501 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.426 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -147.33 -178.99 6.53 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.185 -179.665 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -108.69 122.12 46.46 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.452 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.465 HG23 HD12 ' A' ' 9' ' ' ILE . 3.9 t -109.27 158.78 9.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.341 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.7 m -107.04 154.75 20.66 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.414 0.626 . . . . 0.0 111.81 -179.717 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.493 HG22 ' H ' ' A' ' 21' ' ' GLY . 6.8 mt -125.34 171.9 13.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 114.698 -1.137 . . . . 0.0 109.308 -179.475 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.493 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.251 1.158 0 CA-C-O 118.384 -1.231 . . . . 0.0 111.978 179.59 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.428 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 19.9 m . . . . . 0 C--O 1.233 0.185 0 CA-C-O 120.314 0.102 . . . . 0.0 110.785 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.471 HG12 HD11 ' A' ' 20' ' ' ILE . 4.5 pt -132.38 146.36 33.11 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.392 0 N-CA-C 113.74 1.015 . . . . 0.0 113.74 -179.794 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.465 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 35.2 ttm180 -88.65 96.12 10.52 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 176.265 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.611 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.11 141.33 15.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 120.415 -0.514 . . . . 0.0 109.851 -178.165 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.8 tt0 -93.67 11.01 30.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.49 -178.677 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 46.2 ptt85 -98.39 -169.9 1.87 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.159 179.714 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.486 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.23 176.82 29.49 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.497 -0.859 . . . . 0.0 112.764 -179.412 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -74.23 109.11 1.1 Allowed 'Cis proline' 0 C--N 1.347 0.453 0 C-N-CA 123.151 -1.604 . . . . 0.0 112.51 0.001 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.486 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 71.81 156.82 2.79 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.495 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.0 mpt_? -67.83 133.7 49.64 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 120.789 0.328 . . . . 0.0 110.695 179.445 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.611 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -168.31 -164.61 0.54 Allowed 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.954 -179.626 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.465 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -141.27 137.11 32.27 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.654 179.181 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.529 HG23 HD12 ' A' ' 9' ' ' ILE . 4.1 t -110.77 163.75 7.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.921 -179.362 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.403 ' N ' HG12 ' A' ' 18' ' ' VAL . 53.8 m -108.91 131.59 54.88 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.811 0.815 . . . . 0.0 111.92 -179.895 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.545 HG22 ' H ' ' A' ' 21' ' ' GLY . 4.2 mt -100.63 174.96 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 113.983 -1.462 . . . . 0.0 109.175 179.251 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.545 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.609 -1.106 . . . . 0.0 112.541 179.273 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.4 m . . . . . 0 C--O 1.232 0.167 0 CA-C-O 120.572 0.225 . . . . 0.0 110.619 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.616 HG12 HD11 ' A' ' 20' ' ' ILE . 6.0 pt -130.6 147.85 33.12 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.411 0 CA-C-O 121.112 0.482 . . . . 0.0 112.295 -179.878 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.4 ' HA ' ' O ' ' A' ' 16' ' ' ALA . 75.7 ttt180 -89.64 100.26 13.1 Favored 'General case' 0 N--CA 1.445 -0.71 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 176.043 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.557 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.98 150.59 5.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-O 121.32 0.581 . . . . 0.0 111.854 -176.641 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 62.7 mt-30 -93.61 12.18 26.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.698 -179.811 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -98.1 177.05 5.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.967 -179.174 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.453 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -104.25 -178.88 25.17 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.629 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -74.08 108.4 1.0 Allowed 'Cis proline' 0 C--N 1.345 0.36 0 C-N-CA 123.278 -1.551 . . . . 0.0 112.254 0.02 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.453 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 74.31 148.53 1.49 Allowed Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.346 -179.814 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.502 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -59.79 145.71 44.34 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.823 0.344 . . . . 0.0 110.885 179.806 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.557 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -164.74 -177.19 4.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.928 0.394 . . . . 0.0 111.202 -179.565 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -117.22 123.52 46.83 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.287 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.516 HG22 HG23 ' A' ' 9' ' ' ILE . 20.2 m -113.2 155.92 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.026 178.619 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 42.9 m -99.86 159.46 15.06 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.153 0.502 . . . . 0.0 111.316 -179.633 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.616 HD11 HG12 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -142.09 154.5 18.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.179 -178.69 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.261 0 CA-C-O 118.424 -1.209 . . . . 0.0 113.729 178.696 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 24.0 m . . . . . 0 N--CA 1.452 -0.347 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.8 pt -128.45 146.59 33.66 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.352 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -179.414 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.473 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 53.9 ttp180 -95.83 92.86 6.74 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 176.257 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.452 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -75.99 154.72 5.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.577 -177.379 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.0 pt20 -97.05 12.03 34.04 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.211 -179.363 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.418 ' H ' HG12 ' A' ' 9' ' ' ILE . 97.7 mtt180 -97.44 -178.75 4.25 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.648 -179.345 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.02 -179.56 30.24 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.447 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -77.86 107.76 1.06 Allowed 'Cis proline' 0 C--N 1.346 0.418 0 C-N-CA 123.098 -1.626 . . . . 0.0 112.403 0.028 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.26 153.22 5.53 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.214 -179.865 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 40.1 mmt-85 -66.17 119.93 12.33 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.69 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.84 -179.13 6.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.157 0.504 . . . . 0.0 111.75 -179.458 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.473 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -114.23 125.77 54.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.995 -179.996 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.452 HG23 HD12 ' A' ' 9' ' ' ILE . 5.6 t -110.05 162.99 7.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.705 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 6' ' ' SER . 53.7 m -107.03 158.23 17.2 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.937 -0.305 . . . . 0.0 111.751 -179.464 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.6 mm -99.93 157.29 3.95 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.258 179.68 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.314 -1.27 . . . . 0.0 112.352 179.804 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.475 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.7 m . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.423 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 4.9 pt -131.28 147.82 32.85 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 N-CA-C 113.701 1.0 . . . . 0.0 113.701 -178.874 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.492 ' N ' ' HD2' ' A' ' 8' ' ' ARG . 2.2 mpt_? -86.94 99.72 12.07 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 176.012 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.581 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.85 143.3 12.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 C-N-CA 120.3 -0.56 . . . . 0.0 110.922 -177.452 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.1 pp0? -85.77 11.89 10.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.342 -179.724 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.422 ' H ' HG12 ' A' ' 9' ' ' ILE . 78.9 ttt180 -98.04 158.7 15.39 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.89 -179.64 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.4 ' N ' ' HG2' ' A' ' 11' ' ' ARG . . . -99.73 -170.64 30.16 Favored Glycine 0 N--CA 1.452 -0.27 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.268 179.811 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -83.46 115.96 3.99 Favored 'Cis proline' 0 N--CA 1.462 -0.348 0 C-N-CA 123.091 -1.629 . . . . 0.0 112.592 0.084 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.26 117.43 3.93 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.539 179.747 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.456 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -59.45 121.17 10.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.099 0.476 . . . . 0.0 110.975 179.71 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.581 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -155.18 -168.93 3.01 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.419 -179.498 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.475 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -136.25 145.74 45.93 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.654 179.626 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.7 t -112.44 160.95 11.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.182 -179.711 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 52.0 m -119.93 112.99 19.88 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.132 179.814 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.582 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.1 OUTLIER -110.59 -179.41 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.015 178.983 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.618 -1.101 . . . . 0.0 112.276 179.705 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.1 m . . . . . 0 N--CA 1.455 -0.219 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.681 HG23 HD11 ' A' ' 20' ' ' ILE . 4.8 pt -130.64 148.94 33.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 N-CA-C 112.729 0.641 . . . . 0.0 112.729 -179.127 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 57.3 ttp85 -94.8 94.22 7.94 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 175.994 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.674 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -76.47 153.92 5.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.125 0.488 . . . . 0.0 111.606 -176.569 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.439 ' HA ' ' HD2' ' A' ' 15' ' ' ARG . 62.4 mt-30 -97.14 11.38 36.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.672 -0.695 . . . . 0.0 111.19 -179.523 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.96 159.44 14.93 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.823 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.92 -171.05 32.63 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.765 -179.091 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.76 113.81 2.85 Favored 'Cis proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.977 -1.676 . . . . 0.0 112.62 0.349 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.87 138.26 5.31 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.61 179.859 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.439 ' HD2' ' HA ' ' A' ' 10' ' ' GLN . 55.5 mmt-85 -74.86 125.41 28.76 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.416 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.433 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -151.84 -176.01 5.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.19 0.519 . . . . 0.0 112.006 -179.144 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -106.99 125.1 50.57 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.088 179.885 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.674 HG23 HD12 ' A' ' 9' ' ' ILE . 6.0 t -113.69 162.93 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 178.919 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.409 ' N ' HG12 ' A' ' 18' ' ' VAL . 52.9 m -103.36 151.26 22.95 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.07 0.462 . . . . 0.0 111.439 -179.827 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.681 HD11 HG23 ' A' ' 7' ' ' ILE . 8.2 mt -109.0 164.01 5.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.283 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.44 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 0.978 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.015 179.636 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 m . . . . . 0 CA--C 1.528 0.107 0 CA-C-O 120.527 0.203 . . . . 0.0 110.806 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.706 HG12 HD11 ' A' ' 20' ' ' ILE . 6.0 pt -131.13 150.12 34.15 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.346 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 179.347 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.405 ' O ' ' HG3' ' A' ' 8' ' ' ARG . 17.4 ptt85 -97.14 93.9 6.83 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 176.327 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.52 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.04 144.26 11.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.799 -177.072 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 19.8 tt0 -91.88 7.02 43.95 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.984 0.421 . . . . 0.0 110.966 -179.232 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.404 ' NH1' HG13 ' A' ' 9' ' ' ILE . 15.5 ptt85 -99.14 178.56 4.88 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.701 179.492 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.41 -177.91 32.77 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.523 -179.524 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.46 108.52 1.14 Allowed 'Cis proline' 0 C--N 1.342 0.225 0 C-N-CA 123.405 -1.498 . . . . 0.0 112.561 0.237 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 128.34 0.91 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.936 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.455 ' C ' ' HD2' ' A' ' 15' ' ' ARG . 3.1 tmm_? -65.56 113.65 4.35 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.439 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.52 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -149.02 -169.58 3.41 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.517 0.675 . . . . 0.0 111.89 -179.239 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -107.49 128.18 54.27 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.058 -0.973 . . . . 0.0 111.113 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.448 HG22 HG23 ' A' ' 9' ' ' ILE . 16.4 m -117.44 153.7 19.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.094 178.738 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.405 HG22 ' N ' ' A' ' 20' ' ' ILE . 57.3 m -94.08 158.71 15.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.476 0.655 . . . . 0.0 111.861 -179.048 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.706 HD11 HG12 ' A' ' 7' ' ' ILE . 3.1 mt -141.31 160.62 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-N 114.735 -1.121 . . . . 0.0 109.552 -179.447 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.996 0 CA-C-O 118.365 -1.241 . . . . 0.0 112.448 179.403 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.454 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 9.5 m . . . . . 0 N--CA 1.455 -0.177 0 CA-C-O 120.625 0.25 . . . . 0.0 111.421 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 1.5 pt -132.12 148.3 32.14 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -179.809 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.438 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 28.3 ptt-85 -80.92 104.45 11.43 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 176.114 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.662 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.63 158.77 5.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 C-N-CA 120.039 -0.664 . . . . 0.0 110.622 -177.736 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -99.68 12.31 36.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.819 -178.988 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.422 HH11 ' HD3' ' A' ' 11' ' ' ARG . 49.2 mtt180 -97.61 161.86 13.57 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.805 0.336 . . . . 0.0 110.76 -179.738 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.79 -175.37 30.83 Favored Glycine 0 N--CA 1.452 -0.267 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.564 -179.69 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.62 119.43 6.3 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.978 -1.676 . . . . 0.0 112.412 -0.167 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.77 144.63 6.1 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.186 -179.772 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.5 mpt_? -77.44 117.2 18.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.041 0.448 . . . . 0.0 111.05 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.662 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -136.52 -173.03 3.3 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.823 179.639 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 7' ' ' ILE . 0.4 OUTLIER -130.7 143.62 50.87 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.048 0.451 . . . . 0.0 110.956 179.608 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.579 HG13 HD12 ' A' ' 9' ' ' ILE . 25.8 m -112.43 163.81 9.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.991 -179.542 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.4 m -120.3 123.72 43.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.297 -179.739 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.67 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -114.59 157.05 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 C-N-CA 123.031 0.532 . . . . 0.0 110.798 179.275 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.201 -1.333 . . . . 0.0 112.177 179.933 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.529 0.171 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.551 HG23 HD11 ' A' ' 20' ' ' ILE . 3.1 pt -130.59 151.77 36.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.437 0 CA-C-O 121.312 0.577 . . . . 0.0 112.356 179.932 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.473 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 4.7 ptm85 -96.61 99.29 10.93 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 176.282 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.601 HD13 ' H ' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -77.79 156.56 5.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.242 0.544 . . . . 0.0 111.955 -176.744 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -94.77 12.56 27.52 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.073 179.075 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.2 ttt180 -97.03 -168.32 1.68 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.71 -179.335 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.503 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -107.45 176.43 20.9 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.442 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -73.02 108.71 0.97 Allowed 'Cis proline' 0 CA--C 1.53 0.288 0 C-N-CA 123.311 -1.537 . . . . 0.0 112.369 0.038 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.503 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 65.57 173.61 4.46 Favored Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.673 -179.937 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.459 HH21 ' NE ' ' A' ' 8' ' ' ARG . 16.1 tpt180 -69.33 115.14 8.25 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.766 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.04 -177.94 5.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.172 0.51 . . . . 0.0 111.52 -179.26 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.473 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -115.44 132.02 56.75 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.053 179.887 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.452 HG22 HG23 ' A' ' 9' ' ' ILE . 19.1 m -121.98 161.63 22.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.74 -0.663 . . . . 0.0 109.819 178.838 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 41.5 m -96.7 155.67 16.67 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.015 0.436 . . . . 0.0 111.06 -179.631 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.551 HD11 HG23 ' A' ' 7' ' ' ILE . 20.7 mt -121.27 165.52 16.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.458 179.584 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.478 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.249 1.086 0 CA-C-O 118.202 -1.332 . . . . 0.0 111.982 179.917 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 m . . . . . 0 C--O 1.231 0.125 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.417 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 3.7 pt -131.15 145.96 34.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 113.551 0.945 . . . . 0.0 113.551 -179.411 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.428 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 76.7 mtp180 -82.31 92.67 7.0 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 176.431 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.573 HD13 HG13 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -77.71 148.49 6.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.043 0.449 . . . . 0.0 110.92 -177.524 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -101.15 9.7 41.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.16 0.505 . . . . 0.0 109.884 179.05 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 64.5 mtp180 -99.86 -168.8 1.65 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.754 -179.269 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.7 -176.4 19.67 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 121.197 -0.525 . . . . 0.0 112.047 179.803 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -83.01 113.51 2.95 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.487 -1.464 . . . . 0.0 112.357 -0.075 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.11 128.31 6.03 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.219 -179.836 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 13.9 mmt180 -70.95 96.93 1.35 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.856 0.36 . . . . 0.0 110.728 -179.881 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.449 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -155.27 179.31 9.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.351 -179.842 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.428 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -103.79 147.35 27.38 Favored 'General case' 0 C--N 1.325 -0.5 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.646 179.851 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.573 HG13 HD13 ' A' ' 9' ' ' ILE . 31.3 m -119.18 165.52 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.136 -179.809 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 94.0 m -98.48 153.6 18.49 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.116 0.484 . . . . 0.0 111.03 179.835 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.8 mt -114.24 163.78 11.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.328 -179.237 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.208 -1.329 . . . . 0.0 112.001 179.827 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.6 m . . . . . 0 N--CA 1.453 -0.314 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.68 HG23 HD11 ' A' ' 20' ' ' ILE . 8.0 pt -131.48 146.72 33.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -178.269 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -92.26 93.07 8.47 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 176.175 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.564 HD12 HG23 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -75.31 148.15 7.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.02 0.438 . . . . 0.0 111.026 -176.697 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 69.9 mt-30 -100.16 11.83 38.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.028 -179.384 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -97.78 -169.3 1.81 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.493 -0.322 . . . . 0.0 110.187 -179.864 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.14 -177.17 19.16 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.429 179.772 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -79.55 104.98 0.64 Allowed 'Cis proline' 0 C--N 1.344 0.314 0 C-N-CA 123.485 -1.465 . . . . 0.0 112.143 -0.117 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.49 145.46 13.76 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.97 179.883 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 26.3 mtt180 -78.11 137.29 38.13 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 110.523 -0.177 . . . . 0.0 110.523 179.813 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.439 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -168.53 -173.73 2.01 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-O 121.22 0.533 . . . . 0.0 111.227 -179.782 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -111.97 120.59 42.41 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.359 179.504 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.564 HG23 HD12 ' A' ' 9' ' ' ILE . 4.1 t -110.03 160.5 9.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.313 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 46.2 m -98.51 158.8 15.37 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.889 0.376 . . . . 0.0 110.158 179.356 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.68 HD11 HG23 ' A' ' 7' ' ' ILE . 7.1 mt -119.33 161.58 18.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.527 179.76 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.135 0 CA-C-O 118.455 -1.192 . . . . 0.0 112.22 179.958 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.52 ' OG ' HG23 ' A' ' 19' ' ' THR . 12.3 m . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.534 0.207 . . . . 0.0 111.216 . . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.9 pt -132.64 149.52 32.17 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.343 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -179.956 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.556 ' H ' ' HD3' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -90.1 105.45 17.82 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 175.514 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.584 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -78.57 156.52 4.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 C-N-CA 120.501 -0.479 . . . . 0.0 111.281 -177.436 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.512 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 10.2 mp0 -94.72 10.28 35.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.48 179.904 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -99.67 179.59 4.49 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.858 -179.808 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.15 -176.61 30.41 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.186 179.859 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -76.57 107.68 1.01 Allowed 'Cis proline' 0 N--CA 1.464 -0.242 0 C-N-CA 123.246 -1.564 . . . . 0.0 112.521 0.052 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.21 151.54 7.23 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.835 179.674 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 16.5 mmm180 -60.13 109.97 1.1 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.71 0.29 . . . . 0.0 110.64 179.417 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.584 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -141.06 -177.07 4.93 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.439 -179.937 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.501 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -135.46 146.03 47.78 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.478 179.447 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.0 t -112.99 160.66 12.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.168 -179.495 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.52 HG23 ' OG ' ' A' ' 6' ' ' SER . 83.9 m -126.88 114.83 18.4 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.449 179.633 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.611 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -112.47 161.99 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.762 179.729 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.281 -1.289 . . . . 0.0 112.32 -179.996 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 16.0 m . . . . . 0 N--CA 1.452 -0.332 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 . . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.4 pt -124.07 150.72 28.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 113.237 0.829 . . . . 0.0 113.237 -178.203 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.453 ' HD2' ' O ' ' A' ' 16' ' ' ALA . 14.6 tpt180 -92.22 94.37 9.15 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 176.197 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.474 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.28 148.53 7.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.912 -177.084 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 33.5 mt-30 -97.4 11.51 36.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.188 -179.569 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -98.34 -174.9 2.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.116 179.827 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.446 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.94 175.7 27.7 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.569 -179.763 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -76.46 109.46 1.36 Allowed 'Cis proline' 0 C--N 1.346 0.411 0 C-N-CA 123.247 -1.564 . . . . 0.0 112.438 -0.02 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.446 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 69.52 168.1 5.99 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.292 -179.743 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.454 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 4.8 mpt_? -80.11 134.27 36.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 110.547 179.662 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.474 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -160.95 178.95 8.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.0 -179.751 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -109.85 124.08 50.71 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.917 179.739 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.462 HG22 HG23 ' A' ' 9' ' ' ILE . 12.9 m -114.28 140.01 37.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.399 179.117 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.7 m -101.48 142.15 33.29 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.857 -179.598 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.675 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -112.36 161.14 11.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.986 179.788 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.287 -1.285 . . . . 0.0 112.029 179.985 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.499 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 14.8 m . . . . . 0 N--CA 1.454 -0.232 0 CA-C-O 120.566 0.222 . . . . 0.0 110.937 . . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 2.2 pt -131.9 147.58 32.39 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -179.52 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.568 ' HB3' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -85.74 100.59 12.12 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 176.155 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.474 ' CD1' HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -78.54 158.16 4.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.561 -0.456 . . . . 0.0 110.777 -177.815 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.425 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 13.1 mp0 -100.89 10.17 41.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.86 0.362 . . . . 0.0 110.463 179.249 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 74.2 ttt180 -99.02 165.0 11.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.519 -179.527 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.82 -175.13 33.65 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.205 -179.976 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -74.81 115.83 3.64 Favored 'Cis proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.132 -1.612 . . . . 0.0 112.553 0.314 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.67 124.14 1.01 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.974 -0.632 . . . . 0.0 112.481 179.765 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.3 mtt85 -61.58 98.84 0.1 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.848 0.356 . . . . 0.0 110.418 179.656 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -131.0 -178.91 5.03 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.582 -179.636 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.465 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.3 OUTLIER -117.38 145.28 44.18 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.593 179.765 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.6 t -114.81 161.19 13.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.256 -179.475 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 86.9 m -120.69 109.06 14.75 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.081 179.568 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.582 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -104.44 171.37 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 CA-C-O 120.816 0.341 . . . . 0.0 111.387 -179.813 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.464 -1.187 . . . . 0.0 112.544 179.714 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 25.1 ttp-105 . . . . . 0 N--CA 1.488 1.426 0 N-CA-C 110.462 -0.199 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 62.0 tttp -147.66 152.57 38.08 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.123 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 88.2 p -142.35 156.79 45.26 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.168 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.594 HG23 HD11 ' A' ' 20' ' ' ILE . 3.8 pt -132.01 147.61 32.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 112.113 0.412 . . . . 0.0 112.113 179.157 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.483 ' O ' ' CD ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -91.19 91.6 8.3 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 176.118 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.525 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.59 150.51 6.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.613 -176.776 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 22.5 mp0 -89.0 12.52 15.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.621 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -96.88 177.94 5.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.32 -179.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.501 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.97 178.2 29.4 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.966 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -73.37 108.26 0.95 Allowed 'Cis proline' 0 C--N 1.344 0.326 0 C-N-CA 123.337 -1.526 . . . . 0.0 112.279 0.07 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.501 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 67.41 156.36 0.62 Allowed Glycine 0 C--N 1.333 0.391 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.422 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -60.27 126.04 25.96 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.766 0.317 . . . . 0.0 110.502 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.525 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -149.18 177.84 9.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.887 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -109.67 120.09 41.4 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.674 179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.499 HG22 HG23 ' A' ' 9' ' ' ILE . 15.1 m -109.27 152.8 11.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.759 178.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.6 m -89.44 156.37 18.71 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.957 0.408 . . . . 0.0 111.24 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.594 HD11 HG23 ' A' ' 7' ' ' ILE . 8.3 mt -120.63 163.06 18.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.022 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.425 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.503 -1.165 . . . . 0.0 112.075 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 . . . . . 0 N--CA 1.485 1.289 0 N-CA-C 110.518 -0.178 . . . . 0.0 110.518 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.635 ' HD3' ' N ' ' A' ' 6' ' ' SER . 2.2 tmtp? -138.33 149.91 46.08 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.635 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 14.7 m -140.5 140.76 35.34 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.849 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.536 HG23 ' HE2' ' A' ' 5' ' ' LYS . 1.6 pt -131.43 146.05 34.26 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.567 0 N-CA-C 113.696 0.998 . . . . 0.0 113.696 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -78.8 102.24 8.04 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 176.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.555 HD13 HG13 ' A' ' 18' ' ' VAL . 1.8 pt -77.54 151.28 5.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.657 -177.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -100.95 10.49 41.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.464 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 36.0 ptt180 -109.25 -178.31 3.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.827 0.346 . . . . 0.0 111.017 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.54 -172.64 30.78 Favored Glycine 0 C--N 1.329 0.187 0 C-N-CA 121.108 -0.568 . . . . 0.0 112.308 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.98 117.66 5.33 Favored 'Cis proline' 0 N--CA 1.462 -0.349 0 C-N-CA 123.34 -1.525 . . . . 0.0 112.407 0.143 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 145.64 4.73 Favored Glycine 0 C--N 1.33 0.221 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.293 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.492 ' C ' ' HD2' ' A' ' 15' ' ' ARG . 4.8 ppt_? -66.72 128.8 37.66 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.44 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -169.52 -166.47 0.6 Allowed 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 121.199 0.523 . . . . 0.0 110.593 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.531 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.1 OUTLIER -137.62 152.57 49.5 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.367 179.572 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.555 HG13 HD13 ' A' ' 9' ' ' ILE . 19.5 m -115.75 154.9 17.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.972 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 86.3 m -113.74 110.71 20.61 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.359 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.509 HG13 ' HB3' ' A' ' 5' ' ' LYS . 7.8 pt -100.22 173.06 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.674 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.711 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.242 -1.31 . . . . 0.0 112.287 179.744 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 86.4 mtm180 . . . . . 0 N--CA 1.485 1.298 0 CA-C-O 120.56 0.219 . . . . 0.0 110.789 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.563 ' HD3' ' N ' ' A' ' 6' ' ' SER . 5.3 tmtm? -100.03 147.19 25.89 Favored 'General case' 0 C--O 1.223 -0.34 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.563 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 50.6 m -140.67 154.61 46.46 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 179.236 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.8 pt -130.95 152.04 36.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.318 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -179.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.498 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 22.8 ttm180 -94.97 104.32 16.2 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 175.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.47 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.37 144.29 11.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 C-N-CA 119.845 -0.742 . . . . 0.0 110.791 -177.554 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.1 tp-100 -93.88 12.46 25.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.426 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.3 mtt-85 -97.47 173.46 7.16 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.332 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.415 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.74 -179.83 30.52 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.1 108.63 1.14 Allowed 'Cis proline' 0 C--N 1.345 0.381 0 C-N-CA 123.34 -1.525 . . . . 0.0 112.256 0.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.415 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 75.54 152.18 3.48 Favored Glycine 0 C--N 1.332 0.335 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.467 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.491 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -62.34 152.64 33.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.875 0.369 . . . . 0.0 111.096 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.47 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.17 178.54 3.81 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.998 0.428 . . . . 0.0 111.152 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.498 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.6 OUTLIER -120.56 129.7 53.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.0 179.718 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 6.2 t -120.85 159.92 22.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.8 m -102.77 156.11 17.86 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.204 0.526 . . . . 0.0 111.316 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.49 HD12 ' HD2' ' A' ' 5' ' ' LYS . 8.7 mt -118.1 164.73 14.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.177 -0.92 . . . . 0.0 109.816 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.414 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 0.999 0 CA-C-O 118.416 -1.214 . . . . 0.0 111.977 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 . . . . . 0 N--CA 1.484 1.262 0 CA-C-O 120.632 0.253 . . . . 0.0 110.799 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.457 ' HD2' ' H ' ' A' ' 6' ' ' SER . 0.0 OUTLIER -141.85 147.97 38.06 Favored 'General case' 0 C--O 1.211 -0.959 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.577 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.457 ' H ' ' HD2' ' A' ' 5' ' ' LYS . 17.4 m -141.07 151.66 44.18 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 118.762 0.71 . . . . 0.0 110.588 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.447 ' O ' ' HB2' ' A' ' 17' ' ' PHE . 2.9 pt -132.42 146.04 33.59 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.501 0 N-CA-C 113.933 1.086 . . . . 0.0 113.933 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.509 ' HA ' ' HB2' ' A' ' 17' ' ' PHE . 48.7 mtt85 -86.9 108.92 19.0 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 175.249 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 16' ' ' ALA . 1.3 pt -77.76 157.66 5.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.714 -177.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -100.57 11.0 40.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.598 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 5.3 ttm180 -98.95 -170.13 1.88 Allowed 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -108.95 179.35 21.13 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.155 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.56 112.42 2.34 Favored 'Cis proline' 0 C--N 1.344 0.297 0 C-N-CA 122.971 -1.679 . . . . 0.0 112.44 0.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.5 155.4 6.13 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.353 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.2 ttp85 -62.28 88.22 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.222 0.534 . . . . 0.0 110.293 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.453 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -101.58 -170.81 1.88 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.883 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.509 ' HB2' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -148.74 149.98 32.34 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.38 179.574 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.412 HG12 ' N ' ' A' ' 19' ' ' THR . 5.4 t -121.92 162.23 21.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.72 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.412 ' N ' HG12 ' A' ' 18' ' ' VAL . 89.6 m -111.01 126.95 55.34 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.761 0.791 . . . . 0.0 112.05 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.5 mt -103.22 156.49 5.19 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.901 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.49 -1.172 . . . . 0.0 113.043 179.037 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.486 1.355 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.57 ' HD3' ' N ' ' A' ' 6' ' ' SER . 5.7 tmtm? -124.44 139.6 53.74 Favored 'General case' 0 C--O 1.222 -0.372 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.57 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 16.4 m -142.53 151.3 41.47 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.048 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.421 ' HA ' HH21 ' A' ' 8' ' ' ARG . 3.4 pt -132.0 148.67 32.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -179.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.61 ' HE ' ' H ' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -88.14 102.64 14.98 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 175.586 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.613 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.48 142.23 14.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 120.154 -0.618 . . . . 0.0 110.751 -177.379 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.65 11.47 24.28 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.805 -178.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 14.8 ptm180 -98.28 175.28 6.12 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.734 0.302 . . . . 0.0 110.646 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.49 -177.04 31.34 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.272 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 81.0 Cg_endo -78.87 110.4 1.84 Allowed 'Cis proline' 0 C--N 1.343 0.284 0 C-N-CA 123.062 -1.641 . . . . 0.0 112.796 0.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.06 141.57 4.93 Favored Glycine 0 C--N 1.331 0.299 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.663 179.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.491 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -60.14 142.47 54.22 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.956 0.407 . . . . 0.0 111.156 179.83 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.613 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.28 -168.12 0.69 Allowed 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.113 0.483 . . . . 0.0 110.624 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.446 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -144.56 145.48 31.84 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.486 179.12 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 t -125.61 162.32 28.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.243 -179.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 98.0 m -100.39 152.27 20.54 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.042 0.449 . . . . 0.0 110.8 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.423 HG22 ' N ' ' A' ' 21' ' ' GLY . 7.0 mt -114.47 163.86 11.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.573 -179.146 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.423 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.527 -1.151 . . . . 0.0 112.002 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 33.3 ttt180 . . . . . 0 N--CA 1.486 1.337 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.9 tttp -58.79 147.7 32.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.962 0.41 . . . . 0.0 111.677 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 64.9 m -142.94 150.86 40.3 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.55 178.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.6 pt -131.41 148.44 32.72 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.36 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 -179.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 65.4 mtt85 -85.06 99.06 10.78 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 176.063 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.578 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.59 151.63 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.846 0.355 . . . . 0.0 111.18 -177.23 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -95.09 8.41 43.07 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.392 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 16.4 ptp180 -99.72 -175.89 3.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.458 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.34 -177.73 31.48 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.392 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.79 114.2 3.09 Favored 'Cis proline' 0 C--N 1.343 0.279 0 C-N-CA 123.381 -1.508 . . . . 0.0 112.532 0.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.59 161.81 8.6 Favored Glycine 0 C--N 1.332 0.317 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.5 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -78.35 122.9 26.37 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.148 0.499 . . . . 0.0 111.043 179.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.578 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -160.48 -165.16 1.37 Allowed 'General case' 0 CA--C 1.512 -0.495 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.614 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -135.28 143.96 46.53 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.102 0.477 . . . . 0.0 110.707 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.44 HG22 ' CG2' ' A' ' 9' ' ' ILE . 31.1 m -118.49 168.42 10.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.678 -179.294 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.6 m -96.4 152.22 18.81 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 120.979 0.419 . . . . 0.0 111.071 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.429 HG22 ' N ' ' A' ' 21' ' ' GLY . 9.5 mt -107.85 163.71 5.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.376 -179.53 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.429 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.25 1.12 0 CA-C-O 118.117 -1.379 . . . . 0.0 111.827 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.616 ' HE ' HG22 ' A' ' 19' ' ' THR . 17.8 tpt180 . . . . . 0 N--CA 1.486 1.371 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.545 ' HD3' ' H ' ' A' ' 6' ' ' SER . 5.3 tmtt? -127.19 143.62 51.22 Favored 'General case' 0 C--O 1.218 -0.559 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.545 ' H ' ' HD3' ' A' ' 5' ' ' LYS . 15.9 m -141.59 142.4 33.47 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.01 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.583 HG12 HD11 ' A' ' 20' ' ' ILE . 2.4 pt -132.3 146.68 32.67 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.504 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.46 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 45.9 mtp85 -84.46 103.46 13.63 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.684 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.3 OUTLIER -78.01 153.83 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.188 -177.299 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.514 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 13.3 mp0 -92.61 13.21 20.61 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.241 -179.167 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 49.5 mtp85 -97.3 -176.06 3.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.921 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.76 177.35 30.42 Favored Glycine 0 C--N 1.332 0.323 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.409 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.96 135.9 38.66 Favored 'Cis proline' 0 C--N 1.344 0.317 0 C-N-CA 122.987 -1.672 . . . . 0.0 112.697 0.124 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 59.68 -104.34 0.55 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.112 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 8.0 ttp180 -160.07 134.11 7.31 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.684 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -159.79 -167.96 2.13 Favored 'General case' 0 CA--C 1.516 -0.352 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.599 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.46 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -137.02 148.71 47.01 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.5 179.455 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.544 HG23 HD12 ' A' ' 9' ' ' ILE . 4.4 t -121.52 164.05 18.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.29 -179.241 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.616 HG22 ' HE ' ' A' ' 4' ' ' ARG . 91.7 m -113.55 140.49 48.11 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.981 0.42 . . . . 0.0 111.238 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.641 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -124.98 156.6 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.724 179.705 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.263 -1.299 . . . . 0.0 112.372 179.792 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 72.7 mtt85 . . . . . 0 N--CA 1.485 1.284 0 CA-C-O 120.581 0.229 . . . . 0.0 110.538 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 50.6 mtpt -128.69 154.14 46.61 Favored 'General case' 0 C--O 1.214 -0.778 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 66.4 m -143.93 142.95 31.03 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 178.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.623 HG12 HD11 ' A' ' 20' ' ' ILE . 8.5 pt -131.85 147.35 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 113.564 0.95 . . . . 0.0 113.564 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.682 ' H ' ' HD2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -85.02 101.91 12.78 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 106.325 -1.731 . . . . 0.0 106.325 175.235 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.489 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.1 OUTLIER -76.25 150.05 6.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.911 -176.404 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.439 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 17.7 mp0 -94.11 9.47 37.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.998 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 10.6 ptp180 -99.09 -173.62 2.54 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.908 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.35 -176.1 31.47 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.423 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -80.7 108.98 1.36 Allowed 'Cis proline' 0 CA--C 1.531 0.334 0 C-N-CA 122.886 -1.714 . . . . 0.0 112.597 0.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.23 169.77 38.0 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.682 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -71.36 123.79 23.1 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.742 0.306 . . . . 0.0 110.952 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.489 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -160.96 -169.32 2.33 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.243 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.443 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -145.36 141.15 28.23 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.942 178.994 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.427 HG12 ' N ' ' A' ' 19' ' ' THR . 5.5 t -115.5 163.95 12.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.398 -178.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.427 ' N ' HG12 ' A' ' 18' ' ' VAL . 92.6 m -100.07 158.37 15.89 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.292 0.567 . . . . 0.0 110.786 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.623 HD11 HG12 ' A' ' 7' ' ' ILE . 1.0 OUTLIER -140.99 153.67 20.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.918 -178.762 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.443 -1.198 . . . . 0.0 112.153 179.688 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.413 ' HA ' ' C ' ' A' ' 21' ' ' GLY . 96.4 mtt180 . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 120.616 0.246 . . . . 0.0 110.649 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.429 ' O ' ' N ' ' A' ' 20' ' ' ILE . 1.7 mmmt -139.73 147.78 41.37 Favored 'General case' 0 C--O 1.219 -0.551 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.516 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.523 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.4 m -141.63 135.67 30.21 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.785 179.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 2.8 pt -132.48 147.85 31.91 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -86.67 102.93 14.66 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 175.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.641 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.78 153.63 5.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.859 -177.451 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.406 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 17.3 tt0 -99.02 10.96 40.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.363 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -98.69 -177.03 3.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.751 0.31 . . . . 0.0 110.852 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -108.76 -176.24 21.68 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.245 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -77.37 114.59 3.28 Favored 'Cis proline' 0 C--N 1.343 0.245 0 C-N-CA 122.93 -1.696 . . . . 0.0 112.337 -0.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.91 147.35 6.92 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.109 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.9 mpt_? -77.56 127.01 31.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.996 0.426 . . . . 0.0 110.877 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.641 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -156.19 -169.0 2.91 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.888 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.523 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -133.88 142.18 47.68 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.977 0.418 . . . . 0.0 110.948 179.521 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.544 HG23 HD12 ' A' ' 9' ' ' ILE . 3.8 t -110.58 162.73 7.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.053 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.448 HG23 ' OG ' ' A' ' 6' ' ' SER . 78.8 m -124.91 114.18 18.83 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.83 0.348 . . . . 0.0 111.379 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.599 HD13 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -100.42 179.65 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.774 178.893 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.413 ' C ' ' HA ' ' A' ' 4' ' ' ARG . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.739 -1.034 . . . . 0.0 113.103 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 25.9 ptt180 . . . . . 0 N--CA 1.484 1.254 0 N-CA-C 110.543 -0.169 . . . . 0.0 110.543 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.544 ' CE ' HD12 ' A' ' 20' ' ' ILE . 2.0 tmmm? -156.12 153.69 29.73 Favored 'General case' 0 C--O 1.221 -0.419 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.433 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.3 m -142.96 156.71 44.92 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 120.868 -0.333 . . . . 0.0 111.084 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.43 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 3.4 pt -131.28 145.96 34.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 113.742 1.016 . . . . 0.0 113.742 -179.311 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.3 mtt-85 -83.56 95.64 8.38 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 176.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.538 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.1 OUTLIER -76.37 142.94 13.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.102 0.477 . . . . 0.0 111.19 -176.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 58.7 mm-40 -92.66 11.43 26.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.453 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -98.03 173.25 7.14 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.25 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.7 -175.46 30.95 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.723 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -80.65 119.66 6.6 Favored 'Cis proline' 0 C--N 1.347 0.453 0 C-N-CA 123.326 -1.531 . . . . 0.0 112.34 -0.066 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.67 166.61 41.65 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.548 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.439 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 1.7 mpt_? -89.18 134.99 33.81 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.736 0.303 . . . . 0.0 110.593 179.546 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.538 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -168.85 -166.63 0.67 Allowed 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.141 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.43 ' HA ' ' O ' ' A' ' 7' ' ' ILE . 0.4 OUTLIER -141.75 139.88 32.94 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.923 178.681 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.47 HG22 ' CG2' ' A' ' 9' ' ' ILE . 26.8 m -112.39 166.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.899 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 83.3 m -98.89 156.48 16.87 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.171 0.51 . . . . 0.0 111.594 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.544 HD12 ' CE ' ' A' ' 5' ' ' LYS . 8.5 mt -120.21 167.17 13.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.195 -0.912 . . . . 0.0 109.945 -179.126 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.409 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.247 0.911 0 CA-C-O 118.281 -1.288 . . . . 0.0 112.017 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 38.4 ptt180 . . . . . 0 N--CA 1.484 1.23 0 CA-C-O 120.637 0.256 . . . . 0.0 110.979 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 64.1 tttp -140.1 164.47 29.95 Favored 'General case' 0 C--O 1.217 -0.637 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.1 m -141.46 149.45 40.99 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 117.889 0.313 . . . . 0.0 110.568 178.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.504 HG23 HD11 ' A' ' 20' ' ' ILE . 3.6 pt -130.33 150.41 34.58 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.314 0 CA-C-O 121.022 0.439 . . . . 0.0 112.005 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 12.3 ptm180 -95.67 90.98 5.89 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 176.47 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.868 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -76.92 144.35 11.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.131 -177.122 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -97.87 9.95 41.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.811 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.559 ' HD2' ' N ' ' A' ' 11' ' ' ARG . 2.1 mpt_? -101.84 -179.49 4.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.241 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -102.45 -178.86 27.23 Favored Glycine 0 CA--C 1.516 0.156 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.272 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.47 114.4 3.33 Favored 'Cis proline' 0 C--N 1.346 0.409 0 C-N-CA 123.538 -1.442 . . . . 0.0 111.985 0.055 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 87.5 147.38 12.36 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.394 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 20.2 mmt85 -99.96 122.22 42.54 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.481 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -169.76 -173.86 1.71 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.136 0.494 . . . . 0.0 110.991 -179.305 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.0 120.85 34.82 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.547 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.868 HG23 HD12 ' A' ' 9' ' ' ILE . 5.2 t -109.65 162.04 7.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.417 ' N ' HG12 ' A' ' 18' ' ' VAL . 97.0 m -100.66 158.83 15.65 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.389 0.614 . . . . 0.0 111.802 -179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.504 HD11 HG23 ' A' ' 7' ' ' ILE . 6.2 mt -129.0 165.61 28.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.273 -179.309 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.151 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.192 179.139 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 22.7 mmt85 . . . . . 0 N--CA 1.485 1.305 0 CA-C-O 120.838 0.352 . . . . 0.0 111.448 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.642 ' HD3' ' N ' ' A' ' 6' ' ' SER . 7.5 tmtm? -120.53 151.07 39.88 Favored 'General case' 0 C--O 1.222 -0.395 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.642 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 39.3 m -137.01 141.28 42.52 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.055 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.0 pt -130.46 152.83 38.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.147 -179.571 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.464 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 32.9 ptt180 -95.79 93.36 7.03 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 176.407 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.485 HG23 HG22 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -76.3 148.02 7.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.06 0.457 . . . . 0.0 111.395 -176.872 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.573 HE21 HH21 ' A' ' 15' ' ' ARG . 0.4 OUTLIER -89.85 11.27 20.74 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.805 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 65.2 mtt85 -98.35 -173.54 2.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.352 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.459 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.79 178.19 29.63 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.68 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -75.39 108.06 1.01 Allowed 'Cis proline' 0 C--N 1.344 0.33 0 C-N-CA 123.449 -1.479 . . . . 0.0 112.268 -0.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.459 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 68.97 160.37 2.08 Favored Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.572 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.573 HH21 HE21 ' A' ' 10' ' ' GLN . 16.3 tpp85 -64.42 118.1 8.26 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.576 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.431 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -151.32 -178.55 6.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.249 0.547 . . . . 0.0 111.622 -179.563 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.464 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -111.01 130.0 55.73 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.44 179.567 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.485 HG22 HG23 ' A' ' 9' ' ' ILE . 16.5 m -119.11 142.34 34.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.705 179.206 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 68.1 m -100.11 115.28 29.43 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.479 -179.317 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.491 HG13 ' HB3' ' A' ' 5' ' ' LYS . 7.5 pt -102.19 148.25 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.781 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.187 179.02 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.623 -1.098 . . . . 0.0 112.314 -179.82 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 . . . . . 0 N--CA 1.486 1.327 0 N-CA-C 110.64 -0.133 . . . . 0.0 110.64 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.5 tttp -127.61 151.02 49.45 Favored 'General case' 0 C--O 1.216 -0.681 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.8 m -142.85 152.09 41.78 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 178.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 6.2 pt -131.45 145.07 35.78 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.561 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.47 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 14.4 ptt85 -90.43 98.44 11.78 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 175.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.636 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -78.17 147.04 7.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.963 0.411 . . . . 0.0 111.485 -176.853 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 21.8 mp0 -94.15 9.48 37.68 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.46 -179.762 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.412 HH11 ' HD3' ' A' ' 11' ' ' ARG . 11.3 ptt180 -99.21 -177.75 3.71 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.736 0.303 . . . . 0.0 110.744 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.15 -176.33 30.39 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.466 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -79.08 106.91 0.94 Allowed 'Cis proline' 0 C--N 1.345 0.361 0 C-N-CA 122.958 -1.684 . . . . 0.0 112.779 -0.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.24 148.28 10.12 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.402 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 18.3 mmt85 -65.71 131.79 47.2 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.688 0.28 . . . . 0.0 110.829 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.636 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -167.6 -173.45 2.19 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.033 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.47 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.3 OUTLIER -136.36 138.65 41.84 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.38 179.301 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.541 HG23 HD12 ' A' ' 9' ' ' ILE . 2.6 t -110.28 162.5 7.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.252 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 99.1 m -104.62 152.37 22.53 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.487 0.66 . . . . 0.0 111.063 179.747 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.406 HG22 ' H ' ' A' ' 21' ' ' GLY . 6.9 mt -114.9 166.79 8.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 114.658 -1.155 . . . . 0.0 109.776 -179.113 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.406 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.25 1.111 0 CA-C-O 118.458 -1.19 . . . . 0.0 112.305 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 44.1 mtt85 . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 120.615 0.245 . . . . 0.0 110.513 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.486 ' HB3' HG13 ' A' ' 20' ' ' ILE . 61.5 tttm -146.62 154.81 41.92 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 179.63 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.5 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 13.2 m -142.19 136.8 30.31 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.244 179.533 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.469 HG23 ' NZ ' ' A' ' 5' ' ' LYS . 2.8 pt -132.35 148.23 31.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.369 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -179.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.426 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 82.3 mtm180 -87.08 98.53 11.34 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 175.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.657 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.71 141.96 14.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 120.231 -0.587 . . . . 0.0 110.731 -177.539 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -93.21 12.34 24.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.732 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 37.8 ptt180 -98.53 -175.7 3.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.395 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.79 177.98 29.5 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.496 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -78.99 109.34 1.44 Allowed 'Cis proline' 0 C--N 1.345 0.381 0 C-N-CA 123.223 -1.574 . . . . 0.0 112.506 0.107 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.12 157.84 21.47 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.723 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -74.08 135.32 42.97 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.586 0.232 . . . . 0.0 110.414 179.552 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.657 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.42 -168.13 0.68 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.052 0.453 . . . . 0.0 110.536 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.5 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.1 OUTLIER -139.02 145.48 39.68 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.26 179.129 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.4 t -119.53 161.46 18.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.455 -178.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 90.3 m -117.87 113.45 21.78 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.558 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.486 HG13 ' HB3' ' A' ' 5' ' ' LYS . 34.1 pt -102.24 163.36 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 C-N-CA 122.938 0.495 . . . . 0.0 111.606 -179.745 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.181 0 CA-C-O 117.986 -1.452 . . . . 0.0 113.359 178.791 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.7 tpt180 . . . . . 0 N--CA 1.483 1.224 0 CA-C-O 120.583 0.23 . . . . 0.0 110.561 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.601 ' HD3' ' N ' ' A' ' 6' ' ' SER . 6.0 tmtm? -119.92 142.83 48.37 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.601 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 14.2 m -140.39 136.89 33.56 Favored 'General case' 0 C--N 1.318 -0.786 0 C-N-CA 121.167 -0.213 . . . . 0.0 110.652 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.606 HG12 HD11 ' A' ' 20' ' ' ILE . 1.2 pt -130.9 150.44 34.61 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -179.517 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.521 ' H ' ' HD3' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -89.11 99.82 12.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 176.382 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.588 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -78.7 144.12 11.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.506 -0.478 . . . . 0.0 111.446 -177.542 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 44.9 mt-30 -83.57 11.5 7.05 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.837 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.447 ' H ' HG12 ' A' ' 9' ' ' ILE . 94.2 mtt180 -98.52 -175.07 2.98 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.352 -179.667 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.412 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -102.18 -178.12 27.65 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.288 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.66 107.62 1.0 Allowed 'Cis proline' 0 C--N 1.343 0.265 0 C-N-CA 123.103 -1.624 . . . . 0.0 112.412 0.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.412 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 76.99 155.33 6.55 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.385 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.457 ' NE ' ' H ' ' A' ' 15' ' ' ARG . 0.1 OUTLIER -62.31 111.41 1.98 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.911 0.386 . . . . 0.0 110.723 179.762 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.588 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -144.13 -172.76 3.84 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 115.806 -0.633 . . . . 0.0 109.95 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.511 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -136.17 142.69 44.18 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.526 179.278 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.0 t -111.64 161.26 10.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.26 -179.262 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 71.8 m -118.32 111.0 18.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.579 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.606 HD11 HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -109.02 178.28 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.931 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.758 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.438 -1.201 . . . . 0.0 112.165 179.69 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.469 ' NE ' HG21 ' A' ' 19' ' ' THR . 28.1 ptt180 . . . . . 0 N--CA 1.484 1.229 0 CA-C-O 120.392 0.139 . . . . 0.0 110.819 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -86.49 147.16 26.1 Favored 'General case' 0 C--O 1.219 -0.544 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.928 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.4 m -143.0 145.05 32.57 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.483 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 pt -130.98 149.79 33.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -179.014 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.424 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 7.4 ptm180 -93.32 92.3 7.62 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 176.024 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.538 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.57 147.26 7.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.39 -176.63 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -95.17 11.12 33.41 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.25 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -98.26 -174.72 2.91 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.473 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -100.24 177.74 28.81 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.485 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.98 108.69 1.08 Allowed 'Cis proline' 0 C--N 1.344 0.31 0 C-N-CA 123.096 -1.626 . . . . 0.0 112.264 -0.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.473 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 72.47 150.67 1.19 Allowed Glycine 0 C--N 1.333 0.363 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.347 -179.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.427 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 1.3 mpt_? -73.34 133.26 43.79 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.538 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -164.88 -175.29 3.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.19 0.519 . . . . 0.0 111.31 -179.695 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -106.74 119.05 38.28 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.793 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.489 HG22 HG23 ' A' ' 9' ' ' ILE . 17.4 m -110.02 154.78 11.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.977 179.078 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.469 HG21 ' NE ' ' A' ' 4' ' ' ARG . 98.8 m -105.53 154.44 20.37 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.417 0.627 . . . . 0.0 111.933 -179.373 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -130.42 147.26 33.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.505 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.4 -1.222 . . . . 0.0 112.482 179.702 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 35.8 ptt180 . . . . . 0 N--CA 1.485 1.292 0 CA-C-O 120.806 0.336 . . . . 0.0 110.863 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.407 ' HG2' ' N ' ' A' ' 6' ' ' SER . 88.1 tttt -90.68 162.33 14.97 Favored 'General case' 0 C--O 1.215 -0.737 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.407 ' N ' ' HG2' ' A' ' 5' ' ' LYS . 66.5 m -144.55 150.47 37.57 Favored 'General case' 0 C--N 1.321 -0.666 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.102 179.021 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.58 HG12 HD11 ' A' ' 20' ' ' ILE . 3.9 pt -131.38 148.28 32.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 121.135 0.493 . . . . 0.0 112.219 179.38 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.452 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 38.9 ttt180 -93.8 98.09 10.85 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 176.419 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.488 ' O ' ' HD3' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -75.6 149.21 6.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 C-N-CA 120.766 -0.373 . . . . 0.0 110.558 -177.328 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.435 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 53.7 tt0 -94.68 11.41 31.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.243 -179.089 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.416 ' HG2' ' CG1' ' A' ' 9' ' ' ILE . 5.5 ptp180 -98.48 178.29 5.07 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.461 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.98 -177.01 30.67 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.59 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -77.0 110.7 1.77 Allowed 'Cis proline' 0 C--N 1.343 0.285 0 C-N-CA 123.287 -1.547 . . . . 0.0 112.323 -0.015 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.61 156.22 9.25 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.473 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.488 ' HD3' ' O ' ' A' ' 9' ' ' ILE . 17.7 tpp85 -71.9 129.35 38.37 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 179.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.425 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -152.04 -176.58 5.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.308 0.575 . . . . 0.0 111.875 -179.464 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.452 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -119.34 128.15 53.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.601 179.706 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.478 HG22 HG23 ' A' ' 9' ' ' ILE . 16.9 m -116.5 150.51 18.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.155 178.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 97.0 m -96.1 159.32 15.02 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.518 0.675 . . . . 0.0 111.877 -179.282 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.58 HD11 HG12 ' A' ' 7' ' ' ILE . 2.4 mt -135.48 155.15 36.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 114.537 -1.21 . . . . 0.0 108.945 -179.355 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.302 -1.277 . . . . 0.0 112.559 179.618 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 80.7 mtm-85 . . . . . 0 N--CA 1.484 1.236 0 N-CA-C 110.41 -0.218 . . . . 0.0 110.41 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.577 ' HD2' ' N ' ' A' ' 6' ' ' SER . 5.2 tmmm? -112.63 148.78 33.9 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.577 ' N ' ' HD2' ' A' ' 5' ' ' LYS . 13.4 m -141.06 133.29 28.06 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.682 -0.236 . . . . 0.0 110.778 179.353 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.51 HG12 HD11 ' A' ' 20' ' ' ILE . 1.7 pt -131.79 148.39 32.4 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 N-CA-C 113.313 0.857 . . . . 0.0 113.313 -179.332 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.435 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 5.8 ptm180 -84.38 108.7 17.35 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 175.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.628 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.3 OUTLIER -78.16 152.2 5.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.671 -177.79 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -90.5 11.63 21.19 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.019 -179.382 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.5 mtp85 -98.02 174.89 6.33 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.457 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.4 179.45 32.04 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.65 -179.376 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_exo -70.3 137.8 47.08 Favored 'Cis proline' 0 C--N 1.342 0.196 0 C-N-CA 123.124 -1.615 . . . . 0.0 112.527 0.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.45 ' C ' ' HD2' ' A' ' 15' ' ' ARG . . . 55.75 -145.31 32.98 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.087 -179.838 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.45 ' HD2' ' C ' ' A' ' 14' ' ' GLY . 9.5 mpt_? -117.99 128.16 54.52 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.628 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -149.53 -175.97 5.21 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.55 -179.434 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.469 ' HB2' ' C ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -139.83 148.79 42.64 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.975 179.746 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 6' ' ' SER . 9.1 t -117.68 161.74 16.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.103 -179.661 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.423 ' N ' HG12 ' A' ' 18' ' ' VAL . 80.9 m -118.33 112.57 20.21 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.249 179.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.667 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -117.52 152.69 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-O 120.9 0.381 . . . . 0.0 111.431 -179.728 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.528 -1.151 . . . . 0.0 112.139 -179.737 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 . . . . . 0 N--CA 1.484 1.255 0 CA-C-O 120.672 0.272 . . . . 0.0 110.77 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -148.85 166.44 28.52 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -141.51 149.87 41.44 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 117.857 0.298 . . . . 0.0 111.143 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.456 HG12 HD11 ' A' ' 20' ' ' ILE . 5.9 pt -131.02 146.11 34.44 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-O 121.152 0.501 . . . . 0.0 112.351 179.123 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 13.4 tpt180 -96.87 85.9 3.89 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 176.605 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.79 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -77.31 144.5 11.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.827 -177.354 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 38.6 tt0 -96.52 7.01 47.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.187 0.518 . . . . 0.0 110.131 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -99.43 -177.03 3.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.536 179.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.84 -178.28 29.37 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.126 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -80.14 108.87 1.32 Allowed 'Cis proline' 0 C--N 1.345 0.352 0 C-N-CA 123.428 -1.488 . . . . 0.0 112.328 0.161 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.52 133.06 5.75 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.884 179.611 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -81.61 110.91 17.42 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.497 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -163.29 -168.86 1.81 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.267 0.556 . . . . 0.0 111.087 -179.238 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -97.79 128.19 44.26 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.758 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.79 HG23 HD12 ' A' ' 9' ' ' ILE . 11.5 t -109.13 162.69 6.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 178.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.442 ' N ' HG12 ' A' ' 18' ' ' VAL . 9.2 m -104.22 160.1 15.15 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.561 0.696 . . . . 0.0 111.541 -179.48 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.456 HD11 HG12 ' A' ' 7' ' ' ILE . 9.1 mt -140.71 167.73 17.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.714 -179.557 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.406 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.324 -1.264 . . . . 0.0 112.846 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.511 ' N ' ' O ' ' A' ' 21' ' ' GLY . 13.8 tpt180 . . . . . 0 N--CA 1.484 1.236 0 CA-C-O 120.877 0.37 . . . . 0.0 110.585 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.487 ' HD3' ' H ' ' A' ' 6' ' ' SER . 5.9 tmtt? -123.99 147.17 48.0 Favored 'General case' 0 C--O 1.217 -0.647 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -179.748 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.487 ' H ' ' HD3' ' A' ' 5' ' ' LYS . 14.3 m -141.24 139.02 33.67 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.714 179.337 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 4.0 pt -130.96 149.37 33.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.5 ttp85 -91.95 92.03 8.13 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 176.112 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.58 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.32 145.07 10.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.135 0.493 . . . . 0.0 111.046 -177.034 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -91.92 11.84 23.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.053 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 10.1 mtp-105 -98.31 -168.02 1.59 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.628 -179.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.416 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -115.17 179.81 18.33 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.416 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -75.54 109.6 1.35 Allowed 'Cis proline' 0 C--N 1.344 0.336 0 C-N-CA 123.088 -1.63 . . . . 0.0 112.394 -0.023 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.416 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 82.29 133.32 1.77 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.227 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.43 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -77.97 116.61 18.59 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.786 0.327 . . . . 0.0 110.337 179.672 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.58 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -153.2 -172.22 4.17 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.289 0.566 . . . . 0.0 111.076 -179.343 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -96.55 120.85 37.63 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.062 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.51 HG22 HG23 ' A' ' 9' ' ' ILE . 12.7 m -109.63 148.27 13.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.169 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 65.0 m -113.58 131.46 56.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.128 0.49 . . . . 0.0 111.511 -179.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.472 HG13 ' HB3' ' A' ' 5' ' ' LYS . 4.7 pt -123.33 143.31 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 C-N-CA 123.83 0.852 . . . . 0.0 110.952 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.511 ' O ' ' N ' ' A' ' 4' ' ' ARG . . . . . . . . 0 C--O 1.248 1.029 0 CA-C-O 118.11 -1.383 . . . . 0.0 113.511 179.306 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 56.3 ttp180 . . . . . 0 N--CA 1.483 1.178 0 CA-C-O 120.841 0.353 . . . . 0.0 110.886 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.467 ' HD2' ' N ' ' A' ' 6' ' ' SER . 1.4 tmmt? -143.17 157.14 44.77 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.725 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.467 ' N ' ' HD2' ' A' ' 5' ' ' LYS . 14.5 m -142.1 145.9 34.8 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.21 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.9 pt -131.79 152.27 36.68 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.272 0 CA-C-O 121.257 0.551 . . . . 0.0 112.32 179.908 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.447 ' HD3' ' NH2' ' A' ' 15' ' ' ARG . 28.9 ttm105 -93.71 91.46 7.03 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 107.278 -1.378 . . . . 0.0 107.278 176.555 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.54 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.42 146.58 8.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.836 -177.717 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.54 ' H ' ' CD ' ' A' ' 10' ' ' GLN . 0.1 OUTLIER -98.95 9.54 43.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.906 -179.805 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -99.7 -169.94 1.82 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.224 179.926 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.17 174.2 27.21 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.455 -0.879 . . . . 0.0 112.404 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -81.65 108.13 1.2 Allowed 'Cis proline' 0 C--N 1.345 0.388 0 C-N-CA 123.152 -1.603 . . . . 0.0 112.777 0.132 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.03 137.02 0.66 Allowed Glycine 0 C--N 1.332 0.358 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.788 179.61 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.543 ' C ' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -66.02 130.98 45.12 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.388 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.54 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -170.22 -174.74 1.79 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.136 0.493 . . . . 0.0 111.007 -179.44 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -103.39 121.18 42.26 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.61 179.825 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.462 HG22 HG23 ' A' ' 9' ' ' ILE . 16.9 m -108.96 156.98 9.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.778 178.825 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.485 ' C ' HD13 ' A' ' 20' ' ' ILE . 75.6 m -118.48 148.28 42.76 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.08 0.467 . . . . 0.0 112.157 -178.658 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.599 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -124.97 177.75 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.187 179.119 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.157 0 CA-C-O 118.814 -0.992 . . . . 0.0 113.567 -179.761 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 66.9 mtp180 . . . . . 0 N--CA 1.485 1.295 0 N-CA-C 110.252 -0.277 . . . . 0.0 110.252 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.596 ' HD3' ' N ' ' A' ' 6' ' ' SER . 6.9 tmtm? -111.15 144.42 40.33 Favored 'General case' 0 C--O 1.222 -0.346 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.893 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.596 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 66.3 m -141.37 157.0 45.76 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 179.185 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 pt -130.99 148.13 33.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 -179.502 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 13.7 tpp180 -95.56 91.48 6.17 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 176.037 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.465 HD12 HG23 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -76.47 144.71 11.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.819 -177.237 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.43 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 46.4 tt0 -88.66 11.64 16.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.826 -179.485 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.0 mtp-105 -96.59 -176.04 3.49 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.207 -179.23 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.494 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -107.73 -179.54 22.15 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.849 -179.412 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -73.4 107.28 0.87 Allowed 'Cis proline' 0 C--N 1.343 0.288 0 C-N-CA 123.282 -1.549 . . . . 0.0 112.387 0.172 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.494 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 74.35 141.89 0.71 Allowed Glycine 0 C--N 1.333 0.377 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.534 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.3 124.33 20.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.762 0.315 . . . . 0.0 110.625 179.501 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.426 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -147.33 -178.99 6.53 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.185 -179.665 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -108.69 122.12 46.46 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.452 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.465 HG23 HD12 ' A' ' 9' ' ' ILE . 3.9 t -109.27 158.78 9.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.341 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.7 m -107.04 154.75 20.66 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.414 0.626 . . . . 0.0 111.81 -179.717 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.586 HD12 ' HD2' ' A' ' 5' ' ' LYS . 6.8 mt -125.34 171.9 13.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 114.698 -1.137 . . . . 0.0 109.308 -179.475 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.493 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.251 1.158 0 CA-C-O 118.384 -1.231 . . . . 0.0 111.978 179.59 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.465 ' HA ' ' C ' ' A' ' 21' ' ' GLY . 74.8 ttt180 . . . . . 0 N--CA 1.484 1.231 0 CA-C-O 120.873 0.368 . . . . 0.0 111.031 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -151.51 158.56 43.76 Favored 'General case' 0 C--O 1.217 -0.651 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 178.912 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.428 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 19.9 m -143.22 147.48 34.92 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.785 179.675 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.471 HG12 HD11 ' A' ' 20' ' ' ILE . 4.5 pt -132.38 146.36 33.11 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.392 0 N-CA-C 113.74 1.015 . . . . 0.0 113.74 -179.794 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.465 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 35.2 ttm180 -88.65 96.12 10.52 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 176.265 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.611 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.11 141.33 15.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 120.415 -0.514 . . . . 0.0 109.851 -178.165 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.8 tt0 -93.67 11.01 30.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.49 -178.677 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 46.2 ptt85 -98.39 -169.9 1.87 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.159 179.714 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.486 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.23 176.82 29.49 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.497 -0.859 . . . . 0.0 112.764 -179.412 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -74.23 109.11 1.1 Allowed 'Cis proline' 0 C--N 1.347 0.453 0 C-N-CA 123.151 -1.604 . . . . 0.0 112.51 0.001 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.486 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 71.81 156.82 2.79 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.495 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.0 mpt_? -67.83 133.7 49.64 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 120.789 0.328 . . . . 0.0 110.695 179.445 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.611 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -168.31 -164.61 0.54 Allowed 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.954 -179.626 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.465 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.1 OUTLIER -141.27 137.11 32.27 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.654 179.181 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.529 HG23 HD12 ' A' ' 9' ' ' ILE . 4.1 t -110.77 163.75 7.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.921 -179.362 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.403 ' N ' HG12 ' A' ' 18' ' ' VAL . 53.8 m -108.91 131.59 54.88 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.811 0.815 . . . . 0.0 111.92 -179.895 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.545 HG22 ' H ' ' A' ' 21' ' ' GLY . 4.2 mt -100.63 174.96 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 113.983 -1.462 . . . . 0.0 109.175 179.251 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.545 ' H ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.609 -1.106 . . . . 0.0 112.541 179.273 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 68.0 mtm180 . . . . . 0 N--CA 1.485 1.316 0 CA-C-O 121.209 0.528 . . . . 0.0 111.662 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -144.86 166.0 26.52 Favored 'General case' 0 C--O 1.213 -0.835 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.4 m -142.56 147.21 35.53 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 118.679 0.672 . . . . 0.0 110.619 179.37 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.616 HG12 HD11 ' A' ' 20' ' ' ILE . 6.0 pt -130.6 147.85 33.12 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.411 0 CA-C-O 121.112 0.482 . . . . 0.0 112.295 -179.878 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.4 ' HA ' ' O ' ' A' ' 16' ' ' ALA . 75.7 ttt180 -89.64 100.26 13.1 Favored 'General case' 0 N--CA 1.445 -0.71 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 176.043 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.557 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.98 150.59 5.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-O 121.32 0.581 . . . . 0.0 111.854 -176.641 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 62.7 mt-30 -93.61 12.18 26.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.698 -179.811 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -98.1 177.05 5.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.967 -179.174 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.453 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -104.25 -178.88 25.17 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.629 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -74.08 108.4 1.0 Allowed 'Cis proline' 0 C--N 1.345 0.36 0 C-N-CA 123.278 -1.551 . . . . 0.0 112.254 0.02 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.453 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 74.31 148.53 1.49 Allowed Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.346 -179.814 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.502 ' HD2' ' O ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -59.79 145.71 44.34 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.823 0.344 . . . . 0.0 110.885 179.806 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.557 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -164.74 -177.19 4.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.928 0.394 . . . . 0.0 111.202 -179.565 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -117.22 123.52 46.83 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.287 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.516 HG22 HG23 ' A' ' 9' ' ' ILE . 20.2 m -113.2 155.92 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.026 178.619 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 42.9 m -99.86 159.46 15.06 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.153 0.502 . . . . 0.0 111.316 -179.633 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.616 HD11 HG12 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -142.09 154.5 18.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.179 -178.69 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.261 0 CA-C-O 118.424 -1.209 . . . . 0.0 113.729 178.696 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 35.7 ttm180 . . . . . 0 N--CA 1.486 1.367 0 N-CA-C 110.487 -0.19 . . . . 0.0 110.487 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.476 ' O ' HG12 ' A' ' 20' ' ' ILE . 0.7 OUTLIER -98.4 152.3 19.64 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.956 0.408 . . . . 0.0 111.277 -179.574 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 24.0 m -142.76 157.13 44.94 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.388 178.61 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.8 pt -128.45 146.59 33.66 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.352 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -179.414 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.473 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 53.9 ttp180 -95.83 92.86 6.74 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 176.257 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.452 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -75.99 154.72 5.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.577 -177.379 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.0 pt20 -97.05 12.03 34.04 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.211 -179.363 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.418 ' H ' HG12 ' A' ' 9' ' ' ILE . 97.7 mtt180 -97.44 -178.75 4.25 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.648 -179.345 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.02 -179.56 30.24 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.447 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -77.86 107.76 1.06 Allowed 'Cis proline' 0 C--N 1.346 0.418 0 C-N-CA 123.098 -1.626 . . . . 0.0 112.403 0.028 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.26 153.22 5.53 Favored Glycine 0 C--N 1.331 0.301 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.214 -179.865 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 40.1 mmt-85 -66.17 119.93 12.33 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.69 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.84 -179.13 6.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.157 0.504 . . . . 0.0 111.75 -179.458 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.473 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -114.23 125.77 54.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.995 -179.996 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.452 HG23 HD12 ' A' ' 9' ' ' ILE . 5.6 t -110.05 162.99 7.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.705 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 6' ' ' SER . 53.7 m -107.03 158.23 17.2 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.937 -0.305 . . . . 0.0 111.751 -179.464 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.476 HG12 ' O ' ' A' ' 5' ' ' LYS . 2.6 mm -99.93 157.29 3.95 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.258 179.68 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.314 -1.27 . . . . 0.0 112.352 179.804 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? . . . . . 0 N--CA 1.484 1.266 0 CA-C-O 120.682 0.277 . . . . 0.0 110.475 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.438 ' NZ ' ' CB ' ' A' ' 5' ' ' LYS . 7.9 mtpm? -104.1 148.64 26.03 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.636 179.738 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.475 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 15.7 m -142.93 132.64 23.89 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.043 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.423 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 4.9 pt -131.28 147.82 32.85 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 N-CA-C 113.701 1.0 . . . . 0.0 113.701 -178.874 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.492 ' N ' ' HD2' ' A' ' 8' ' ' ARG . 2.2 mpt_? -86.94 99.72 12.07 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 176.012 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.581 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.85 143.3 12.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 C-N-CA 120.3 -0.56 . . . . 0.0 110.922 -177.452 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.1 pp0? -85.77 11.89 10.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.342 -179.724 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.422 ' H ' HG12 ' A' ' 9' ' ' ILE . 78.9 ttt180 -98.04 158.7 15.39 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.89 -179.64 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.4 ' N ' ' HG2' ' A' ' 11' ' ' ARG . . . -99.73 -170.64 30.16 Favored Glycine 0 N--CA 1.452 -0.27 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.268 179.811 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -83.46 115.96 3.99 Favored 'Cis proline' 0 N--CA 1.462 -0.348 0 C-N-CA 123.091 -1.629 . . . . 0.0 112.592 0.084 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.26 117.43 3.93 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.539 179.747 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.456 ' HD3' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -59.45 121.17 10.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.099 0.476 . . . . 0.0 110.975 179.71 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.581 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -155.18 -168.93 3.01 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.419 -179.498 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.475 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -136.25 145.74 45.93 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.654 179.626 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.7 t -112.44 160.95 11.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.182 -179.711 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 52.0 m -119.93 112.99 19.88 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.132 179.814 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.582 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.1 OUTLIER -110.59 -179.41 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.015 178.983 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.618 -1.101 . . . . 0.0 112.276 179.705 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.41 ' C ' ' HD2' ' A' ' 4' ' ' ARG . 1.2 tmm_? . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.582 0.23 . . . . 0.0 110.638 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -110.66 157.48 19.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.978 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.1 m -142.43 151.58 41.92 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.006 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.681 HG23 HD11 ' A' ' 20' ' ' ILE . 4.8 pt -130.64 148.94 33.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 N-CA-C 112.729 0.641 . . . . 0.0 112.729 -179.127 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 57.3 ttp85 -94.8 94.22 7.94 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 175.994 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.674 HD12 HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -76.47 153.92 5.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.125 0.488 . . . . 0.0 111.606 -176.569 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.439 ' HA ' ' HD2' ' A' ' 15' ' ' ARG . 62.4 mt-30 -97.14 11.38 36.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.672 -0.695 . . . . 0.0 111.19 -179.523 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.96 159.44 14.93 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.823 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.92 -171.05 32.63 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.765 -179.091 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.76 113.81 2.85 Favored 'Cis proline' 0 N--CA 1.462 -0.338 0 C-N-CA 122.977 -1.676 . . . . 0.0 112.62 0.349 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.87 138.26 5.31 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.61 179.859 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.439 ' HD2' ' HA ' ' A' ' 10' ' ' GLN . 55.5 mmt-85 -74.86 125.41 28.76 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.416 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.433 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -151.84 -176.01 5.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.19 0.519 . . . . 0.0 112.006 -179.144 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -106.99 125.1 50.57 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.088 179.885 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.674 HG23 HD12 ' A' ' 9' ' ' ILE . 6.0 t -113.69 162.93 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 178.919 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.409 ' N ' HG12 ' A' ' 18' ' ' VAL . 52.9 m -103.36 151.26 22.95 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.07 0.462 . . . . 0.0 111.439 -179.827 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.681 HD11 HG23 ' A' ' 7' ' ' ILE . 8.2 mt -109.0 164.01 5.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.283 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.44 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.248 0.978 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.015 179.636 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 . . . . . 0 N--CA 1.484 1.268 0 CA-C-O 120.651 0.262 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.519 ' CE ' HD12 ' A' ' 20' ' ' ILE . 5.4 tmmm? -154.36 165.27 36.9 Favored 'General case' 0 C--O 1.214 -0.788 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 180.0 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.4 ' N ' ' HD2' ' A' ' 5' ' ' LYS . 15.5 m -142.81 152.12 41.88 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 118.42 0.555 . . . . 0.0 110.806 179.995 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.706 HG12 HD11 ' A' ' 20' ' ' ILE . 6.0 pt -131.13 150.12 34.15 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.346 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 179.347 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.405 ' O ' ' HG3' ' A' ' 8' ' ' ARG . 17.4 ptt85 -97.14 93.9 6.83 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 176.327 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.52 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.04 144.26 11.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.799 -177.072 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 19.8 tt0 -91.88 7.02 43.95 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.984 0.421 . . . . 0.0 110.966 -179.232 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.404 ' NH1' HG13 ' A' ' 9' ' ' ILE . 15.5 ptt85 -99.14 178.56 4.88 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.701 179.492 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -98.41 -177.91 32.77 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.523 -179.524 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.46 108.52 1.14 Allowed 'Cis proline' 0 C--N 1.342 0.225 0 C-N-CA 123.405 -1.498 . . . . 0.0 112.561 0.237 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 128.34 0.91 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.936 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.455 ' C ' ' HD2' ' A' ' 15' ' ' ARG . 3.1 tmm_? -65.56 113.65 4.35 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.439 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.52 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -149.02 -169.58 3.41 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.517 0.675 . . . . 0.0 111.89 -179.239 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -107.49 128.18 54.27 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.058 -0.973 . . . . 0.0 111.113 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.448 HG22 HG23 ' A' ' 9' ' ' ILE . 16.4 m -117.44 153.7 19.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.094 178.738 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.405 HG22 ' N ' ' A' ' 20' ' ' ILE . 57.3 m -94.08 158.71 15.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.476 0.655 . . . . 0.0 111.861 -179.048 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.706 HD11 HG12 ' A' ' 7' ' ' ILE . 3.1 mt -141.31 160.62 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-N 114.735 -1.121 . . . . 0.0 109.552 -179.447 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.996 0 CA-C-O 118.365 -1.241 . . . . 0.0 112.448 179.403 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.581 ' N ' ' NE ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.484 1.27 0 CA-C-O 120.69 0.281 . . . . 0.0 110.649 . . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.603 ' HE3' HG23 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -107.12 145.9 31.92 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 178.726 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.506 ' H ' ' HD2' ' A' ' 5' ' ' LYS . 9.5 m -141.05 140.26 34.21 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 120.284 -0.566 . . . . 0.0 111.421 -179.874 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.603 HG23 ' HE3' ' A' ' 5' ' ' LYS . 1.5 pt -132.12 148.3 32.14 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -179.809 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.438 ' HG3' ' O ' ' A' ' 8' ' ' ARG . 28.3 ptt-85 -80.92 104.45 11.43 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 176.114 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.662 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -77.63 158.77 5.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 C-N-CA 120.039 -0.664 . . . . 0.0 110.622 -177.736 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -99.68 12.31 36.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.819 -178.988 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.422 HH11 ' HD3' ' A' ' 11' ' ' ARG . 49.2 mtt180 -97.61 161.86 13.57 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.805 0.336 . . . . 0.0 110.76 -179.738 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.79 -175.37 30.83 Favored Glycine 0 N--CA 1.452 -0.267 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.564 -179.69 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.62 119.43 6.3 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.978 -1.676 . . . . 0.0 112.412 -0.167 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.77 144.63 6.1 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.186 -179.772 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 10.5 mpt_? -77.44 117.2 18.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.041 0.448 . . . . 0.0 111.05 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.662 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -136.52 -173.03 3.3 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.823 179.639 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 7' ' ' ILE . 0.4 OUTLIER -130.7 143.62 50.87 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.048 0.451 . . . . 0.0 110.956 179.608 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.579 HG13 HD12 ' A' ' 9' ' ' ILE . 25.8 m -112.43 163.81 9.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.991 -179.542 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.4 m -120.3 123.72 43.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.297 -179.739 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.67 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -114.59 157.05 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 C-N-CA 123.031 0.532 . . . . 0.0 110.798 179.275 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.201 -1.333 . . . . 0.0 112.177 179.933 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.448 ' HG2' ' N ' ' A' ' 5' ' ' LYS . 11.6 ttp180 . . . . . 0 N--CA 1.487 1.411 0 N-CA-C 110.27 -0.27 . . . . 0.0 110.27 . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.627 ' HD2' HD12 ' A' ' 20' ' ' ILE . 5.4 tmtm? -143.67 144.86 32.05 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.809 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.567 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 0.9 OUTLIER -139.21 152.27 47.22 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.772 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.551 HG23 HD11 ' A' ' 20' ' ' ILE . 3.1 pt -130.59 151.77 36.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.437 0 CA-C-O 121.312 0.577 . . . . 0.0 112.356 179.932 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.473 ' HB3' ' CE2' ' A' ' 17' ' ' PHE . 4.7 ptm85 -96.61 99.29 10.93 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 176.282 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.601 HD13 ' H ' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -77.79 156.56 5.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.242 0.544 . . . . 0.0 111.955 -176.744 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -94.77 12.56 27.52 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.073 179.075 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 11.2 ttt180 -97.03 -168.32 1.68 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.71 -179.335 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.503 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -107.45 176.43 20.9 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.442 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -73.02 108.71 0.97 Allowed 'Cis proline' 0 CA--C 1.53 0.288 0 C-N-CA 123.311 -1.537 . . . . 0.0 112.369 0.038 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.503 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 65.57 173.61 4.46 Favored Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.673 -179.937 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.459 HH21 ' NE ' ' A' ' 8' ' ' ARG . 16.1 tpt180 -69.33 115.14 8.25 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.766 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.04 -177.94 5.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.172 0.51 . . . . 0.0 111.52 -179.26 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.473 ' CE2' ' HB3' ' A' ' 8' ' ' ARG . 0.4 OUTLIER -115.44 132.02 56.75 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.053 179.887 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.452 HG22 HG23 ' A' ' 9' ' ' ILE . 19.1 m -121.98 161.63 22.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.74 -0.663 . . . . 0.0 109.819 178.838 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 41.5 m -96.7 155.67 16.67 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.015 0.436 . . . . 0.0 111.06 -179.631 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.627 HD12 ' HD2' ' A' ' 5' ' ' LYS . 20.7 mt -121.27 165.52 16.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.458 179.584 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.478 ' N ' HG22 ' A' ' 20' ' ' ILE . . . . . . . . 0 C--O 1.249 1.086 0 CA-C-O 118.202 -1.332 . . . . 0.0 111.982 179.917 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.5 tpp85 . . . . . 0 N--CA 1.487 1.377 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -142.56 148.97 38.42 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 110.197 -0.297 . . . . 0.0 110.197 179.551 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 m -143.75 152.99 41.95 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.076 178.999 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.417 ' C ' ' HB2' ' A' ' 17' ' ' PHE . 3.7 pt -131.15 145.96 34.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.442 0 N-CA-C 113.551 0.945 . . . . 0.0 113.551 -179.411 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.428 ' HA ' ' CB ' ' A' ' 17' ' ' PHE . 76.7 mtp180 -82.31 92.67 7.0 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 176.431 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.573 HD13 HG13 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -77.71 148.49 6.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.043 0.449 . . . . 0.0 110.92 -177.524 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -101.15 9.7 41.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.16 0.505 . . . . 0.0 109.884 179.05 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 64.5 mtp180 -99.86 -168.8 1.65 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.754 -179.269 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.7 -176.4 19.67 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 121.197 -0.525 . . . . 0.0 112.047 179.803 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -83.01 113.51 2.95 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.487 -1.464 . . . . 0.0 112.357 -0.075 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.11 128.31 6.03 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.219 -179.836 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 13.9 mmt180 -70.95 96.93 1.35 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.856 0.36 . . . . 0.0 110.728 -179.881 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.449 ' O ' HG12 ' A' ' 9' ' ' ILE . . . -155.27 179.31 9.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.351 -179.842 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.428 ' CB ' ' HA ' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -103.79 147.35 27.38 Favored 'General case' 0 C--N 1.325 -0.5 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.646 179.851 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.573 HG13 HD13 ' A' ' 9' ' ' ILE . 31.3 m -119.18 165.52 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.136 -179.809 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 94.0 m -98.48 153.6 18.49 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.116 0.484 . . . . 0.0 111.03 179.835 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 7.8 mt -114.24 163.78 11.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.328 -179.237 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.208 -1.329 . . . . 0.0 112.001 179.827 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 82.1 mtt-85 . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.445 ' HB3' HD12 ' A' ' 20' ' ' ILE . 55.9 mtpt -58.89 146.55 37.21 Favored 'General case' 0 C--O 1.222 -0.342 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.015 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.6 m -141.14 147.76 38.98 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.102 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.68 HG23 HD11 ' A' ' 20' ' ' ILE . 8.0 pt -131.48 146.72 33.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -178.269 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -92.26 93.07 8.47 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 176.175 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.564 HD12 HG23 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -75.31 148.15 7.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.02 0.438 . . . . 0.0 111.026 -176.697 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 69.9 mt-30 -100.16 11.83 38.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.028 -179.384 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -97.78 -169.3 1.81 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.493 -0.322 . . . . 0.0 110.187 -179.864 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.14 -177.17 19.16 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.429 179.772 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -79.55 104.98 0.64 Allowed 'Cis proline' 0 C--N 1.344 0.314 0 C-N-CA 123.485 -1.465 . . . . 0.0 112.143 -0.117 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.49 145.46 13.76 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.97 179.883 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 26.3 mtt180 -78.11 137.29 38.13 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 110.523 -0.177 . . . . 0.0 110.523 179.813 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.439 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -168.53 -173.73 2.01 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-O 121.22 0.533 . . . . 0.0 111.227 -179.782 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 8' ' ' ARG . 0.2 OUTLIER -111.97 120.59 42.41 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.359 179.504 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.564 HG23 HD12 ' A' ' 9' ' ' ILE . 4.1 t -110.03 160.5 9.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.313 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 46.2 m -98.51 158.8 15.37 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.889 0.376 . . . . 0.0 110.158 179.356 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.68 HD11 HG23 ' A' ' 7' ' ' ILE . 7.1 mt -119.33 161.58 18.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.527 179.76 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.135 0 CA-C-O 118.455 -1.192 . . . . 0.0 112.22 179.958 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.484 ' C ' ' HD2' ' A' ' 4' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 120.437 0.161 . . . . 0.0 110.711 . . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.535 ' HD3' ' N ' ' A' ' 6' ' ' SER . 4.2 tmtm? -138.93 140.99 38.48 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.952 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.535 ' N ' ' HD3' ' A' ' 5' ' ' LYS . 12.3 m -141.4 135.27 30.22 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.216 179.63 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.9 pt -132.64 149.52 32.17 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.343 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -179.956 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.556 ' H ' ' HD3' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -90.1 105.45 17.82 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 175.514 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.584 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -78.57 156.52 4.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 C-N-CA 120.501 -0.479 . . . . 0.0 111.281 -177.436 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.512 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 10.2 mp0 -94.72 10.28 35.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.48 179.904 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -99.67 179.59 4.49 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.858 -179.808 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.15 -176.61 30.41 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.186 179.859 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -76.57 107.68 1.01 Allowed 'Cis proline' 0 N--CA 1.464 -0.242 0 C-N-CA 123.246 -1.564 . . . . 0.0 112.521 0.052 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.21 151.54 7.23 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.835 179.674 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 16.5 mmm180 -60.13 109.97 1.1 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.71 0.29 . . . . 0.0 110.64 179.417 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.584 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -141.06 -177.07 4.93 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.439 -179.937 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.501 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.2 OUTLIER -135.46 146.03 47.78 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.478 179.447 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.0 t -112.99 160.66 12.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.168 -179.495 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.52 HG23 ' OG ' ' A' ' 6' ' ' SER . 83.9 m -126.88 114.83 18.4 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.449 179.633 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.611 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -112.47 161.99 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.762 179.729 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.281 -1.289 . . . . 0.0 112.32 -179.996 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.1 ptp85 . . . . . 0 N--CA 1.485 1.278 0 CA-C-O 120.426 0.155 . . . . 0.0 110.681 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -114.15 135.11 54.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.657 179.626 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 16.0 m -140.92 135.82 31.64 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.929 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.4 pt -124.07 150.72 28.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 113.237 0.829 . . . . 0.0 113.237 -178.203 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.453 ' HD2' ' O ' ' A' ' 16' ' ' ALA . 14.6 tpt180 -92.22 94.37 9.15 Favored 'General case' 0 N--CA 1.446 -0.631 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 176.197 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.474 HD13 ' O ' ' A' ' 16' ' ' ALA . 0.2 OUTLIER -76.28 148.53 7.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.912 -177.084 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 33.5 mt-30 -97.4 11.51 36.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.188 -179.569 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 9.0 ptm180 -98.34 -174.9 2.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.116 179.827 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.446 ' HA2' ' N ' ' A' ' 14' ' ' GLY . . . -99.94 175.7 27.7 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.569 -179.763 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -76.46 109.46 1.36 Allowed 'Cis proline' 0 C--N 1.346 0.411 0 C-N-CA 123.247 -1.564 . . . . 0.0 112.438 -0.02 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.446 ' N ' ' HA2' ' A' ' 12' ' ' GLY . . . 69.52 168.1 5.99 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.292 -179.743 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.454 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 4.8 mpt_? -80.11 134.27 36.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 110.547 179.662 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.474 ' O ' HD13 ' A' ' 9' ' ' ILE . . . -160.95 178.95 8.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.0 -179.751 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -109.85 124.08 50.71 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.917 179.739 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.462 HG22 HG23 ' A' ' 9' ' ' ILE . 12.9 m -114.28 140.01 37.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.399 179.117 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.7 m -101.48 142.15 33.29 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.857 -179.598 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.675 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -112.36 161.14 11.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.986 179.788 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.287 -1.285 . . . . 0.0 112.029 179.985 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.413 ' HA ' ' NE ' ' A' ' 4' ' ' ARG . 15.4 mmp_? . . . . . 0 N--CA 1.483 1.223 0 CA-C-O 120.729 0.3 . . . . 0.0 110.841 . . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 29.7 ttmt -126.35 149.14 49.38 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 178.653 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.499 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 14.8 m -141.55 132.8 26.48 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.937 179.268 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 2.2 pt -131.9 147.58 32.39 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -179.52 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.568 ' HB3' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -85.74 100.59 12.12 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 176.155 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.474 ' CD1' HG23 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -78.54 158.16 4.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.561 -0.456 . . . . 0.0 110.777 -177.815 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.425 ' CD ' ' N ' ' A' ' 10' ' ' GLN . 13.1 mp0 -100.89 10.17 41.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.86 0.362 . . . . 0.0 110.463 179.249 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 74.2 ttt180 -99.02 165.0 11.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.519 -179.527 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.82 -175.13 33.65 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.205 -179.976 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -74.81 115.83 3.64 Favored 'Cis proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.132 -1.612 . . . . 0.0 112.553 0.314 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.67 124.14 1.01 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.974 -0.632 . . . . 0.0 112.481 179.765 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.3 mtt85 -61.58 98.84 0.1 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.848 0.356 . . . . 0.0 110.418 179.656 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -131.0 -178.91 5.03 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.582 -179.636 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.465 ' CE2' ' HB3' ' A' ' 6' ' ' SER . 0.3 OUTLIER -117.38 145.28 44.18 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.593 179.765 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 6' ' ' SER . 3.6 t -114.81 161.19 13.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.256 -179.475 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 86.9 m -120.69 109.06 14.75 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.081 179.568 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.582 ' N ' HD13 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -104.44 171.37 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 CA-C-O 120.816 0.341 . . . . 0.0 111.387 -179.813 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.464 -1.187 . . . . 0.0 112.544 179.714 . . . . . . . . 0 0 . 1 stop_ save_